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1 Abstracts 
1.1 Summary 
Proteins play a pivotal role in cellular processes. As proteins represent the major ‘workforce’ of 
biomolecules, changes in protein abundances and in posttranslational modifications indicate changes in 
the behavior of cells on the molecular level. Analysis of proteins improves our understanding of 
physiological and pathophysiological mechanisms. Today, there are numerous technologies and methods 
available for protein analysis. For semi-quantitative detection, Western-Blotting still represents the gold 
standard and is probably the most widespread method for protein analysis.  
The DigiWest approach which is described in this thesis is based on the Western-Blot. Transfer onto a 
bead-based microarray platform creates hundreds of replicas of an initial blot. Proteins are separated by 
SDS-PAGE and blotted onto a membrane as performed for a classical Western-Blot. The membrane 
containing the size-separated proteins is then cut into molecular weight fractions. Proteins are eluted 
from the molecular weight fractions and each fraction is loaded onto a distinct color-coded Luminex 
bead set. The color code of the bead sets retains the molecular weight information and allows pooling of 
all bead sets loaded with proteins into a bead-mix which represents the initial Western-Blot with a 
resolution of 0.5 mm. As only a small aliquot of a bead-mix is required for an antibody-incubation, a 
bead-mix loaded with protein from a single Western-Blot is sufficient for hundreds of antibody 
incubations which are performed in microtiter plates. After fluorescence-based readout on the Luminex 
instrument, the color code of the beads allows digital reconstruction of the initial Western-Blot lanes 
using the antibody specific signal obtained on the different bead-sets representing molecular weight 
fractions of the initial blot. Therefore, the method was named ‘DigiWest’. The digital data allow fast 
quantification of the antibody specific signal without image processing and the data can also be used to 
create gray-scale images mimicking classical Western-Blot images. Although hundreds of replicas are 
generated, allowing hundreds of antibody incubations in fast and automatable assays, DigiWest uses the 
same sample amount that is usually used for a single Western-Blot while it keeps sensitivity and signal 
linearity comparable to high-end Western-Blot readout platforms. The results are robust and highly 
comparable to classical Western-Blots. Application of the DigiWest method allowed a comprehensive 
analysis of laser capture microdissected samples which are barely sufficient for a single Western-Blot.  
Mouse models play an important role in toxicology and the liver, the most important organ for drug 
metabolism, gains special attention. Besides its homogenous appearance the liver is built from lobules as 
repeated units and zonation results in different metabolic competences for the hepatocytes dependent 
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on their position within a lobule. Proximal periportal and pericentral zones from liver lobules were 
isolated by LCM from formalin fixed mouse liver sections derived from a time-course treatment study 
with the non-genotoxic carcinogen TCPOBOP. About 200 Western-Blot equivalents were performed with 
the resulting samples. The analysis of the isolated zones provided new insights into cellular signaling in 
liver zonation and changes occurring during the treatment time course. An important role for serine and 
threonine phosphorylations and phosphatases was found for regulation of zone specific metabolism. 
Inhibition of the phosphatase PP2A in the periportal zone was found to direct insulin dependent 
signaling. The TCPOBOP treatment time-course analysis showed that mainly the pericentral zone is 
exposed to oxidative stress resulting in activation of a stress-survival response while other TCPOBOP 
induced effects were found to affect both zones. TCPOBOP was found to induce a pronounced 
disturbance in cellular signaling within the first 24 hours after treatment. 
 
1.2 Zusammenfassung 
Proteine spielen eine zentrale Rolle in zellulären Prozessen. Da Proteine unter den Biomolekülen die 
wichtigsten „Arbeitskräfte“ darstellen, deuten Änderungen in der Menge an Proteinen und an 
posttranslationalen Modifikationen auf Änderungen im Verhalten von Zellen auf molekularer Ebene. Die 
Analyse von Proteinen verbessert unser Verständnis von physiologischen und pathophysiologischen 
Vorgängen. Heutzutage steht uns eine große Anzahl an Technologien und Methoden zur Proteinanalyse 
zur Verfügung. Für den semiquantitativen Nachweis stellt der Western-Blot immer noch den Gold-
Standard dar und ist wahrscheinlich die am weitesten verbreitete Methode für die Proteinanalyse. 
Die DigiWest Methode die in dieser Doktorarbeit beschrieben wird basiert auf dem Western-Blot. Durch 
Überführung auf eine Bead-basierte Mikroarray Plattform werden aus einem initialen Blot hunderte 
Repliken erzeugt. Proteine werden mittels SDS-PAGE aufgetrennt und auf eine Membran geblottet wie 
es für einen klassischen Western-Blot durchgeführt wird. Die Membran, die die nach Größe aufge-
trennten Proteine enthält, wird dann in Molekulargewichtsfraktionen geschnitten. Die Proteine werden 
aus den Molekulargewichtsfraktionen eluiert und jede Fraktion wird auf eine unterscheidbare, 
farbkodierte Luminex Bead-Population geladen. Die Farbkodierung der Beads bewahrt die 
Molekulargewichtsinformation und erlaubt es, alle mit Proteinen beladenen Bead-Populationen in einem 
Bead-Mix zu vereinigen welcher den ursprünglichen Western-Blot mit einer Auflösung von 0.5 mm 
darstellt. Da nur ein kleines Aliquot eines Bead-Mixes für eine Antikörperinkubation benötigt wird, ist ein 
Bead-Mix der mit Protein aus einem einzelnen Western-Blot beladen ist ausreichend für hunderte 
Antikörperinkubationen welche in Mikrotiter-Platten durchgeführt werden. Nach dem 
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fluoreszenzbasierten Auslesen auf einem Luminex-Gerät erlaubt die Farbkodierung die digitale 
Rekonstruktion der ursprünglichen Western-Blot Spuren unter Verwendung des Antikörper-spezifischen 
Signals welches auf den unterschiedlichen Bead-Populationen erhalten wurde die die Molekular-
gewichts-Fraktionen des ursprünglichen Blots darstellen. Daher wurde die Methode „DigiWest“ genannt. 
Die digitalen Daten erlauben eine schnelle Quantifizierung des Antikörperspezifischen Signals ohne 
Bildverarbeitung wobei die Daten auch dazu verwendet werden können Graustufenbilder zu erzeugen 
welche klassische Western-Blot Bilder nachahmen.  
Obwohl hunderte Repliken erzeugt werden, welche hunderte Antikörperinkubationen in schnellen und 
automatisierbaren Assays erlauben, verwendet die DigiWest Methode die selbe Proben-Menge die 
üblicherweise für einen einzelnen Western-Blot verwendet wird während eine Sensitivität und Signal-
Linearität beibehalten wird die mit High-End Western-Blot Auslese-Systemen vergleichbar ist. Die 
Ergebnisse sind robust und bestens mit klassischen Western-Blots vergleichbar. Die Anwendung der 
DigiWest Methode erlaubte eine umfangreiche Analyse von mittels Laser-Mikrodissektion isolierter 
Proben welche kaum für einen einzelnen Western-Blot ausreichen.  
Maus-Modelle spielen eine wichtige Rolle in der Toxikologie und die Leber als wichtigstes Organ für 
Medikamenten-Metabolismus bekommt besondere Aufmerksamkeit. Abgesehen vom homogenen 
Erscheinungsbild der Leber ist diese aus Läppchen als sich wiederholende Einheiten aufgebaut deren 
Zonierung darin resultiert dass Hepatozyten unterschiedliche metabolische Kompetenzen besitzen, 
abhängig von ihrer Position innerhalb eines Läppchens. Stammnahe periportale und perizentrale Zonen 
der Leberläppchen wurden mittels LCM aus Formalin fixierten Mausleberschnitten isoliert welche aus 
einer Behandlungszeitreihen-Studie mit dem nicht-genotoxischen Karzinogen TCPOBOP stammten. 
Ungefähr 200 Western-Blot Äquivalente wurden mit den resultierenden Proben durchgeführt. Die 
Analyse der isolierten Zonen brachte neue Einblicke in die zelluläre Signalübertragung in der 
Leberzonierung und in Änderungen während der Behandlungs-Zeitreihe. Es wurde eine wichtige Rolle 
von Serin- und Threonin-Phosphorylierungen und Phosphatasen für die Regulation des Zonen-
spezifischen Metabolismus gefunden. Es stellte sich heraus dass die Inhibierung der Phosphatase PP2A in 
der periportalen Zone die Insulin-vermittelte Signalübertragung lenkt. Die Analyse der TCPOBOP 
Behandlunszeitreihe zeigte dass hauptsächlich die perizentrale Zone oxidativem Stress ausgesetzt ist was 
eine Stress-Überlebens-Antwort hervorruft während andere TCPOBOP-induzierte Effekte beide Zonen 
betreffen. Es stellte sich heraus dass TCPOBOP eine ausgeprägte Störung der zellulären Signalüber-
tragung innerhalb der ersten 24 Stunden nach der Behandlung verursacht.  
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2 Introduction 
2.1 Of signaling and cancer 
An adult human being is composed of about 3.7x1013 cells (Bianconi et al., 2013). Perfect interplay and 
communication between all these cells and tight regulation of their behavior is vital to maintain 
homeostasis and adapt to changes of the inner and outer environment (Scanlon, 2007). Yet being a 
human is more than just homeostasis. Although all cells possess the same almost invariable genes, they 
are highly differentiated to fulfil their purposes. Therefore, they express different proteins for 
metabolism and signaling. There are various molecular mechanisms for regulation of intercellular 
communication and intracellular signaling. Cell surfaces are strewn with receptors and other proteins 
which receive signals from outside the cells or transmit signals from inside the cells (Gomperts, Kramer, 
& Tatham, 2009; Karp, 2009). 
While several fundamental principles are known on cellular signaling, yet we are still at the beginning of 
under-standing the complexity of signaling networks and of deciphering the nexuses. One important and 
frequently employed mechanism of cellular signaling starts with binding of a ligand, often a soluble 
extracellular protein, to a receptor at the surface of a cell. The receptor changes its conformation or 
forms a dimer and thereby transmits the signal to the inside of the cell. The activated receptor can 
provide a binding platform for intracellular proteins and enzymes. Many receptors themselves contain 
enzymatic subunits which are activated by ligand binding. A wide spread enzymatically transmitted signal 
is phosphorylation. Kinase activity leads to phosphorylation of proteins at specific hydroxyl-groups and 
thereby induces a conformational change. This conformational change leads to activation or inactivation 
of enzymatic activity, a change of specificity or it can lead to uncovering or hiding of interaction sites. 
Thereby, phosphorylation provides a powerful signaling mechanism. Activation of few receptor proteins 
or even a single receptor protein activates a kinase which may then phosphorylate and thereby activate 
many target proteins which can themselves be kinases that can activate many new target proteins. This 
phenomenon is known as a kinase cascade which has a strong amplifying effect. Important substrates for 
kinases are transcription factors resulting in transcriptional changes. Phosphatases can dephosphorylate 
proteins and thereby inverse the signal (Chang & Karin, 2001; Gomperts et al., 2009; Krauss, 2006). 
Most signaling pathways depend on kinase activity and mechanisms to keep the amplifying effect of 
kinase cascades under control have evolved. The so called G-proteins can control initial steps of a 
cascade and have the function of a time switch getting inactivated after a short period of time to prevent 
signaling from getting out of control (Chang & Karin, 2001; Gomperts et al., 2009; Krauss, 2006). 
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Most kinases involved in signaling have a number of targets and the outcome of their activation depends 
on many factors. Formation of complexes with other proteins influences their microenvironment such as 
location, interaction partners and substrate availability. Therefore, cellular signaling has to be seen as a 
complex spatiotemporal process with different cell types responding differently upon signaling events 
(Kholodenko, 2006; Krauss, 2006; Volmat & Pouysségur, 2001).  
Diseases which are not caused by pathogens directly are often based on defects in cellular signaling. 
Disturbances in signaling are a frequent cause of cancer development. Most tumors bear one or more 
mutations in genes which code for proteins that play central roles in cellular signaling. These mutations 
often lead to constitutively active signaling (Hanahan & Weinberg, 2000, 2011; Weber, 2007). For 
example, two thirds of all malignant melanoma bear an activating mutation in the B-RAF gene coding for 
a kinase involved in the MAP-kinase cascade leading to a constitutive active signaling status that 
promotes tumor growth (H. Davies et al., 2002). But cancer is not a defined disease and a single 
mutation in a gene coding for an important signaling protein is not sufficient for carcinogenesis. Current 
research postulates six hallmarks of cancer which are required for a cell to become malignant (Hanahan 
& Weinberg, 2000, 2011). Most tumor types are highly diverse in respect to mutations and this 
characteristic makes treatment difficult (Gabriel, 2007).  
Errors in DNA replication are naturally occurring in our genome. Most of them get repaired by specific 
repair mechanisms, while cells with major defects undergo apoptosis or are eliminated by the immune 
system. Not all initial mutations are repaired and thereby, mutations accumulate during life time 
resulting in increased cancer risk with prolonged life (Hoeijmakers, 2009; Lombard et al., 2005).  
Besides DNA replication, major causes for mutation are radiation and chemicals. Substances known to be 
mutagenic are classified as carcinogens (Weber, 2007). A special subgroup of carcinogens is known as 
non-genotoxic carcinogens (NGCs). These substances do not cause mutations directly but still induce 
tumor formation. Their mode of action has not yet been elucidated but they are thought to promote 
tumor formation from preneoplastic lesions i.e. genetically and phenotypically altered cells (Hernández, 
van Steeg, Luijten, & van Benthem, 2009). 
In an attempt to get a closer understanding of NGCs, rodent tumor models can be employed. A common 
experimental system is based on tumor initiation and promotion. Rodents are injected with a single dose 
of a genotoxic agent like DEN (diethylnitrosamine) to induce mutations followed by long term treatment 
with a tumor promoting agent (Boorman, Maronpot, & Eustis, 1994; Schulte-Hermann, 1985). The 
mutagen DEN initiates mouse liver tumor formation and analysis of the tumor cells showed that they 
frequently harbor mutations in the MAP-kinase cascade, mutations in H-RAS in ~50% or B-RAF in ~20% of 
tumors were found (Jaworski, Buchmann, Bauer, Riess, & Schwarz, 2005). When this initiation is followed 
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by tumor promotion with a phenobarbital-like promoter, a NGC, the resulting tumors harbor almost 
exclusively mutations in Ctnnb1, the gene coding for β-catenin (Aydinlik, Nguyen, Moennikes, 
Buchmann, & Schwarz, 2001; Loeppen et al., 2002). These chemical substances seem to provide a 
growth advantage to preneoplastic lesions harboring activating β-catenin mutations in the liver. Pheno-
barbital-like inducers activate the nuclear receptor CAR which is a central regulator of xenobiotic meta-
bolism. Activation of CAR results in induction of several drug metabolizing enzymes and hepatomegaly 
which is based on liver hypertrophy and hyperplasia. The strongest known phenobarbital-like tumor 
promoter is TCPOBOP (1,4-Bis[2-(3,5-Dichloropyridyloxy)] Benzene) (W. Huang et al., 2005; Kodama & 
Negishi, 2008). 
Although different classes of NGCs seem to have different modes of action, they are often referred to 
epigenetic carcinogens as their tumor promoting effect coincides with epigenetic perturbations including 
DNA methylation.  The effects of non-genotoxic carcinogens are dose and time dependent. Carcinogenic 
effects only occur beyond a certain threshold and usually only in long term treatment (Bolt, Foth, 
Hengstler, & Degen, 2004; Fukushima et al., 2005; Klein & Costa, 1997). The liver is the main organ for 
drug metabolism and several known NGCs promote tumors in the liver. Therefore, the liver gains special 
attraction for investigation of NGCs in rodents (Melnick, Kohn, & Portier, 1996; S. P. S. Monga & Cagle, 
2010). 
 
2.2 The liver 
The liver is the largest visceral organ and the second most complex after the brain. The most important 
function is to maintain homeostasis of the blood. It regulates content of nutrients and other blood 
components and removes disused components. An important part of this function is metabolism and 
removal of xenobiotics – foreign chemical substances like drugs. There are at least a dozen different cell 
types present in the liver of which hepatocytes account for about 60% of the total cell number and 80% 
of the volume. Other prevalent cells are sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells 
and biliary epithelial cells (Arias, 2009; Malarkey, Johnson, Ryan, Boorman, & Maronpot, 2005; S. P. S. 
Monga & Cagle, 2010). 
Most nutrients enter our body through our intestine and are delivered to the liver by the portal vein. 
Oxygen rich blood is supplied to the liver by the hepatic artery. In combination with the biliary duct, 
these blood vessels form the so called portal triad. The three vessels of the portal triad form a unit and 
branch into smaller vessels interfusing the liver. Blood leaves the liver through the central vein which 
forms from fusion of smaller vessels which interfuse the liver. The functional unit of the liver is the liver 
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lobule. Lobules are defined by final branches of the central vein surrounded by final branches of the 
portal triad with a distance of about 10 hepatocytes from central vein to portal triad in a mouse liver. 
The hepatocytes are arranged in cell plates which are interfused by sinusoids and biliary ducts. Sinusoids 
are tiny, fenestrated blood vessels connecting the central veins and the portal triads. The lobules are 
arranged as repeated units throughout the liver. Blood flows along the porto-central axis from the portal 
triad to the central vein while bile, which is secreted from the liver into the biliary ducts, flows into the 
opposing direction and leaves the liver through the bile duct. The oxygen rich blood supplied by the 
hepatic artery leads to an oxygen gradient with a higher oxygen pressure close to the portal triad. Within 
each lobule the hepatocytes are equipped with different enzymes depending on their position along the 
porto-central axis. Therefore, three functional or metabolic zones can be defined which provide different 
metabolic competences. The periportal zone contains the hepatocytes surrounding the portal triad, the 
pericentral zone the ones surrounding the central vein whereas the midlobular zone is located in 
between (Arias, 2009; S. P. S. Monga & Cagle, 2010; Ruijter, Gieling, Markman, Hagoort, & Lamers, 
2004).   
 
 
FIGURE 1 STRUCTURE AND FUNCTIONS OF THE ZONATED LIVER LOBULE. 
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a) Overview of a liver lobule as three-dimensional draft. Lobules are defined by a branch of the central 
vein in the middle and branches of the portal triad at the edges connected by liver plates. b) Detail of a 
liver cell plate: A branch of the portal triad on the periportal side and a branch of the central vein on the 
pericentral side connected by sinusoidal blood vessels and biliary ducts interfusing the hepatocytes. Blood 
flow and bile flow are indicated, blood flows from the portal triad through the lobule to the central vein. 
c) Zonal functions: Hepatocytes provide different metabolic competences depending on their position 
along the porto-central axis. Three zones can be defined, the periportal zone (zone 1), the midlobular 
zone (zone 2) and the pericentral zone (zone 3). Zonation of some metabolic competences is indicated. 
Besides several zonated enzymes for energy and ammonia metabolism there are also several drug 
metabolizing enzymes underlying zonation. Taken from Sabine Colnot and Christine Perret, (S. P. S. 
Monga & Cagle, 2010). 
 
Removal of xenobiotics is one of the important functions of the liver and is performed by hepatocytes 
expressing drug metabolizing enzymes. There is a repertoire of nuclear receptors like CAR (constitutive 
androstane receptor) which serve as xenobiotic sensors and are activated by presence of certain 
xenobiotic substances. They induce transcription of defined sets of drug metabolizing enzymes. These 
enzymes are functionally grouped in phase I, II and III drug metabolizing enzymes. Phase I enzymes 
perform modifications by introducing reactive or polar groups into their substrates, many phase I 
enzymes are oxygenases including the prominent cytochrome P450 family of monooxygenases. Phase II 
enzymes perform conjugations. Thereby they increase the molecular weight of their substrates leading 
to decreased activity and increased solubility and they support transport and excretion of the 
xenobiotics. Phase III enzymes are transporters which excrete the conjugated xenobiotics (Arias, 2009; 
Dufour & Clavien, 2009; R Gebhardt, 1992; Malarkey et al., 2005; S. P. S. Monga & Cagle, 2010; Ruijter et 
al., 2004). 
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2.3 Antibody based protein detection 
Cellular signaling is a complex spatiotemporal process influenced by many factors. This complexity 
demands for analysis of many proteins and protein modifications to uncover their interplay.  
Cells or tissues commonly analyzed in life science research contain a complex mixture of biomolecules 
including a large number of different proteins. Some proteins are highly abundant others are rare and 
concentration differences are ranging over several orders of magnitude. Most proteins contain post-
translational modifications which can be indicative of cellular signaling events. Antibodies proved to be 
versatile tools for detection of proteins in complex mixtures (N. L. Anderson, 2002; Hagen, 2011; Wild, 
2013). 
Utilizing the capabilities of the immune system provides life science research with the possibility to 
generate antibodies against a broad range of molecular structures. The highly specific binding of anti-
bodies to their antigen makes them invaluable tools for research and diagnostics. Selective antibodies 
able to recognize protein variants that carry defined posttranslational modifications are available and are 
used for analyzing cellular signaling processes. A large number of companies have commercialized 
antibody production and today there are thousands of antibodies available (Baker, 2015; Taussig et al., 
2007). An ambitious project is the human protein atlas aiming to generate antibodies against all human 
proteins – the human proteome (M. Uhlen et al., 2015; Mathias Uhlen et al., 2010). Versatile methods 
and technologies have been developed for life science research and diagnostics which use antibodies as 
detection reagents.  
The Western-Blot is a protein detection method developed by Towbin et al. and was first published in 
1979 (Towbin, Staehelin, & Gordon, 1979). Proteins are separated by gel electrophoresis and blotted 
onto a membrane. Specific antibodies are employed to detect proteins which are visualized by a labelled 
secondary antibody that specifically binds to the first one. In the resulting images, the specific signal 
shows a band at the molecular weight of the protein the antibody detected. Due to its simplicity and to 
the highly informative results this approach is still a gold standard and routinely used in most laborato-
ries working on protein based life science research. In the last 35 years, Western-Blot readout has 
evolved resulting in highly sensitive readout platforms based on chemiluminescence or fluorescence. As 
the Western-Blot became a standard method, the majority of commercially available antibodies are 
suitable for Western-Blot. 
Disadvantages of the Western-Blot are the fact that it is designed for detection of one protein and that 
there are limitations in the number of samples that can be analyzed. Different strategies have been 
developed to overcome these limitations. Some readout platforms allow analysis of two or three prote-
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ins on the same blot, for analysis of more proteins it is necessary to process several blots which is time 
consuming and also multiplies the amount of sample needed.  
Antibodies are often not completely selective for one protein but also bind other proteins containing 
similar epitopes (Baker, 2015; Michaud et al., 2003) or show background signal. The information of the 
molecular weight provided by the Western-Blot proved to be especially valuable as it allows 
discrimination of specific and unspecific signals. 
The evolution of life science research demands methods that are capable of handling more samples and 
that provide the possibility to detect more analytes to cope with the complexity of cellular signaling. 
Therefore, protein microarray platforms have been developed which employ the principles of 
miniaturization and parallelization of the analysis. Miniaturization results in lower consumption of 
samples and detection reagents which is especially important for limiting amounts of samples and 
parallelization results in higher throughput for samples and analytes (Korf, 2011; Templin et al., 2002).  
Directly addressing the limitations of the Western-Blot, reverse phase protein microarrays (RPPMs) were 
developed which are based on a dot blot. In this approach the proteins are not separated by gel electro-
phoresis but the samples are directly immobilized on a membrane or another hydrophobic carrier 
resulting in so called planar arrays. The molecular weight resolution is sacrificed for higher throughput. 
Employment of spotting robots allows highly reproducible immobilization of very small sample amounts. 
This gives the opportunity to print many samples, up to several hundred, onto an area of a few square 
centimeters. The sample spots are arranged in an array and it is possible to print hundreds of these 
arrays (Kambhampati, 2006). For example the contactless printers used for the ZeptoSens platform use 
only 0.5 nl sample per spot and the resulting spots have a diameter of about 100 µm allowing to print 
hundreds of arrays from microliters of samples (Voshol, Ehrat, Traenkle, Bertrand, & van Oostrum, 
2009).  
This approach substantially increases sample and analyte throughput compared to a Western-Blot. Yet it 
demands advanced and expensive equipment and requires a complex workflow which is a general dis-
advantage of microarray platforms that employ planar arrays. RPPMs mainly use Western-Blot anti-
bodies and a disadvantage of RPPM data is that the signal obtained on a sample is represented by a spot 
without molecular weight resolution which does not allow discrimination of specific and unspecific 
signal.  
Other protein microarray variants are based on binding molecules, usually antibodies, immobilized on a 
surface. These binders can capture proteins from a complex sample followed by washing and removal of 
the remainder of the sample. For detection, the proteins in the samples can be labelled in a direct 
labelling approach or a detection antibody targeting another epitope on the same protein than the 
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binder can be employed. This sandwich assembly employing two antibodies improves specificity for the 
target protein but for analysis of several proteins there is a limitation in the number of detection 
antibodies which can be employed per array. Therefore, these microarrays allow high throughput in 
respect to the number of samples but are limited in the number of analytes. This qualifies them for 
diagnostic approaches but often makes their use in research applications difficult (Kambhampati, 2006). 
For microarrays, the binders can be immobilized on planar carriers as used for RPPM. Another possibility 
is to use microspheres, often called beads, for immobilization. There are several bead-based microarray 
platforms available. Luminex as a commercially important technology employs beads in micrometer 
scale which provide carboxyl groups for covalent immobilization. The microspheres contain up to three 
internal fluorescent dyes in different concentrations which are used as a color code for bead 
identification and classification. Thereby the instrument can distinguish up to 500 different bead sets. 
This platform can be used for different kinds of bio-assays. The distinguishable bead sets can be loaded 
with different binders, mixed and used for measuring several parameters in multiplex. Readout employs 
the principle of flow cytometry. The beads are soaked through a needle and pass the laser based 
detection system which performs the classification of the bead sets by detecting the internal dyes and 
quantification of the assay signal which is based on a reporter fluorescent dye. The resulting data 
represent the median fluorescence intensities (MFIs) for the reporter dye on each bead sets in each well 
(Korf, 2011; Wild, 2013).  
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2.4 Aim of this work 
The complexity of cellular signaling demands for comprehensive analyses. Western-Blot has proved to be 
a valuable tool for detection of proteins and protein modifications involved in cellular signaling and is 
probably the most wide spread method for semi-quantitative protein detection. The vast number of 
commercially available antibodies for Western-Blot analysis underlines the importance of this method.  
The major limitation of the Western-Blot is the fact that only one or very few proteins can be analyzed 
by this approach. Methods like reverse phase protein microarrays address this limitation and allow 
analysis of more samples and more analytes but they do sacrifice data quality. It is the separation of 
proteins by gel electrophoresis and the resulting molecular weight information that proved to be an 
important advantage of Western-Blot. Discrimination of specific and unspecific signal results in more 
reliable data.   
Aim of this work was development of a method that bridges the gap between Western-Blot and reverse 
phase protein microarrays. The method should be based on a Western-Blot and allow generation of 
many copies or replicas of the blot. This would give the possibility to analyze many more proteins than 
from a single Western-Blot without losing the molecular weight separation.  
For analysis of cellular signaling it is helpful to examine tissue samples as the complex signaling and 
communication between cells depends on their environment and the natural environment of a cell is the 
associated tissue. But tissues usually contain different types of cells and the behavior of a cell also 
depends on its position and environment within the tissue. For example hepatocytes in the liver express 
different enzymes and fulfill different metabolic functions depending on their position within a liver 
lobule. Laser capture microdissection is a method which allows isolation of small areas or even single 
cells from tissue sections but results in very limited amounts of samples. With an approach that allows 
analysis of proteins and posttranslational modifications in these cells, novel information on cellular 
signaling within the different functional zones of liver lobules might be obtained. Isolation of 
hepatocytes from different functional zones within liver lobules is elaborate but possible. It is worth the 
effort when a comprehensive analysis can be performed on the limited number of cells. These samples 
would hardly be sufficient for a single Western-Blot but having a method that creates many replicas from 
a Western-Blot could allow a comprehensive analysis. 
Therefore, a method which creates many replicas of a Western-Blot might be a valuable tool for protein 
detection and bring the Western-Blot towards a proteomic tool allowing systems biology approaches. 
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3 Results 
3.1 The DigiWest project 
Is it possible to generate copies of Western-Blots? It started with an idea. Markus came up with the idea 
of transferring a Western-Blot onto the Luminex platform. That meant generating molecular weight size-
fractions by cutting a Western-Blot membrane into defined pieces and coupling of the proteins 
contained in the resulting membrane-snippets onto Luminex beads. As the Luminex platform uses color-
coded beads, the molecular weight information could be retained in the up to 500 distinct bead sets 
which could then be pooled into a bead-mix containing the whole Western-Blot.  
The beads generated from one Western-Blot lane should be sufficient for dozens or even several 
hundred antibody incubations. The signal obtained from each antibody on the different molecular-
weight fractions could be used to digitally reconstruct the initial Western-Blot lanes. Good antibodies 
should show stable and low background signal for most fractions and a peak composed of few fractions 
representing the Western-Blot band at the corresponding molecular weight. The digital nature of 
Luminex data could be used to easily quantify these peaks. We named this method ‘DigiWest’ because it 
represents digital reconstructions of Western-Blots. 
 
Approaching this idea, the workflow should be composed of the following steps: 
a) Separation of proteins by molecular weight, that means a classical SDS-PAGE. 
b) Blotting the proteins onto a Western-Blot membrane. 
c) Cutting the membrane into defined pieces, each containing the separated proteins of a certain 
molecular weight range followed by elution of the proteins from the generated molecular weight 
fractions. 
d) Coupling of the proteins from each molecular weight fraction onto distinct, color coded Luminex 
bead sets. 
e) Pooling of the Luminex bead sets into a bead-mix retaining the size fraction information in the 
color code. 
f) Incubation of aliquots of the pooled bead-mixes using standard Western-Blot antibodies 
followed by fluorescent secondary antibodies for Luminex readout. 
g) Analysis of the Luminex signals obtained from the different bead sets representing the molecular 
weight fractions and graphical representation of the generated data. 
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FIGURE 2 WORKFLOW OF THE DIGIWEST METHOD 
Proposed workflow of the DigiWest method, steps a) to g) as described on the previous page.  
 
Transfer of the Western-Blot to a Luminex bead-mix would allow easy handling as it could be handled 
like a liquid or in case of magnetic Luminex beads appropriate equipment could be employed. Antibody 
incubations could be performed in microtiter plates with quick and automatable washing steps followed 
by fast and automated readout on a Luminex machine. 
 
3.2 Technical considerations 
3.2.1 Sensitivity and comparison with existing Western-Blot readout platforms 
Readout of a Western-Blot is usually based on chemiluminescence or fluorescence. For chemilumi-
nescence as readout, horseradish peroxidase-labelled (HRP) secondary antibodies are commonly used. 
HRP catalyzes the oxidation of luminol to 3-aminophtalate using hydrogen peroxide as oxidizing reagent. 
This reaction causes emission of photons. The photons can be detected by high-end CCD cameras over 
long periods of time (up to several hours) as long as no substrate depletion occurs and unspecific 
background signal does not emerge. This makes chemiluminescent readout a very sensitive technology. 
Alternatively, fluorescence based labels are used which provide a wider linear range of the obtained 
signals. Sensitive confocal laser scanners are available for readout. The infrared fluorescence based Licor 
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Odyssey platform has a similar sensitivity than chemiluminescent readout. (Durrant, 1994; Mathews, 
Plaisance, & Kim, 2009; Thorpe, Kricka, Moseley, & Whitehead, 1985) 
One big concern at the beginning of the project was whether Luminex readout is capable of competing 
with these highly sensitive readout systems. Chemiluminescence based readout can be exposed for 
prolonged times to increase signal and fluorescence based systems can use increased laser power to gain 
the same effect. As Luminex is a flow based readout system there is no comparable possibility to further 
increase the signals. 
 
3.2.2 Protein transfer from membrane to beads 
The use of the standard protein coupling method for Luminex-beads – activation of the carboxyl-groups 
on the surface of the beads to NHS-esters followed by reaction of these NHS-esters with primary amine-
groups to form covalent amide-bonds – leads to a loading density that is directly dependent on protein 
concentration. Since a large number of fractions are generated, protein concentration was expected to 
be low and varying between the fractions, therefore this was seen as a principle problem. In addition, 
the quick hydrolysis of the activated ester was seen to be critical. This hydrolysis prevents the 
quantitative coupling of all protein-molecules contained in the solution onto the NHS-activated beads 
using prolonged reaction times. The half-life of NHS-esters in aqueous solutions is in a range from 10 
minutes to 5 hours dependent on pH and temperature (Hermanson, 2008).  Therefore another coupling 
strategy was chosen.  
Streptavidin is a protein originally purified from the bacterium Streptomyces avidinii. It is a homo-tetra-
mer containing a biotin binding site in each subunit. The interaction of biotin and streptavidin is one of 
the strongest non-covalent interactions known. It has a Kd of about 10
-15 mol/L. The valeric acid 
substituent of biotin makes it ideal for attaching it covalently to e.g. proteins, a process called 
biotinylation. Due to these advantages the streptavidin biotin interaction is routinely used in molecular 
biology approaches (Hermanson, 2008).  
There is a huge variety of commercially available biotinylation reagents. Due to the availability and good 
accessibility in proteins, amino-reactive biotinylation reagents were chosen. These kinds of reagents are 
usually composed of biotin followed by a spacer, which defines the distance of the biotin from the bio-
tinylated protein, the solubility of the reagent and the flexibility, followed by an amine-reactive NHS-
ester (Dundas, Demonte, & Park, 2013; Häfeli, Schütt, Teller, & Zborowski, 1997; Hermanson, 2008). 
The coupling strategy chosen for method development was biotinylation of the proteins and loading 
onto streptavidin coated beads.  
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3.3 Method development 
The proposed workflow of the method is suggested in section 3.1. All steps of the workflow contribute to 
the final results and none of them could be neglected. Method development started with best-guess 
conditions followed by optimization of each part of the workflow. Several rounds of re-optimization 
were necessary for each step till the finally optimized conditions were defined. An important aspect for 
decisions throughout the method development process was applicability in a routine workflow as the 
final workflow needed to be robust and reproducible. 
The following section does not represent the whole method development which included more than 
hundred experiments but an overview containing some crucial examples of experiments for each step. 
 
3.3.1 Western-Blotting 
Western-Blotting is a standard method and each laboratory has its established procedure. In our group, 
the commercial NuPAGE system (Life Technologies) is used. Optimized conditions for gel electrophoresis 
and blotting onto membranes were already established. These conditions were used as basis for method 
development.  
 
3.3.2 Protein biotinylation 
The idea of the DigiWest method is to transfer proteins from a Western-Blot onto Luminex beads. The 
strategy chosen to achieve efficient loading of the proteins onto the beads was biotinylation of the 
proteins and loading onto streptavidin coated beads. Therefore, protein biotinylation was the first step 
of the workflow that had to be optimized. Typical samples used for Western-Blotting are cell or tissue 
lysates. Besides proteins they contain many ‘contaminants’ which might interfere with the biotinylation 
reaction including the routinely used Tris-based lysis buffers. Excess biotinylation reagent needs to be 
removed after biotinylation as it competes with the biotinylated proteins for binding sites on the strept-
avidin coated beads.  
Biotinylation of proteins immobilized on the membrane after blotting seemed to be straight forward as 
membranes can easily be handled and excess biotinylation reagent can be washed off. It also allows 
removal of all the buffer substances and other interfering substances from the sample preparations 
which could disturb the biotinylation reaction. This allows flexibility in respect to selection of samples 
and lysis buffers and also in respect to running and blotting buffers and prevents loss of proteins during 
the washing steps. 
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After blotting, membranes were washed excessively in PBST to remove the Tris-based transfer buffer 
and other molecules which could interfere with the biotinylation reaction. PVDF and nitrocellulose 
membranes bind proteins and other molecules mainly through hydrophobic interactions. When 
performing classical Western-Blots, membranes are blocked using an excess amount of protein, usually 
BSA or milk powder, to saturate membranes with protein after blotting. For biotinylation, this blocking 
step had to be omitted. Only the detergent Tween-20 present in PBST is used for partial blocking of the 
membranes. This blocking effect proved to be sufficient to prevent biotinylation reagent from binding to 
the membranes.  
In the initial experiments NHS-LC-LC-Biotin was used as biotinylation reagent which provides an effective 
spacer length of 30.5 Å. Later and in the final workflow, NHS-PEG12-Biotin is used which provides a 
spacer length of 56 Å. The PEG-structure of the spacer is also contained in Tween-20 which might 
contribute to the observation that no excess biotinylation reagent was bound to the membrane after 
washing. 
Different biotinylation conditions and concentrations were evaluated. The following experiment is taken 
from investigation of the effect of different concentrations of biotinylation reagent. A lysate of the 
mouse hepatoma cell line 55.1c was used as sample. 4 Lanes of a gel were loaded, each with 40 µg 
protein. After electrophoresis and blotting, a 12 mm high and 2 mm wide piece was cut from each lane 
covering the molecular weight range from about 48 kDa to 28 kDa. These pieces were biotinylated using 
NHS-LC-LC-Biotin. The excess of biotinylation reagent relative to the amount of protein was based on an 
estimation of the number of proteins bound on the membrane pieces which was assumed to be about 
0.2 nmol. An excess of biotinylation reagent of factor 5, 50, 200 and 500 was used for biotinylation in a 
constant volume of 350 µl PBST. After biotinylation and washing, the membrane pieces were each cut 
into 24 molecular weight fractions with a height of 0.5 mm each. Proteins were eluted and loaded onto 
streptavidin coated Luminex bead-sets. After loading, the beads were pooled into bead-mixes and used 
for a Luminex assay applying a selection of Western-Blot antibodies. Primary antibodies were incubated 
overnight followed by PE-labelled secondary antibody incubation for 1 hour and read-out on a Luminex 
100. The data are represented as diagrams (Fig. 3) showing the signal obtained on the 24 molecular 
weight size fractions.  
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FIGURE 3 EFFECT OF THE EXCESS OF BIOTINYLATION REAGENT ON ASSAY SIGNAL 
55.1c cell lysate was subjected to SDS-PAGE and protein fractions were generated. The eluates 01 to 24 
represent 24 molecular weight fractions covering the range from about 48 to 28 kDa. Biotinylation 
reagent was used in a 5-, 50-, 200- and 500-fold excess relative to the estimated number of proteins. 
Shown are the results from PKA C alpha (42 kDa) and eIF2 (38 kDa) specific antibodies. Data are shown as 
diagrams representing the MFI values obtained on each of the 24 molecular weight size fractions for each 
concentration of biotinylation reagent. The 50-fold excess of biotinylation reagent resulted in the highest 
signals for the two antibodies shown here. The same effect was observed for the other antibodies used in 
this assay. 
 
The results of this experiment show that there is an optimum in the amount of used biotinylation 
reagent. The signals obtained in the Luminex assay were the highest using a 50-fold excess of 
biotinylation reagent.   
As mentioned before, there are different biotinylation reagents available. The NHS-PEG12-Biotin has an 
increased spacer length when compared to the NHS-LC-LC-Biotin or the even shorter NHS-LC-Biotin. The 
following experiment compares the long PEG12- to the short LC-spacer containing biotinylation reagent. 
A 55.1c cell lysate was used as sample and, after electrophoresis and blotting, 12 mm high membrane 
pieces were cut covering the molecular weight range from about 48 to 28 kDa. Both biotinylation 
reagents were used in a 50-fold excess relative to the estimated number of proteins. The membrane 
pieces were cut into 24 molecular weight fractions, eluted and loaded onto streptavidin coated Luminex 
beads. The resulting bead-mixes were used to perform an assay employing a selection of Western-Blot 
antibodies. 
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FIGURE 4 COMPARISON OF TWO BIOTINYLATION REAGENTS 
55.1c cell lysate was subjected to SDS-PAGE and protein fractions were generated. The eluates 01 to 24 
represent 24 molecular weight fractions covering the range from about 48 to 28 kDa. Biotinylation 
reagents were used in a 50-fold excess relative to the estimated number of proteins. Shown are the data 
obtained from ERK1/2 (42/44 kDa) and PKA C α/β phospho (42 kDa) specific antibodies. Data are 
represented as diagrams with the MFI values obtained on the 24 molecular weight fractions for each 
biotinylation reagent. The longer PEG-12 spacer results in slightly better signals compared to the shorter 
LC-spacer. The same effect was observed for the other antibodies used in this assay. 
 
The NHS-PEG12-Biotin with the longer spacer results in slightly better signals compared to the 
biotinylation reagent with the shorter spacer. Although the spacer length seems to have only minor 
effects in the experiment shown here the NHS-PEG12-Biotin was chosen for the final workflow 
conditions. The NHS-PEG12-Biotin has an additional property which is often seen as disadvantage but for 
workflow optimization it was seen as advantage. This biotinylation reagent comes as a wax-like 
substance which needs to be dissolved in an organic solvent while the LC-spacer based reagents come as 
powders which are completely water soluble. As NHS-esters hydrolyze in aqueous solutions the reagents 
cannot be stored in a dissolved state. The PEG12-spacer based reagent was dissolved in DMSO and 
stored at -20°C in aliquots. Using these aliquots helped achieving reproducible biotinylation.  
For the final workflow, the excess of biotinylation reagent was translated into a defined concentration 
and the blots are biotinylated as a whole. 
 
3.3.3 Cutting membranes 
During most time of method development, membranes were cut using ruler and scalpel. Single lanes 
were processed and cut into a smaller number of molecular weight fractions representing a selection of 
the Western-Blot lane. An important milestone during method development was size reduction of the 
molecular weight fractions. Smaller fractions not only improved the resolution of the data but also lead 
to an increase in sensitivity and to a reduced background. This observation might be due to the fact that 
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an increase in fraction numbers and the corresponding reduction of the fraction size result in relative 
enrichment for a given protein within a size fraction and also the unspecific background signal is lowered 
by distribution over several fractions. The binding surface of the Luminex beads is limited. An increased 
number of fractions might also contribute to more robust results by increase of the overall binding 
capacity.  
The following experiment directly compares a resolution of 1 mm per molecular weight fraction to a 
resolution of 0.5 mm. The sample used for this experiment was the mouse hepatoma cell line 55.1c. The 
molecular weight range used was about 48 to 28 kDa. The membrane pieces were either cut into 12 
molecular weight fractions with a height of 1 mm or 24 fractions with a height of 0.5 mm. In this 
experiment NeutrAvidin coated Luminex beads were used. 
 
 
FIGURE 5 EFFECT OF RESOLUTION 
55.1c cell lysate was subjected to SDS-PAGE and protein fractions were generated. The eluates 01 to 24 
represent 24 molecular weight fractions covering the range from about 48 to 28 kDa. This experiment 
shows a direct comparison of a resolution of 1 mm and 0.5 mm. Shown are two analytes from the 
Luminex assay. The higher resolution results in higher data quality and more peak-like structures. The 
decrease in background which can be seen here might be due to distribution of the unspecific signal over 
more fractions.  
 
The resolution has an obvious effect on data quality. The resulting data show more peak-like structures 
and the background signal is reduced for the higher resolution.  
A whole lane representing the molecular weight range from more than 400 kDa to about 10 kDa from a 
Western-Blot based on the mini gel format results in 96 molecular weight fractions when a resolution of 
0.5 mm is used. As 96 well plates or 384 well plates are standard formats for laboratory equipment, this 
resolution was chosen. A higher resolution would demand for more bead sets while the Luminex 
platform is limited to 500 bead sets.  
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In the final workflow, 384 bead sets are used allowing 4 samples with 96 fractions each to be pooled into 
one DigiWest bead-mix. As cutting these fractions manually is time consuming and error prone, a cutting 
plotter was employed. The plotter cuts the lanes to a comb like structure and the 0.5 mm molecular 
weight fractions are sorted into 96 well plates using a forceps.  
 
3.3.4 Protein elution from membranes 
There are several published protocols for efficient protein elution from Western-Blot membranes. Most 
of them were developed for mass spectrometry applications and many of them claim to be able to elute 
the membrane bound proteins quantitatively applying very different approaches. Some methods employ 
organic solvents. One interesting approach tested is to use nitrocellulose membranes and dissolve the 
membrane snippets containing the molecular weight fractions in acetone (e.g. (P. J. Anderson, 1985)). 
The dissolved nitrocellulose can be precipitated by adding an aqueous buffer. When a buffer containing 
carrier protein, e.g. 10 mg/ml BSA, was added, this method worked nicely. But the acetone is not ideal 
for polystyrene-based Luminex beads and could therefore not be used for workflow development. Other 
methods described in literature use detergents, usually in alkaline buffers or even in a moderate sodium 
hydroxide solution (e.g. (Jørgensen et al., 2004)). Several of these recipes were tested using Triton X-100, 
Tween-20, SDS or mixtures of detergents.  
An experiment comparing different elution buffers is shown in detail. As the protein elution efficacy from 
nitrocellulose and PVDF membranes might differ, both membranes were used. The sample was a mouse 
whole liver lysate. 2D well gels were used which provide one lane for a molecular weight marker and one 
6 cm wide lane which was used to separate 400 µg of mouse liver lysate. One gel was blotted onto a 
PVDF membrane and one onto a nitrocellulose membrane. Areas surrounding the position of glutamine 
synthetase (42 kDa) were cut from each membrane, each 4.5 mm high and 10 mm wide. After 
biotinylation, these areas were cut into 3 molecular weight fractions each 1.5 mm high and 10 mm wide. 
These stripes were cut into 5 snippets each 2 mm wide for elution under 5 different conditions.  The 
buffer used for preparation of the elution buffers was 100 mM Tris-HCl with a pH of 9.5. The composition 
of the elution buffers used in this experiment was as follows: 
‘Detergent-Mix’   0.4% PVP 10000, 0.4% PVP 40000, 0.7% Triton X100 and 0.5% Tween-20 
‘Detergent-Mix Urea’  same as ‘Detergent-Mix’ with additional 4 M Urea 
‘1% Triton 8 M Urea’  1% Triton X100 and 8 M Urea 
‘1% Triton 4 M Urea’  1% Triton X100 and 4 M Urea 
‘1% Triton’   1% Triton 
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For each elution buffer there are 3 molecular weight fractions for each membrane type resulting in 30 
eluates. Elution was performed in a volume of 50 µl for 2 hours at 70°C with heavy shaking (1200 rpm). 
Eluates were diluted 1:5 in PBS and used for loading onto streptavidin coated Luminex beads. An assay 
was performed applying a selection of antibodies. 
 
 
FIGURE 6 COMPARISON OF DIFFERENT ELUTION BUFFERS 
Mouse liver proteins were separated by SDS-PAGE in 6 cm wide lanes. One gel was blotted onto a 
nitrocellulose membrane and one onto a PVDF membrane. Areas with a height of 4.5 mm and 10 mm 
wide were cut from the membranes at the molecular weight around 42 kDa. After biotinylation, the 
membrane pieces were cut into 1.5 mm high stripes (molecular weight fractions) and each stripe was cut 
into 5 pieces each 2 mm wide. The resulting 5 replicates of the 3 molecular weight fractions (upper, 
middle, lower fraction) for each membrane were used for elution with 5 different elution buffers. 
The eluates were loaded onto streptavidin coated beads and used to perform an assay with a selection of 
antibodies. 
 
The differences in the pattern seen for glutamine synthetase between the membranes might be based 
on slightly different cutting positions. From this selection of elution buffers in this experiment, the 
‘Detergent-Mix’ seems to be the best buffer for elution from nitrocellulose membrane while for PVDF 
membrane the ‘1% Triton 8 M Urea’ buffer performed best. For the ERK1/2 antibody the patterns on the 
3 molecular weight fractions are more distinct on the PVDF membrane than on the nitrocellulose 
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membrane. This could also be based on the cutting positions of the fractions and the fact that 1.5 mm 
molecular weight fractions were used which do not provide a good resolution.   
This is just one out of many experiments performed for optimization of protein elution conditions from 
membranes. As cutting of the membrane pieces into 1.5x2 mm snippets by hand is not so precise there 
might also be a bias from the cutting procedure in this experiment.  
The best working method which made it into the final workflow is 1% Triton X-100 and 8 M urea in an 
alkaline buffer, Tris-HCl at pH 9.5 as also described by (Jørgensen et al., 2004). The combination of urea 
and Triton changes their behavior. Urea or Triton alone is way less effective. This effect is also described  
(Jørgensen et al., 2004). Besides the better performance on PVDF membranes, this elution buffer is so 
harsh that it partially degrades nitrocellulose membranes. Therefore it was decided to use PVDF 
membranes in the final workflow which are chemically more stable.  
Elution in the urea-Triton based elution buffer and most of the other methods were tested under differ-
ent conditions. Elution for 90 minutes with heavy shaking at room temperature resulted in reproducible 
protein recovery. A helpful property of the elution buffer is that the PVDF membrane snippets turn 
transparent and thereby almost invisible in this buffer. After dilution of the elution buffer, they turn 
white again. 
 
3.3.5 Loading proteins onto Luminex beads 
For immobilization of the biotinylated proteins, beads were coated with either streptavidin or Neutr-
Avidin. NeutrAvidin (pI 6.3) has a more neutral isoelectric point than streptavidin (pI 4.6). It is a deglyco-
sylated avidin which has a similar affinity for biotin (Kd 10
-15 M) compared to streptavidin and can be 
used interchangeably. In one phase of method development, NeutrAvidin and streptavidin coated beads 
were used in parallel and loaded with biotinylated proteins in multiplex. NeutrAvidin showed a better 
overall performance for this application which might be due to the more neutral isoelectric point. The 
difference between the two biotin binding proteins varied for different analytes. The isoelectric point of 
NeutrAvidin rendered it more universal and therefore NeutrAvidin was chosen for the final workflow.  
As urea is a strong denaturing reagent and even the very stable NeutrAvidin and streptavidin cannot 
tolerate 8 M urea, the elution buffer had to be diluted after elution of the proteins. During method 
development, eluted proteins were usually transferred to new vials and diluted in PBS. In the final 
workflow, where elution is performed in 96 well plates, the membrane snippets remain in the plate 
while the proteins are being loaded onto the Luminex beads. The dilution buffer in the final workflow is 
PBST containing BSA which meant to block the membrane snippets and prevent rebinding of the 
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biotinylated proteins. Loading of the eluted biotinylated proteins onto streptavidin or NeutrAvidin 
coated beads was usually performed overnight at 4°C or later at room temperature with gentile shaking.  
To avoid aggregation of the beads, they were blocked with an excess of biotin after being loaded with 
biotinylated proteins. Deactivated biotinylation reagent in a Tris-buffer or a biotinylated peptide was 
used to occupy the remaining biotin binding sites on the Luminex beads. The peptide moiety was used to 
measure remaining free biotin binding sites on the beads after protein loading by incubation with a 
peptide specific antibody. All bead sets were able to bind peptide showing that the beads were not 
completely saturated with biotinylated protein. The blocking step might not be required as the beads did 
not tend to aggregate during the overnight loading procedure. On the other hand most proteins contain 
more than one biotin after biotinylation and there are free biotins detectable on the surface of the 
beads. This can be exploited to perform an on-bead protein loading control by simply incubating the 
beads with PE-labelled streptavidin which will be discussed in detail later.  
The following experiment compares the performance of streptavidin and NeutrAvidin coated Luminex 
beads directly. In this experiment a lysate from the mouse hepatoma cell line 55.1c was used and 400 µg 
lysate were separated on a 2D well gel in a 6 cm wide lane. An area with a height of 12 mm and 4 mm 
wide was cut from the membrane covering the molecular weight range from about 48 to 28 kDa. After 
biotinylation, the stripe was cut into 24 molecular weight fractions with a height of 0.5 mm each. The 
resulting 24 protein eluates were used to simultaneously load streptavidin and NeutrAvidin coated 
Luminex beads in multiplex. An assay was performed with the resulting bead-mixes applying a selection 
of antibodies. 
 
 
FIGURE 7 COMPARISON OF STREPTAVIDIN AND NEUTRAVIDIN COATED LUMINEX BEADS 
Lysate from 55.1c cell line was separated by SDS-PAGE and blotted. An area covering the molecular 
weight from about 48 to 28 kDa was used for biotinylation and cut into 24 molecular weight fractions. 
Proteins were loaded onto streptavidin and NeutrAvidin coated Luminex beads in multiplex. The resulting 
bead-mixes were used to perform assays. The NeutrAvidin coated beads show a slightly better perfor-
mance.  
Method development Results 
25 
As NeutrAvidin coated Luminex beads showed a slightly better overall performance in all experiments 
where both kinds of beads were used, the NeutrAvidin coated beads were chosen for the final workflow.  
 
3.3.6 Luminex bead preparation 
In the experiments described so far, 12 bead-sets of MicroPlex Luminex beads were used and the 24 
fractions shown in most experiments were distributed on 2 bead-mixes. The magnetic MagPlex Luminex 
beads provide additional options for bead handling. Therefore, it was decided to integrate these into the 
final workflow. 
The Luminex beads for the final workflow were MagPlex beads coated with NeutrAvidin in a modified 
procedure employing a KingFisher magnetic particle processor which allows parallel coupling of 96 bead 
sets in 96 well plates. 400 bead sets were coated with NeutrAvidin and used to arrange 384 bead sets 
into 4 times 96 sets. The coupling procedure is the same than for manual bead coupling except for the 
fact that the beads are transferred sequentially to new plates containing the next reagent or washing 
buffer instead of removing the buffer or reagent from the vials. Due to the stickiness of the KingFisher 
consumables, all buffers were supplemented with Triton X-100. Beads were washed in activation buffer 
and the carboxyl groups were activated to sNHS-esters using EDC and sNHS. After washing in coupling 
buffer they were coated with NeutrAvidin in coupling buffer. Followed by blocking in a BSA containing 
buffer and washing they were transferred back to vials and adjusted to a defined volume of 1 ml. After 
bead count on a Luminex FlexMap 3D, they were adjusted to a defined concentration. The biotin binding 
capacity, as determined using a biotinylated peptide and an antibody directed against this peptide, 
showed a CV of less than 3% for the 384 bead sets used for the main experiments in this thesis. The 
same was true for repeated coupling rounds. 
The Beads, for the final workflow 384 sets, were then arranged to 4 times 96 bead sets which were used 
to generate master plates and bead plates. The master plates contained a defined volume with a defined 
bead concentration. A pipetting robot equipped with a head for 96 pipetting tips was employed to 
generate bead plates containing a defined number of beads per well. These bead plates were vacuum 
sealed and stored at 4°C. For DigiWest experiments, the beads were transferred into the plates 
containing the biotinylated and eluted proteins using a 96-well magnet head from a KingFisher magnetic 
particle processor. The 4 different bead-plates were used to pool 4 samples, each represented by 96 
molecular weight fractions, into one bead-mix.  
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3.3.7 DigiWest assays: merging two worlds 
Although most immunoassays run on Luminex instruments employ ELISA-suitable antibodies and buffers 
based on ELISA buffers, DigiWest uses Western-Blot antibodies. As Western-Blot is a standard method in 
molecular biology, a vast number of Western-Blot qualified antibodies are available. Most of them are 
not suitable for ELISA. The DigiWest method successfully employs Western-Blot antibodies on the 
Luminex platform giving access to this huge repertoire. As we are also working with reverse-phase 
protein microarrays (RPPM) which do employ Western-Blot antibodies, a large repertoire of antibodies 
was available in the lab.  
In case of DigiWest, the Luminex beads are NeutrAvidin coated and loaded with biotinylated proteins. 
Each bead set represents a molecular weight fraction from the initial Western-Blot. These beads are 
incubated with the primary antibodies followed by species specific, PE-labelled secondary antibodies.  
Several buffers were tested during method development. The buffer with the best overall performance, 
in the following sections called ‘assays buffer’ is ‘Blocking Reagent for ELISA’ (Roche) supplemented with 
0.2% milk powder, so a hybrid of an ELISA buffer and a Western-Blot buffer. This is not too surprising as 
the method is a hybrid of a Western-Blot and a bead-based Luminex assay. 
 
The buffer has a major impact on the DigiWest results. As for every buffer used for immunoassays, it 
needs to stabilize the interaction of the antibody and the antigen but it also needs to prevent unspecific 
binding and reduce background. The following experiment compares a classical Western-Blot buffer – 1% 
BSA in TBST – with an ELISA buffer –Blocking Reagent for ELISA (Roche). A cell lysate of the human 
hepatocyte cell line HepG2 was used as sample. 24 molecular weight fractions were cut representing the 
molecular weight range from about 65 to 25 kDa. An assay was performed employing a selection of 
antibodies in each of the buffers.  
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FIGURE 8 COMPARISON OF A WESTERN-BLOT AND AN ELISA BUFFER FOR DIGIWEST 
In this assay the same bead-mixes loaded with proteins from a HepG2 cell lysate were incubated with 
antibodies either in 1% BSA in TBST or in Blocking Reagent for ELISA. Results from four antibodies are 
shown. In all four cases the ELISA buffer results in massively reduced background combined with reduced 
specific signal.  
 
Although the ELISA buffer results in reduced signals compared to the Western-Blot buffer, the decreased 
background still results in a better signal-noise ratio for the ELISA buffer. The other classical Western-
Blot buffer – 1% milk powder in TBST – resulted in almost complete loss of the background but also of 
the specific signal.  
Both, the specific signal and unspecific signal depend on the antibody which is applied. Although the 
ELISA buffer performed well for many antibodies, there were still some antibodies which showed a high 
unspecific signal. As mentioned, the milk powder based Western-Blot buffer had a massive blocking 
effect. When the Blocking Reagent for ELISA was supplemented with 0.2% milk powder, the blocking 
effect of the milk powder still resulted in decreased specific signal but also in a decrease of the unspecific 
signal and therefore it resulted in a better signal-noise ratio for antibodies which tended to high 
unspecific signals.  
The following experiment shows the effect of milk powder for an antibody which showed a massive 
background. In this experiment a lysate from a human cell line was used and the whole molecular weight 
range from about 420 to 14 kDa was used to generate a DigiWest bead-mix with 96 molecular weight 
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fractions. In this experiment the Blocking Reagent for ELISA was used with and without 0.25% milk 
powder supplemented. 
 
 
FIGURE 9 COMPARISON OF AN ELISA BUFFER WITH AND WITHOUT MILK POWDER 
The two antibodies selected for this figure are not representative. Shown is an antibody detecting p27 
which showed massive background in the DigiWest assay using the ELISA buffer. It is compared to incuba-
tion in the same ELISA buffer supplemented with 0.25% milk powder. Only few antibodies showed that 
strong effects when milk powder was supplemented. The second antibody shown is more representative. 
The milk powder results in a slightly reduced specific signal but also reduces the unspecific signal resulting 
in a better signal-noise ratio. 
 
For the final workflow, the Blocking Reagent for ELISA supplemented with 0.2% milk powder is used 
referred to as ‘assay buffer’ in the following sections.   
 
3.3.8 DigiWest assays in general 
DigiWest assays contain the following steps: Dilution of the antibodies in assay buffer. Usually a dilution 
of factor 5 less than recommended for Western-Blots and not more than 1 µg/ml is used. For example an 
antibody which is recommended to be diluted 1:1000 for Western-Blots is diluted 1:200. One big 
advantage of the DigiWest method is that it requires only 30 µl antibody dilution per well. 
An assay plate is filled with 50 µl per well assay buffer. An aliquot of the DigiWest bead-mix or if more 
than 4 samples are used the bead-mixes is added to the assay buffer. For readout on the Luminex 
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machine, 200 beads per set and well are sufficient for a good assay performance. So, if for example 
40000 beads are loaded from each molecular weight fraction, the resulting DigiWest bead-mixes are 
sufficient for 200 antibody incubations. After pre-incubation of the bead-mixes in assay buffer, the assay 
plates are placed on a 96-well magnet plate, the buffer is discarded and 30 µl per well of the antibody-
dilutions in assay buffer are added. They are incubated overnight on a cooled shaker.  
The next day the beads are washed twice with PBST on a magnet plate and PE-labelled secondary 
antibodies are added. They are usually diluted 1:200 in assay buffer. 30 µl are added per well and 
incubated for 1 hour at room temperature. The beads are washed twice with PBST and PBST is added for 
readout. The 96-well plate format gives the opportunity to incubate up to 96 different antibodies and 
therefore test 96 different analytes in 1 plate. Readout takes about 45 minutes to one hour per plate and  
has to be performed on the Luminex FlexMAP 3D as this is the biggest Luminex instrument and capable 
of handling 384 or more different bead sets, the other instruments have limitations in multiplexing. The 
Luminex instrument provides relative fluorescence intensities for each bead set and each well of the 
assay plate. The fluorescence intensities represent the median intensities (MFI) of all measured beads for 
each bead set in each well.  
 
 
 
3.3.9 Improvements during method development 
The following figure shows a comparison of an experiment which was performed in the middle of the 
method development process and a comparable experiment performed under final workflow conditions. 
For both experiments a lysate of the mouse hepatoma cell line 55.1c was used as sample. For the final 
workflow condition 20 µg protein was used, the earlier experiment used approximately 27 µg protein. 
The early experiment was presented before (see Fig. 7) for comparison of streptavidin and NeutrAvidin 
coated Luminex beads. The data were taken from the NeutrAvidin coated beads. In this experiment 24 
molecular weight fractions were used covering the molecular weight range from about 48 to 28 kDa with 
a fraction size of 0.5 mm. In the experiment performed under final workflow conditions, the whole 
molecular weight range was used covering the range from about 600 to 12 kDa represented by 96 
molecular weight fractions with a resolution of also 0.5 mm.  
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FIGURE 10 COMPARISON OF FINAL WORKFLOW CONDITIONS TO AN EARLIER EXPERIMENT 
Direct comparison of four antibody incubations from an experiment performed in the middle of the 
method development process and an experiment performed under final workflow conditions. The same 
sample was used for both experiments and the same antibodies were used for the assays. The smaller 
diagrams show data from the earlier experiment, the bigger diagrams show data from the final workflow 
condition. Data quality and signal intensities are massively improved when the final conditions are used.  
 
This figure demonstrates the improvements made during method development. The overall improve-
ments are the payoff from all the optimization and re-optimization steps. As mentioned in the beginning, 
all steps of the workflow needed to be optimized as each step is essential for making the DigiWest 
method work. One technical difference between the final workflow conditions and earlier experiments is 
that the photo-multiplier of the Luminex instrument was set to the high PMT mode to increase signals. 
This increases all signals, specific and unspecific, by about 10-fold. The data obtained under final 
workflow conditions give analyzable signals for most antibodies.  
 
3.3.10 Enhancing signal intensities 
As readout platforms for Western-Blots have the possibility to increase signals by longer exposure times 
or higher laser intensities, one question was whether a similar effect can be applied to the DigiWest 
method besides the setting for the photo multiplier.   
Method development Results 
31 
A possibility to increase signals in the DigiWest method is to use polymer-based buffers. The so called 
‘polymer effect’ can be described as an increase in the local concentration of antibody and antigen as 
they are excluded from the volume of the solvated polymer which implies a dependency on the polymer 
concentration (Milone, 2012). Addition of high molecular weight polymers like PVA or PVP in concen-
trations of 2-4% to the assay buffer increases the signals in DigiWest assays by several folds. But this also 
demands addition of more blocking reagent like milk powder to restrain the background signal. As for 
increased exposure times or higher laser intensities, it does not improve the signal-noise ratio but 
increases all signal, specific and unspecific.  
The following experiment shows the effect of a polymer based buffer. It is the same experiment as 
presented in the previous section under final workflow conditions with 55.1c cell lysate as sample. The 
same DigiWest bead-mix was used for an assay with different buffers. One buffer was the DigiWest assay 
buffer (Blocking Reagent for ELISA supplemented with 0.2% milk powder) the other buffer was a polymer 
buffer which was also based on the ELISA buffer supplemented with 4% PVP (average MW 360.000) and 
1% milk powder. 
 
 
FIGURE 11 SIGNAL IMPROVEMENT USING POLYMER BUFFER 
Comparison of two assays using the DigiWest assay buffer and a polymer based variation. The upper 
diagrams show the DigiWest data for a selection of antibodies using the DigiWest assay buffer, the lower 
diagrams show the same antibodies using a polymer based variation. Signals are improved by about 4-
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fold in this experiment when the polymer buffer is used. The unspecific signals are also increased. The 
Western-Blot image at the bottom right (turned 90°) represents the same antibody on the same sample 
as the DigiWest data above (c-Jun pSer63). The image was taken using chemiluminescence readout on a 
Kodak imager with an exposure time of 30 minutes. 
 
The c-Jun phospho antibody shown at the right in the previous figure showing weak signal in the assay 
buffer is giving a more stable signal in the polymer-based buffer. The Western-Blot image shown under 
these diagrams (turned 90° to the left) shows the same antibody on the same sample (55.1c lysate). The 
image was taken using chemiluminescence readout on a Kodak Image Station 440 CF with an exposure 
time of 30 minutes (1800 seconds). 
All antibodies used in our group are routinely validated for application in RPPMs using Western-Blots. 
Therefore, a Western-Blot image collection for several hundred antibodies is available. The 30 minutes 
exposure time which was used for the c-Jun phospho antibody shown in the previous figure is the 
longest exposure time which can be found in this collection. This antibody still gives analyzable signals 
for DigiWest. So the DigiWest under final workflow conditions has a sensitivity which might be able to 
compete with Western-Blotting.  
Polymers can increase the signals of DigiWest assays but the increased viscosity makes polymer based 
buffers difficult to handle. The effect of pushing the signals correlates with the concentration of polymer 
in the buffer but concentrations higher than 4% cannot be handled anymore. They cannot be pipetted 
properly due to high viscosity and the washing steps become difficult. Several experiments were 
performed testing different polymers and buffer compositions. The one shown here based on ELISA 
buffer and supplemented with PVP and milk powder proved to be one of the best combinations which 
were tested. 
Nevertheless, this buffer is not routinely used for DigiWest assays due to the described handling issue. 
But it can be used if pushing signals seems to be necessary. 
 
3.3.11  Summary of the final workflow conditions 
This section represents a summary of the workflow. More details are described in the materials and 
methods section. The commercial NuPAGE system is used for protein separation and blotting. The gels 
are precast 4-12% BisTris gradient gels with a size of 8x8 cm. The MES buffer system as described in the 
manual is usually used as running buffer. The blotting modules are based on the wet blotting procedure 
and proteins are blotted onto PVDF membranes. The membranes are washed in PBST and a Ponceau S 
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stain is performed to visualize the transferred proteins. The positions of the lanes are labelled using a 
pencil before the blots are destained in PBST.  
After washing in PBST, biotinylation of the whole membrane is performed in 20 ml PBST containing 
50 µM NHS-PEG12-Biotin for one hour at room temperature. After washing, the membrane is dried. 
Membrane cutting is performed on a Silhouette SD cutting plotter. Each lane is cut into 96 molecular 
weight fractions with a resolution of 0.5 mm resulting in a comb-like structure. The fractions are picked 
with a forceps and sorted into 96 well plates.  
For protein elution, 10 µl of the elution buffer are added to each well. It is necessary to ensure that the 
membrane snippets are completely covered with buffer. A helpful property of the elution buffer is that 
the membrane snippets turn transparent and thereby almost invisible in this buffer, after dilution of the 
elution buffer, they turn white again. The plates are sealed and placed on a shaker for 90 minutes with 
1200 rpm at room temperature.  
The eluted proteins are diluted by adding 90 µl BSA containing buffer per well. As described, ready to use 
bead plates are used. There are 4 different bead plates each equipped with 96 different NeutrAvidin 
coated Luminex bead sets. The bead plates contain a defined number of beads per well. A 96-well 
magnet comb is used to transfer the beads from the bead plate to the diluted protein eluates. The plates 
are sealed and incubated overnight at room temperature with gentile shaking.  
The next day, an excess of Tris-inactivated biotinylation reagent is added and incubated for one hour to 
block remaining biotin binding sites. Then the beads from up to 4 plates are pooled together using the 
96-well magnet comb and an 8-channel magnet comb. The beads are transferred to a vial and after 
washing in CBS they are adjusted to a defined concentration. The resulting bead-mix contains up to 384 
bead sets representing 4 samples with 96 molecular weight fractions each. The number of samples can 
be scaled by generating several DigiWest bead-mixes. A typical DigiWest bead-mix contains 40000 beads 
from each bead-set and is sufficient for 200 antibody incubations. This number is also scalable. 
DigiWest assays are performed in 96 well plates. Plates are pre-incubated with assay buffer and an 
aliquot of the DigiWest bead-mix(es) is added. The buffer is discarded and 30 µl per well of the anti-
bodies diluted in assay buffer are added. Primary antibodies are incubated overnight. The assay plates 
are placed on magnet plates and the buffer is discarded, PBST is added and discarded again. Plates are 
washed twice. PE-labelled secondary antibodies are diluted in assay buffer and 30 µl are added per well. 
After incubation for 1 hour at room temperature and two washing steps, the plates are filled with PBST 
for readout which is performed on a Luminex FlexMAP 3D. A full plate with 4 samples on 384 bead sets 
and 96 wells results in almost 37000 data points representing 384 Western-Blot lane equivalents. The 
Luminex data are used for data analysis. 
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3.4 Data analysis 
The DigiWest method creates hundreds of Western-Blot equivalents. For analysis of this amount of data 
it is necessary to identify, integrate and quantify the specific signals. The initial Western-Blot lanes need 
to be reconstructed and the antibody specific signals need to be identified. An advantage of the digital 
nature of Luminex based DigiWest data is that the antibody signals can be quantified without any image 
processing as usually performed for Western-Blot quantification. Therefore, I created an Excel based 
analysis tool which is able to handle the data.  
The Luminex output file contains several blocks of data. One of the data blocks contains the median of 
the reporter dye (PE) fluorescence for each bead set in each well. Luminex uses a relative fluorescence 
unit called MFI (median fluorescence intensities). The Luminex data for DigiWest contain data for up to 
96 wells per plate and up to 384 bead sets resulting in almost 37000 data points per plate. Each of the 
antibody incubations on each sample is represented by 96 values which are represented as diagrams for 
visualization during data analysis. These diagrams represent equivalents of Western-Blot lanes and the 
antibody specific signals appear as peaks which are equivalent to bands in Western-Blot images.  
 
The analysis tool contains three visible sheets. The first sheet is meant for input of the Luminex data, the 
second is for data analysis and the third contains the quantified signals from the selected peaks. The 
analysis tool can handle all the data derived from one 96 well plate. The whole data block from the 
Luminex output file can be pasted in one. Information on which antibodies were incubated in which well 
and which bead-mix containing which samples was used can be added. 
There are some options built in for background subtraction including species specific background sub-
traction which needs additional information on the species the antibodies are derived from. Background 
subtraction is mandatory as the Luminex beads themselves show some background fluorescence and the 
species specific secondary antibodies can also show background signal.  
The tool can handle antibodies derived from 5 different species at a time and a sixth option for 
streptavidin-PE which is used for on-bead protein determination as shown in section 3.6.  
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FIGURE 12 LUMINEX DATA-INPUT FOR ANALYSIS 
Shown is a detail from the data-input sheet of the DigiWest analysis tool. The data block containing the 
measured MFI values is copied from the Luminex output file. The information on which well the data are 
derived from is adopted from the Luminex output file for quality control. Antibody or analyte labels and 
species information are added for each well. The molecular weight assigned to each bead set is shown. 
There is an additional block where more antibody and assay related data can be added which can be used 
for additional information and quality control. This block is hidden in this screenshot. 
    
An extrapolated molecular weight marker which assigns a molecular weight to each Luminex bead set is 
the key for the following data analysis. The basis for this marker can be the molecular weight marker 
which is run together with the samples and contained on the blot. The positions of the marker bands can 
be measured and used for marker calculation. For a more precise marker the peak-positions of a 
selection of analytes in the assay can be used. The Excel plug-in XLfit is used for fitting the molecular 
weight marker followed by extrapolation of the marker for all 96 bead-sets representing the molecular 
weight fractions. This extrapolated marker can be used for all 4 samples or it can be calculated for each 
sample individually.  
The data-analysis sheet is the core component of the analysis tool. In the upper-left is a control panel 
with buttons which are linked to Visual Basic based macros.  Right to the control panel there are 4 dia-
grams representing the DigiWest data. The diagrams represent the data of the selected analyte which 
can be changed by clicking onto the analyte names. The diagrams can be scaled individually or they can 
be aligned to the same scale for all 4 samples. There is also an option for manual scaling of all four dia-
grams which can be used to zoom into the data. The lower part contains information on the selected 
peaks for up to 4 samples and up to 96 analytes. The tool can select and integrate two peaks from each 
diagram. 
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A major part of this analysis sheet is a control system which validates all input data including the raw 
Luminex data and all calculation steps resulting in error messages in case something went wrong or 
invalid data or values were used. An error report can be shown using the control panel. This control 
system also detects which analytes and which samples are being used for calculation and dismisses the 
unused ones. 
The main function of this sheet is to integrate the peaks in the diagrams representing specific signal of 
the applied antibodies on the indicated samples. Therefore the data need to be background subtracted. 
The correct peaks need to be selected and integrated which needs calculation of a baseline. There are 
several options built into this tool which allow integration of (almost) every peak-like structure.  
 
 
FIGURE 13 DIGIWEST DATA ANALYSIS SHEET: SCREEN SHOT OF THE DIGIWEST ANALYSIS SHEET 
The analysis shown is taken from the mouse liver LCM experiment which is presented later in this thesis. 
The control panel is in the upper-left and the 4 diagrams representing the selected analyte on the 4 
samples used in this DigiWest bead-mix are right of the panel. The sheet is in the overview mode showing 
the results only. The detailed error report from the control system and the panel with additional options 
for calculation (explained in detail in the text and next figure) are superimposed. They can be shown using 
the corresponding buttons from the control panel. The tool can select and quantify 2 peaks from each 
diagram. In the overview mode there are 6 columns for each sample which contain the baseline position, 
information on peak 1, integrated signal of peak 1, and if the second peak is used also information and 
signal of peak 2 and the integrated signal for both peaks. Details for calculation will be discussed.       
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The main function of this sheet is quantification of signals by integration of the specific peaks for each 
antibody on each sample. The first calculation is subtraction of background signal. As mentioned, the 
beads show some background which is bead set specific. The secondary antibodies for rabbit and mouse 
which are used for DigiWest often do not show any specific background. Therefore it is sufficient to 
subtract the general, bead-derived background. But in many situations, also for this example where 
some mouse-derived antibodies are used on mouse tissue samples, it is mandatory to subtract the signal 
derived from the secondary antibody as well. Therefore, there are some options integrated in the 
options panel. One option is to use species-specific background subtraction so that for each antibody 
derived from the same species the corresponding blank is subtracted. The blank is the secondary 
antibody control which is therefore mandatory for each assay. Alternatively, a background independent 
of the secondary antibody and only dependent on the bead-set can be subtracted. This option subtracts 
a given quantile over all measured wells for each bead-set. Setting this quantile to 0 results in 
subtraction of the minimum but as the Luminex data underlie some variation of a few fluorescence units 
(about +/- 5 MFI for stable measurements, about +/- 10 MFI for less stable ones) the preset value is 0.05 
so the 5% quantile which means that 95% of the values are higher and 5% are lower resulting in more 
stable data. Negative values are eliminated and set to 0. 
After background subtraction, peaks are selected. The peak selection process is based on the molecular 
weight marker. The analysis tool allows one or two peaks to be selected. When the molecular weight of 
the analyte is entered, the tool searches for the peak (local maximum) in a definable area around this 
molecular weight. The preset for the first peak is +/- 20% of the given molecular weight and for the 
second peak, because related proteins often have similar molecular weights, the preset is +/- 10%. For 
good data with clear peaks and no or minor additional peaks it is sufficient to give the molecular weight 
for selection and integration of the peaks. As it can happen that a peak is only partially contained in the 
defined area, an algorithm validates that the selected maximum is a real maximum and in case it is 
positioned in a slope of a peak a warning is given. 
The peaks are defined by the local maximum with declining values left and right. The neighboring values 
need to be same or smaller. Sometimes peaks are not shaped that perfectly but are bogus and show for 
example a ‘shoulder’. To select these peaks, a factor was introduced with the inglorious name ‘Bad Peak 
Factor’ which is set to 1 by default. If it is increased for example to 1.1 the neighboring values can be up 
to this factor, in this case 10% higher, which helps selecting a bogus peak. The factor can also be set 
smaller than 1 resulting in a decline which needs to be reached by neighboring values to be included in 
the peak. The borders of the peaks are defined by the positions where the given criteria are not met 
anymore. Another option is the selection of two peaks and integration of both peaks into one. So double 
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peaks can be selected as two separate peaks or integrated into one peak. This function can also be used 
for selection of bogus peaks. The combination of the ‘Bad Peak Factor’ and the possibility to integrate 
two peaks into one allows selection of almost all peak-like structures.  
For integration of the peak areas it is necessary to define baselines. There are several options for calcula-
tion of these baselines. The default setting is that the local background around the peaks is used for 
baseline calculation. The number of data points left and right of the peak which are used can be 
specified, the default setting is 5 data points from each side. A quantile is used again for calculation of 
the baseline from these by default 10 values. The default setting is 25% so the baseline is set at the 
position that 25% of the values are below and 75% are above the baseline. The quantile is set globally for 
all calculations in the sheet. This global setting can also be switched off which unlocks the possibility to 
change the setting for each sample and analyte individually.  
The preset values are empirically determined and give good results for the vast majority of analyses. An 
alternative option is to calculate the baseline by the given quantile over all 96 values in the diagram inde-
pendent of the peak position.  
 
 
FIGURE 14 DIGIWEST DATA ANALYSIS: PEAK SELECTION 
Shown are some examples for graphical illustration of the peak quantification procedure.  
a) Diagram showing the 96 values from the background subtracted Luminex data for one analyte on one 
sample. The molecular weight marker is shown on the x-axis and the values of the 96 Luminex data points 
on the y-axis are shown as light gray bars. 
b) Detail of the input screen. When the analysis tool is switched to the ‘Edit Mode’ these columns are 
shown for each sample allowing selection of the peaks for all analytes. The molecular weight of the 
analyte needs to be given for one or two peaks in the first 2 columns. For most analyses this is sufficient 
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for integration of the peaks and quantification of the analyte specific signal. The next column allows 
integration of both peaks to one peak by placing a ‘y’. The next 2 columns define the allowed deviance 
from the given molecular weight for the peak-search algorithm which can be adjusted. The next column 
contains the described ‘Bad Peak Factor’ and the last column is locked. It can be unlocked to set individual 
quantiles for baseline calculation. By default a global quantile is used for all analytes and samples in the 
sheet.  
c) Shows the options for calculation. Options which are switched on are highlighted in green. The global 
quantile for baseline calculation can be set followed by the option for global or individual quantile usage. 
The option ‘Baseline optimized’ switches between the algorithm for local background around the peak or 
the quantile over all 96 data points. The next option disables highlighting of peaks when the correspond-
ing signal is dismissed as ‘weak’. The Peak-Position control is inactive by default. If a number is given, for 
example 2, then the positions of the peaks for each analyte are compared between the 4 samples for 
their relative position which in this example has to be smaller or equal 2 data points. This validates that 
peaks with the same molecular weight are selected for all samples. The next options are for background 
subtraction mentioned earlier. The last two options represent cut-off filters for low signals. This is 
necessary as the algorithms always find a local maximum even in background noise. The first filter uses 
the signal-noise ratio and the second filter the integrated peak signal. Both filters need to be passed to 
give an analyzable signal. The default setting is factor 4 over baseline and an integrated signal of more 
than 50.  
d) Shown are the same data as in a) with the peak selected. The peak-area which is being integrated is 
represented in dark gray, the remainder in light gray. The baseline is shown. The data-points under the 
red bars were used for baseline calculation (local background, 5 data points from each side).  
e) An example of a peak with a ‘shoulder’ where the ‘Bad Peak Factor’ was used for peak selection.  
f) An example where two peaks were selected. The first peak is highlighted in dark gray, the second peak 
in medium gray. The overlap is highlighted in striped dark/medium gray. The area of the overlap is 
attributed half to each peak. 
 
The integrated signals for each peak are shown in the analysis sheet. Peaks which failed passing the cut-
off filters are dismissed as ‘weak’. There is an option build-in to switch off highlighting of the peaks when 
the signals are dismissed. The integrated signals still have a relative unit now called AFI for ‘assembled 
fluorescence units’. An export macro writes all AFI values into the last sheet of the analysis tool from 
where the data can be copied and used for further analysis and statistics.  
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3.5 Benchmarking DigiWest performance  
As the Western-Blot represents the ancestor of the DigiWest method it was mandatory to perform a 
direct comparison between these methods. In the 35 years since Western-Blot was invented there were 
permanent efforts for optimizing the method. These efforts lead to development of several highly 
sensitive readout systems. A widely used readout is the enhanced chemiluminescence (ECL) combined 
with high end cameras, other systems use fluorescence based readout employing confocal laser 
scanners. The methods which were used for comparison of the DigiWest method were 
chemiluminescence readout employing the commercial substrate ‘Super Signal West Pico’ and readout 
on the Fuji LAS 4000 imaging system and the infrared fluorescence based Licor Odyssey scanner. The 
DigiWest method was compared to Western-Blots under qualitative and quantitative aspects. 
 
 
3.5.1 Qualitative comparison to Western-Blot 
A sample frequently used during method development was HepG2 cell lysate. This material has also 
been used for the antibody validation approach for reverse phase protein microarrays in our group. 
Therefore, a collection of Western-Blot images is available for several hundred antibodies. The image 
collection was used for a qualitative comparison to the DigiWest data. 
20 µg HepG2 lysate were used to generate a DigiWest bead-mix containing 40000 beads per set, so 
sufficient for 200 antibody incubations. The bead-mix represented 96 molecular weight fractions at a 
resolution of 0.5 mm. Assays with more than 100 antibodies were performed using this bead-mix to 
generate DigiWest data which were compared to the corresponding Western-Blot images. 
The digital data obtained from the Luminex instrument can be used to reconstruct Western-Blot-like 
images (see Fig. 15) by translating the 96 values into a grayscale image. The MEV software package was 
used to create such grayscale maps from the background subtracted data. These maps represent the 
initial Western-Blot lanes as 96 rectangles with no signal represented in white and the maximum values 
in black. The values in between are represented in different gray-values. The resulting maps look edgy 
due to the 96 rectangles but after application of a Gaussian diffusor the resulting images show high 
similarity to real western-Blot images. Images generated by this method were named ‘Western-Blot 
mimics’. Using this approach, Western-Blot images from our image collection and DigiWest data from 
more than 100 antibodies could be compared. Some examples are shown here, a comprehensive 
collection of 104 antibodies is shown in Appendix 1.  
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FIGURE 15 QUALITATIVE COMPARISON OF WESTERN-BLOT AND DIGIWEST 
Direct comparison of Western-Blots and DigiWest data. HepG2 lysate was used as sample, antibodies as 
indicated. Data from 4 antibodies are shown. a) Full diagrams of the DigiWest data used for generation 
of the Western-Blot mimics. The diagrams represent the signal obtained on the 96 molecular weight 
fractions. Specific signal is shown in black, unspecific signal in gray. b) Comparison to Western-Blots. The 
left columns show Western-Blot images, the diagrams in the middle show the Luminex data (same data 
as in a)) in  reduced diagram form with the specific band highlighted in black, the right columns show the 
Western-Blot mimics generated from the DigiWest data.  
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Using the Western-Blot mimics for representation, the similarity of DigiWest and Western-Blot becomes 
obvious. Unlike the diagram representation of the DigiWest data, this Western-Blot-like representation is 
familiar. The additional bands which can be seen in the Western-Blots for the eIF2 alpha antibodies can 
also be seen in the DigiWest data which underlines the similarity. The following figure shows a collection 
of 96 different antibodies incubated on the HepG2 lysate loaded DigiWest bead-mix. 
 
 
FIGURE 16 DIGIWEST DATA FROM A COLLECTION OF ANTIBODIES 
DigiWest data from a collection of 96 antibodies on HepG2 lysate represented as Western-Blot mimics. 
Antibodies recognizing large, small or medium-size proteins were selected, also antibodies showing a 
single band at the correct molecular weight and antibodies showing additional bands. A comparison to 
Western-Blot images for all of these and some more antibodies is shown in Appendix 1. 
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Data generated by the DigiWest method correlate well with Western-Blots. Almost all antibodies tested 
which gave a specific signal on Western-Blot on this sample also gave a specific signal on DigiWest. For 
many antibodies which showed additional bands on the Western-Blot the same additional bands were 
visible on DigiWest data. In some cases the additional bands showed different intensities when 
compared to Western-Blot and in some cases additional bands appeared or disappeared. But these 
differences are not more distinctive than the differences between Western-Blots which are blocked with 
BSA or blocked with milk powder. For Western-Blots, a BSA based buffer was used while for DigiWest an 
ELISA buffer supplemented with milk-powder was used. Even antibodies which were imaged with long 
exposure times on Western-Blots gave acceptable signals for the DigiWest method.  
 
3.5.2 Long term stability 
An important aspect is the long-term stability of the DigiWest bead-mixes. The NeutrAvidin biotin inter-
action, which is used to immobilize the proteins, might show low off-kinetics resulting in exchange of 
biotinylated proteins in between the bead sets which are stored in a mix containing all 384 bead sets 
representing 4x96 molecular weight size fractions from the initial blots. This might lead to a loss of 
specific signal and disintegration in the DigiWest bead-mixes over time. The use of bead-mixes after 6 
months or even two years storage showed good performance and sharp peaks and no measurable effect 
on the quality of the DigiWest assays was detected. A planned and scheduled long term storage 
experiment is still missing.  
 
3.5.3 Linearity, sensitivity and quantification in comparison to Western-Blot 
Important aspects for validation of the new method are the analyte-signal relationship i.e. linearity and 
linear range, reproducibility and direct comparison to a high-end Western-Blot readout system in regard 
to sensitivity. To determine these aspects, an experiment was designed in which DigiWest was compared 
to the infrared fluorescence based Licor Odyssey.   
In the experiment, a dilution series of a GST fusion protein was spiked into a constant amount of cell 
lysate. The spiked lysates were used to perform blots for a DigiWest experiment and classical Western-
Blots. HepG2 lysate was spiked with GST-ERK2. The GST-tag has a molecular weight of 26 kDa and shifts 
the 42 kDa ERK2 to 68 kDa which allows discrimination of the spiked protein and the intrinsic ERK2 in the 
cell lysate. The dilution series covered a dilution factor of 1024 in 6 different dilutions and ranged from 
20 ng GST-ERK2 per 10 µg HepG2 lysate to about 20 fg GST-ERK2 per 10 µg HepG2 lysate. These samples 
were used to prepare 4 Western-Blots and blots for DigiWest.  
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For DigiWest, each sample was applied in triplicates resulting in 18 lanes each containing 10 µg HepG2 
lysate. For the Western-Blots the higher spike-amounts were applied in duplicates and the lower ones in 
triplicates resulting in 15 lanes. As the PVDF membranes which are used for DigiWest are not suitable for 
fluorescence readout, 2 of the Western-Blots were performed using Nitrocellulose membranes and 2 
using PVDF membranes.  
The 18 lanes from the DigiWest blots were used to prepare DigiWest bead-mixes sufficient for 100 
antibody incubations. To reduce the number of bead-mixes, only a limited molecular weight range from 
about 115 to about 40 kDa represented by 32 molecular weight fractions was used. A DigiWest assay was 
performed employing a monoclonal ERK1/2 specific antibody which detects the intrinsic ERK1/2 and the 
spiked GST-ERK2. As there were enough beads for 100 antibody incubations for DigiWest assays, the 
assay was performed with 4 repeated measurements. 
The Western-Blots were either blocked with BSA or blocked with milk-powder and used for 
chemiluminescent readout on the Fuji LAS-4000 and for fluorescent readout on the Licor Odyssey. For 
the blots blocked with BSA, the obtained GST-ERK2 specific signal from chemiluminescent readout on 
PVDF membrane massively levelled out and showed more a curve than a linear relationship. The signal 
from fluorescent readout using the 800 nm channel of the Odyssey scanner on nitrocellulose membrane 
also levelled out and showed only linearity for the lower 4 spike amounts. Therefore, the blot on 
nitrocellulose blocked with milk-powder was used for fluorescent readout. The GST-ERK2 specific signal 
showed good linearity for all spike-amounts. 
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FIGURE 17 SENSITIVITY AND SIGNAL LINEARITY OF DIGIWEST COMPARED TO LICOR ODYSSEY 
a) The Western-Blot on nitrocellulose membrane blocked with milk powder on the Licor Odyssey using 
Licor secondary antibody on the 800 nm channel. The lower image is the same than the upper one with 
changed gray-scale settings to visualize the weaker bands. The laser power used for readout was the 
highest possible without saturated pixels within the area of interest. 
b) Representative examples from the DigiWest measurement for each spike amount shown as diagrams. 
The peaks corresponding to the spiked GST-ERK2 are shown in medium gray and the peaks corresponding 
to the intrinsic ERK2 from the HepG2 lysate are shown in black. The peak in light gray corresponds to 
intrinsic ERK1 which is also detected by the antibody. The different peak shapes which are very obvious 
for the intrinsic (black) ERK2 correspond to differences in the exact cutting position.  
c) Signal linearity: both methods show a slight s-curve which is typical for fluorescence based immuno-
assays. The diagrams are in log10 scale on both axes. The coefficients of determination are good for both 
methods. Error bars are shown representing standard deviations, for the Western-Blot only for the 3 
lower spike-amounts because there are only 2 values available for the higher spike amounts. The 
DigiWest data contain error bars for all spike-amounts including the repeated measurements. 
 
The whole dataset for the DigiWest measurement including the 4 repeated measurements is shown in 
Appendix 2. The DigiWest assay was performed under final workflow conditions using the DigiWest assay 
buffer. Utilization of a polymer based buffer might further increase the detection limit. Licor based 
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Western-Blot and DigiWest were both able to detect the 20 pg GST-ERK2 but both methods seem to be 
close to their detection limit. The Western-Blots with chemiluminescent readout on the LAS 4000 and 
with BSA-based buffer on the Licor Odyssey were both also able to detect the 20 pg spiked GST-ERK2 but 
they were both very close to their detection limits as the intensities of the bands were close to the 
background signal.  
The peaks in the DigiWest data obtained from the intrinsic ERK2 show that the shape of the peaks varies 
dependent of the exact cutting position of the molecular weight fractions. But independent of the shape 
of the peaks, the integrated signals are robust. 
The signal obtained from the intrinsic ERK2 in the Western-Blot (15 lanes, 1 blot) shows a CV of 6.44%, 
the signal obtained from DigiWest (18 lanes, 3 blots) shows a CV of 9.57%. This shows that reproducibi-
lity of the DigiWest method is good even for 18 lanes which are distributed over 3 blots. Distribution 
over 3 blots was necessary because empty lanes are needed in between for cutting the membranes for 
DigiWest. The increased variation of the DigiWest data compared to the Western-Blot can mainly be 
imputed to the three blots. In smaller spike-in experiments, where only one blot was used for generation 
of the DigiWest bead-mixes, the variation was lower.  
The signals obtained from the spiked GST-ERK2 can be used as standard curve for absolute quantifi-
cation. The intrinsic ERK2 in 10 µg HepG2 lysate can be calculated to 62.25 fmol (6.2 fmol/µg) using the 
Western-Blot and 70.99 fmol (7.1 fmol/µg) from the DigiWest data. For these calculations the standard 
curves from the GST-ERK2 spikes were fitted using XL-Fit and the different molecular weights of ERK2 
and GST-ERK2 were taken into account. The discrepancy in between the two methods of about 14% is in 
an acceptable range for two different methods for protein quantification (Wild, 2013). 
This experiment shows that DigiWest performs well in respect to signal linearity, reproducibility and 
sensitivity. It can compete with the highly sensitive Licor Odyssey platform. One aspect which should be 
mentioned here again is that for the DigiWest experiment the same sample and spike amount was used 
but the resulting DigiWest bead-mixes were sufficient for 100 antibody incubations, so only 1/100 of the 
sample amount was used per measurement compared to the Western-Blot. 
 
3.6 On bead protein determination 
Protein biotinylation usually results in the covalent attachment of more than one biotin per protein. 
Since the immobilization of biotinylated proteins on the Luminex beads only requires one biotin, there 
are still biotins available that are detectable on the bead-bound proteins. These biotins can be used for 
on-bead protein estimation. In this example, HepG2 lysate was used again as sample. To address the 
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limited sample amount in the following laser capture microdissection experiment, a linear dilution series 
from 6 to 1.5 µg HepG2 lysate was loaded. The DigiWest bead-mix was incubated with streptavidin-PE in 
assay buffer in 3 different dilutions (1:50, 1:200, 1:800) in duplicates. As milk powder contains biotin, a 
milk powder free buffer (CBS: 1% BSA, 0.05% Tween-20, 0.05% sodium azide in PBS) was also tested. 
Streptavidin-PE was incubated under secondary antibody conditions, 1 hour at 23°C.  
 
 
FIGURE 18 ON-BEAD PROTEIN DETERMINATION 
a) DigiWest diagrams taken from the DigiWest analysis table, the whole molecular weight ranges were 
used for signal integration. HepG2 lysate dilution series: 6 µg, 4.5 µg, 3 µg and 1.5 µg protein. Incubated 
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with streptavidin-PE, diluted 1:200 in assay buffer. A clear correlation of signal and sample amount can 
be seen.  b) Quantified signal from the dilution series in assay buffer (R) and in CBS (C) both as means of 
duplicated measurements. The signal obtained from streptavidin-PE shows good linearity.  
 
The signal of streptavidin-PE in this assay represents free biotins on the Luminex beads. There is a clear 
linear correlation of the streptavidin-PE signal and the sample amount loaded onto the Luminex beads.  
The signals in assay buffer are marginally lower than in CBS but signal linearity is still good. Other 
dilutions of Streptavidin-PE have been tested, all showed good signal linearity. The 1:200 dilutions 
resulted in the lowest Y-axis-intercept of the linear fit. The milk powder contained in the assay buffer 
which might contain biotin does not affect the measurement except for slightly lower signals. 
This experiment proves that simple incubation of DigiWest bead-mixes with streptavidin-PE can be used 
for relative on-bead protein determination which results in good signal linearity. Another method 
involving a reactive dye has also been tested but there was no need for this as streptavidin-PE is simple 
and robust.  
On-bead protein determination is useful for data normalization on total protein in the samples. The on-
bead protein determination can be used as loading control and for normalization of the data as an 
alternative to β-Actin or GAPDH.  
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3.7 Lapatinib resistance in a cell line model 
Lapatinib (GlaxoSmithKline) is a kinase inhibitor specifically inhibiting the receptor tyrosine kinases Her2 
and EGFR (Her1). It is used in cancer therapy especially in cases where tumors overexpress one of these 
receptors. An important issue in cancer treatment is that tumors frequently develop resistance to anti-
cancer drugs and relapse (C. R. Chong & Jänne, 2013). 
In this experiment, the mucoepidermoid pulmonary carcinoma cell line H292 was employed to study this 
phenomenon. The motivation was to identify differences that occur during development of resistance to 
Lapatinib. The experiment was performed in collaboration with Benjamin Ruprecht in the group of 
Bernhard Küster (Chair of Proteomics and Bioanalytics, TUM) at the Technical University of Munich.  
First, a Lapatinib resistant cell line was established in the laboratory of Bernhard Küster. By cultivating 
the cells in very low doses of Lapatinib which the cells managed to survive, the dose was slowly 
increased over several months so that the cells adapted to the drug and developed resistance. The 
resulting resistant cell line was able to grow in presence of high concentrations of Lapatinib. The IC50 of 
the resistant cell line was about 800 nM compared to about 10 nM of the parental cell line. The resistant 
cell line had to be cultured in presence of Lapatinib to conserve the generated resistance; the term 
‘resistant’ is used here although the term ‘tolerating’ might be more appropriate.  
 
3.7.1 Kinase enrichment using Kinobeads 
Kinases play a pivotal role in cellular signaling and are therefore often targets in drug development. Most 
kinases use ATP as substrate for phosphorylation of hydroxyl groups on their target proteins or mole-
cules. The main target of kinase inhibitors is the ATP binding site which allows efficient inhibition of the 
enzymatic activity but often results in inhibition of more than one kinase due to high similarity of ATP 
binding sites. This observation led to the development of Kinobeads as a tool for kinase enrichment. 
They are based on a collection of broad-selectivity kinase inhibitors immobilized on sepharose. This 
allows them to bind the majority of the kinome – the entity of all kinases. Thereby Kinobeads can be 
used to enrich kinases from complex samples usually followed by mass-spectrometry readout. For 
testing selectivity or binding affinity of a kinase inhibitor to a kinase, the Kinobeads can be used in a 
competitive experimental setup where the free target drug is used to compete with kinase binding to the 
Kinobeads (Bantscheff et al., 2007).   
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3.7.2 Experimental setup and correlation of mass spectrometry and DigiWest 
In an experiment performed by Benjamin at TUM, Kinobeads were used to enrich the kinome of both the 
Lapatinib resistant and the parental H292 cell line. Besides the kinases, the Kinobead pulldows also 
contained some kinase-interacting proteins.   
Benjamin analyzed the Kinobead pulldowns in mass spectrometry. For mass spectrometry analysis, 
Kinobead bound kinases and non-kinases were analyzed but only the kinases were taken into account. 
The mass spectrometry data analysis identified a set of 24 kinases which showed statistically significant 
changes for resistant versus parental H292 cell line.  
For further analysis, DigiWest bead-mixes sufficient for 200 antibody incubations were generated from 
whole cell lysates and Kinobead pulldowns from Lapatinib resistant and parental H292 cell lines. 
In the first part of the experiment, the set of 24 kinases from the mass spectrometry analysis was re-
analyzed using DigiWest. The semi-quantitative results obtained from mass spectrometry and DigiWest 
were compared in respect to their correlation. 
 
 
FIGURE 19 EXPERIMENTAL SETUP AND MASS SPECTROMETRY ANALYSIS 
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a) Overview of the experimental setup. Parental and resistant cell lines were lysed. One part was used for 
DigiWest analysis, the other for Kinobead pulldown. Pulldowns were analyzed using mass spectrometry 
and DigiWest. All analyses were performed in triplicates. b) Volcano plot of the MS analysis. Significantly 
changed kinases were determined by the following criteria: p-value (ANOVA) < 0.001, fold change > 2 
(Log2 >1), number of peptides ≥ 2. c) The set of 24 significantly changed kinases was analyzed using 
DigiWest and compared to the MS analysis. There was no working antibody available for EphB6. The 
correlation coefficient for mass spectrometry and DigiWest analysis was 0.98.  
 
One protein (EphB6) could not be detected in DigiWest because none of the tested antibodies worked. 
Her2 and EGFR, which are inhibited by Lapatinib and are therefore inhibited from binding to Kinobeads, 
were underrepresented. Her2 was not detectable and EGFR was massively reduced in the Kinobead pull-
downs of the resistant cell line. EGFR was almost undetectable in the DigiWest analysis leading to an 
even bigger Log2 fold change than in the MS analysis. The correlation coefficient for the two methods 
(excluding EGFR) was calculated to be 0.98.  
Although mass spectrometry and DigiWest are completely different methods for protein quantification 
this experiment shows that they correlate well. One important aspect for this correlation is the quality of 
the antibodies. All antibodies used here seem to be highly specific for their targets. 
 
3.7.3 Analysis of cell lysates and Kinobead pulldowns using DigiWest 
In a second experimental part, the crude cell lysates were analyzed by DigiWest. This type of sample is 
difficult to be analyzed by mass spectrometry due to the complex sample composition. The immuno-
assay based DigiWest method can – like Western-Blot – handle such complex samples. The Kinobead 
pulldowns were also further investigated. This gave the opportunity to investigate non-kinase analytes 
and phosphorylation of proteins within the Kinobead pulldowns and the initial cell lysates.  
Analytes were selected based on the set of significantly changed kinases including several phosphory-
lations of these kinases. Other analytes were associated proteins and analytes based on literature on 
receptor tyrosine kinase inhibitor mechanisms.  
The DigiWest bead-mixes can be stored and used to perform several assays. Some beads were kept for 
follow up analyses. Benjamin performed an Ingenuity pathway analysis of the interim results.  
For this analysis, all DigiWest data available at this time (all except for 5 analytes including p53) were 
analyzed by use of the Ingenuity (Qiagen) software package. If data were available for whole cell lysates 
and Kinobead pulldowns, the data from the whole cell lysates were used. As Ingenuity cannot handle 
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phosphorylation of proteins, the data on total protein abundance and phosphorylation were separately 
used to perform two analyses. Both analyses pointed towards down-regulation of p53 as the top 
upstream regulator.  
As p53 is not a kinase, this down-regulation was not visible in the Kinobead pulldown analyses. Therefore 
some of the remaining DigiWest beads were used to analyze p53 in the whole cell lysates. The down-
regulation of p53 was confirmed.  
A study on resistance mechanisms for EGFR inhibitors using the inhibitor Cetuximab and clonal selection 
for resistant H292 cells already showed that loss of p53 is the key player in this setup (S. Huang et al., 
2011).  Our results show that p53 is the key player for Lapatinib resistance as well and that resistance is 
based on down-regulation of p53 for reversible Lapatinib resistance in H292 without clonal selection. 
 
As the DigiWest results showed low variance within the replicates, no normalization was performed. For 
statistical analysis, the DigiWest data were normalized on the mean of the parental cell line (control) and 
log2 transformed. The resulting data represent the log2 fold change of the Lapatinib resistant H292 cell 
line relative to the parental cell line. T-tests with Welch approximation were performed using MEV. All 
analytes with a fold change greater than 2 (log2 >1) and a p-value below 0.02 were defined as statisti-
cally significant.  
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Cell lysates 
   
Kinobead pulldowns 
  
Log 2 fold change of Lapatinib resistant 
relative to parental cell line    
Log 2 fold change of Lapatinib resistant 
relative to parental cell line   
Analyte log2 fold p-Value 
 
Analyte log2 fold p-Value 
DUSP6 (MKP3) -4.046 8.08E-05 
 
EGFR -9.778 9.07E-05 
IRAK4 Phospho Thr345/Ser346 2.537 0.00299 
 
Cyclin B1 -4.027 0.00058 
IKK ε -2.525 0.00023 
 
EphA2 Phospho Ser897 -3.915 0.00026 
DUSP9 (MKP4)  2.387 0.00025 
 
PKC θ Phospho Thr538 -3.407 0.00344 
Aurora A - phospho Thr288 2.382 0.00219 
 
PKC θ -3.363 0.00469 
p27(Kip1) - phospho - (CDKN1B) Ser10 2.312 0.00097 
 
IKK ε -2.954 0.00025 
PKC θ -2.290 0.00538 
 
JNK/SAPK - phospho Thr183/Tyr185 -2.744 0.00015 
CDK6 2.236 0.00020 
 
LRRK2 Phospho Ser935 -2.465 0.00517 
EGFR - phospho Tyr1068 -2.212 0.00033 
 
IRAK4 Phospho Thr345/Ser346 2.374 0.00590 
Cyclin B1 -2.211 0.00053 
 
EphA4 2.360 0.00126 
LATS2 2.140 0.00871 
 
cdc2 (CDK1) -2.355 0.00090 
PKC θ Phospho Thr538 -2.113 0.00046 
 
Aurora A (AIK) -2.244 0.00326 
Cytokeratin 8 -2.011 0.00056 
 
EphB3 2.117 0.00073 
Caveolin-1 -1.902 0.00017 
 
Fyn 2.063 0.00126 
Aurora A (AIK) -1.864 0.00334 
 
EphB4 -1.904 0.00097 
Caspase 9 1.774 0.00323 
 
Aurora B (AIM1) -1.879 0.00114 
p53 -1.753 0.00168 
 
LRRK2 -1.824 0.00332 
p27(Kip1) (CDKN1B) 1.703 0.00329 
 
ASK1 Phospho Thr845 -1.762 6.43E-05 
EGFR 1.685 0.00407 
 
ATM -1.746 0.00507 
EphA2 -1.652 0.00193 
 
Cytokeratin 8 -1.720 0.00394 
Aurora B (AIM1) -1.633 0.01806 
 
EphA2 -1.712 0.00073 
EGFR - phospho Tyr845 -1.476 0.00019 
 
MKK6 1.702 0.00446 
RSK 1/2/3 1.468 0.00198 
 
Caveolin-1 -1.677 0.00218 
Src - phospho Tyr416 -1.453 0.00026 
 
ASK1 -1.648 0.00022 
Pyk2 / FAK 2 1.448 0.00651 
 
LATS2 1.639 0.00015 
Erk1/2 (MAPK p44/42) - phospho Thr202/Tyr204 -1.436 0.00118 
 
MKK3/6 - phospho Ser189/207 1.603 0.00142 
YAP - phospho Ser127 1.383 0.00405 
 
RSK 1 1.597 0.01071 
Her2 - phospho Tyr1248 -1.378 0.00773 
 
EphB6 -1.511 0.00712 
RSK 1 1.351 7.24E-05 
 
RSK 1 (p90RSK) - phospho Ser380 -1.422 0.00168 
Her2 1.232 0.00254 
 
RSK 4 - phospho Ser235 1.378 0.01601 
p21/Waf1/Cip1 -1.224 0.00063 
 
Caspase 7 1.325 0.00365 
cdc2 (CDK1) -1.205 0.00144 
 
IRAK4 1.296 0.00532 
Caspase 8 -1.175 0.00394 
 
MKK3/MKK6 Phospho S218/T222 S207/T211 1.295 0.00347 
MKK6 1.158 0.00787 
 
Erk1/2 (MAPK p44/42) - phospho Thr202/Tyr204 -1.271 0.00658 
ABL2 (phosphorylated) -1.148 0.00778 
 
RSK 1/2/3 1.234 0.00611 
p53 - phospho Ser392 -1.112 0.00488 
 
CDK6 (phospho-Tyr24) -1.216 0.00620 
GSK3 beta - phospho Ser9 -1.100 0.00018 
 
Aurora A/B/C - phospho Thr288/Thr232/Thr198 -1.170 0.01950 
AMPK alpha - phospho Thr172 -1.063 0.00234 
 
Mnk1 - phospho Thr197/202 -1.167 0.00082 
Caspase 7 1.061 0.00016 
 
GSK3 beta - phospho Ser9 -1.165 0.01106 
MEK1 -1.034 0.00231 
 
LIMK1 -1.101 0.01594 
HIF-1beta (ARNT) -1.017 0.00250 
 
Pyk2 / FAK 2 1.048 0.00051 
TABLE 1 DIGIWEST ANALYSIS OF LAPATINIB RESISTANT H292 CELL LYSATES AND KINOBEAD PULLDOWNS 
DigiWest results of Lapatinib resistant and parental H292 cell lysates and Kinobead pulldowns. The table 
shows the significantly changed analytes in the Lapatinib resistant cell line relative to the parental cell 
line as log2 fold changes. Analytes are sorted by absolute log2 fold changes. P-values are derived from t-
tests with Welch approximation. Significantly changed analytes were defined as log2 fold change >1 and 
p-value <0.02. Within the cell lysates and the Kinobead pulldowns 41 analytes were significantly changed. 
All analytes from all assays including the follow-up containing p53 are included.  
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FIGURE 20 DIGIWEST DATA ANALYSIS 
a) Volcano plot representing the DigiWest results of the Kinobead pulldowns. These data include all data 
from all assays performed. Shown are the log2-fold changes of the Lapatinib resistant relative to the 
parental H292 cell line on the x-axis and the p-values of the t-test on the y-axis. The data contained in the 
volcano plots are derived from almost 1000 Western-Blot lane equivalents. b) Volcano plot of the results 
from whole cell lysate analysis. c) Detail of the Ingenuity pathway analysis of the first large part of 
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DigiWest data indicating that p53 should be down-regulated as a key player. This is only a detail of the 
analyses summarizing the identified targets of p53 (4 phosphorylations and 10 total protein abundances). 
d) Western-Blot mimics representing the 34 most significantly changed analytes in the cell lysates sorted 
alphabetically. p53 from the last assay is included. 
 
The combination of unbiased mass spectrometry combined with DigiWest as high-output Western-Blot-
like approach and combined with Ingenuity pathway analysis proved to be a powerful team although the 
slim experiment without follow-up represents more a feasibility study than a serious investigation of the 
resistance mechanism. Nevertheless this approach resulted in identification of p53 as the top upstream 
regulator for induced Lapatinib resistance in H292 lung cancer cells and the experiment showed that 
mass spectrometry and DigiWest, which use completely different principles for protein detection, show a 
good correlation. 
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3.8 Mouse liver zonation and zonal response to TCPOBOP 
treatment 
Animal models play an important role in pharmaceutical and toxicological research as the effects of drug 
treatment are different in cell culture when compared to the effects of drug in an organ or the whole 
organism. The liver, the most important organ for drug metabolism, is a target of known non-genotoxic 
carcinogens and thereby serves as a model to detect these substances. Non-genotoxic carcinogens 
promote tumor growth and the NGC TCPOBOP induces hepatomegaly and liver hypertrophy followed by 
liver tumors in mice (Donthamsetty et al., 2011; S. P. S. Monga & Cagle, 2010).  
Most studies on mouse liver and drug treatment use whole liver lysates and do not take the architecture 
of the liver into account. The liver is organized in lobules which are defined by centrilobular veins and 
portal triads which are connected by sinusoids and hepatocytes with a distance of about 10 hepatocytes 
from portal triad to central vein in mice. Depending on their position within a lobule, the hepatocytes 
have different metabolic competences and are equipped with different enzymes. Some of the enzymes 
involved in drug metabolism are also known to underlie zonation (S. P. S. Monga & Cagle, 2010; Ruijter 
et al., 2004). 
Separation of the different functional zones in the liver is technically possible by laser capture micro-
dissection (LCM) which results in very limited sample amounts and demands for appropriate methods for 
analysis. The DigiWest method allows detection and relative quantification of several hundred proteins 
and protein modifications from limited material. This gave the opportunity to investigate laser capture 
microdissected material from the different liver zones. The aim of the following experiment was to 
investigate the pericentral and periportal zones separately upon TCPOBOP treatment to get new and 
more detailed insights into the processes and changes with a focus on cellular signaling. This is the first 
time that a drug treatment time course was investigated with zonal resolution on protein level.  
 
3.8.1 Protein analysis of a TCPOBOP treatment time course with zonal resolution 
The experiment was performed in cooperation with Albert Braeuning at the Department of Toxicology at 
University of Tuebingen in the group of Michael Schwarz. At the Department of Toxicology, four groups 
of C3H/He mice were treated with intraperitoneal injections of corn oil as control or TCPOBOP dissolved 
in corn oil (3 mg/kg) for 24, 48 and 72 hours. Details of the experimental setup of the time course study 
can be found in Braeuning et al. (Braeuning et al., 2011). As it is known that there is a gender difference 
and that female mice show a stronger response to TCPOBOP treatment (Braeuning et al., 2011) only 
female mice were chosen for this experiment. 
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Fresh frozen mouse liver sections were used as source material. The 10 µm thick sections were placed on 
LCM slides (MembraneSlide 1.0 PEN), formalin fixed and stained with a mouse derived glutamine 
synthetase (GS) antibody to visualize liver zonation. This was performed by Elke Zabinsky in the 
Department of Toxicology. These stained sections were kept frozen till used for LCM. The formalin 
fixation step was found to be necessary to prevent loss of phosphorylations. Formalin fixation is not ideal 
for lysis of tissue sections and impairs protein quality and yield but without fixation there was a massive 
loss of phosphorylations observed in initially performed experiments. 
LCM was performed on a PALM MicroBeam (Zeiss). The MembraneSlide is based on a microscopy slide 
and a membrane which holds the section. Slide and usable area of the membrane are separated by a 
thin air bed. This allows cutting of the tissue section together with the membrane using an UV laser. The 
cut areas are then catapulted onto a cap which is placed above the section (AdhesiveCap 200 opaque, 
Zeiss) by a defocused laser shot.  Areas surrounding the portal triad (GS negative vessels) and areas 
surrounding the central veins (GS positive vessels) were cut using the UV laser and collected.  
 
 
FIGURE 21 STUDY DESIGN: MOUSE LIVER AND DRUG TREATMENT 
This study consisted of 16 female C3H/He mice in 4 groups. A control group and groups treated with 
TCPOBOP for 24, 48 and 72 hours. Liver sections were formalin fixed and GS stained. Periportal and 
pericentral areas from the liver sections were isolated by LCM for DigiWest analysis. 
 
As indicated in figure 21 only the proximal 1-2 cell layers surrounding the blood vessels were collected 
representing the proximal pericentral and proximal periportal zones. An area of about 3.7 mm² was 
collected for each zone which represents most areas of interest surrounding vessels which can be found 
in one section. The liver sections from the 16 mice resulted in 32 samples. These were analyzed in a 
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DigiWest experiment. 8 bead-mixes were generated, each containing 4 samples and sufficient for 200 
antibody incubations. 
 
 
FIGURE 22 LASER CAPTURE MICRODISSECTION 
a) GS stained mouse liver section. Central vein (cv) and portal vein (pv) are clearly visible. b) GS stained 
mouse liver section as seen under the PALM MicroBeam. Staining was still visible but contrast was pretty 
bad, this might be based on settings of the microscope. The contrast was better for lower magnifications. 
c) Areas selected for cutting. d) Section after cutting. e) Cut areas collected on the LCM cap. 
 
As the number of cells isolated by LCM is low, antibodies were tested on less precious material. This 
were smaller sets of LCM samples (one set contained periportal and pericentral LCM material from a 
control mouse, another set additionally contained LCM material from a mouse treated with TCPOBOP for 
48 hours) or on 3 µg of a mouse whole liver lysate. A bulk of about 660 antibodies was tested, several 
antibodies using up to 6 different assay conditions resulting in far more than 1000 test assays.  
The proteins of interest were selected based on literature on liver zonation and on literature on 
TCPOBOP treatment but as the main interest was cellular signaling and changes thereof in respect to 
zonation and drug treatment, a large set of antibodies covering signaling pathways was included.  
204 antibodies were finally selected for the DigiWest analysis on the 32 mouse liver LCM samples and 
the intense pretesting ensured that most of them gave analyzable signals. Some of the assays were 
performed using the polymer buffer. 
As the resulting samples were very limited, no protein determination of the samples was performed. 
Based on protein determination for pre-experiments the protein amount was expected to be about 
2.5 µg. The data were normalized on the signal obtained with Streptavidin-PE which can be used for 
relative on-bead protein determination as demonstrated.  
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As GS staining was used for visualization of zonation (see Fig. 22) and areas surrounding blood vessels 
showing GS staining were collected as pericentral areas and unstained areas surrounding blood vessels 
were collected as periportal areas, purity of the collected cells was tested using an anti-GS antibody in a 
DigiWest assay. The average ratio of the GS signal obtained for GS positive (pericentral) relative to GS 
negative (periportal) areas was 470 (mean) or 480 (median) over all 32 samples (16 mice). The periportal 
marker E-cadherin did only give analyzable signal on the periportal samples and no analyzable signal on 
the pericentral samples. So the periportal and pericentral areas were properly separated. Different 
cytochrome P450 antibodies were also included as an additional quality control. For cytochrome P450s 
which have been described to be induced by TCPOBOP treatment, antibodies recognizing members of 
the Cyp3A, Cyp2B and Cyp2C families were used. All three cytochrome P450 antibodies showed the 
expected induction.  
 
 
FIGURE 23 QUALITY CONTROL OF THE LCM EXPERIMENT 
As quality control, the zonal markers glutamine synthetase (pericentral) and E-cadherin (periportal) and 
cycochrome P450 antibodies (Cyp3A and Cyp2B) were used. a) Western-Blot mimics generated from 
background subtracted raw data. The slight differences in the positions of the bands are based on the 
initial Western-Blots and the cutting positions for the molecular weight fractions. b) Diagrams 
representing the integrated signals of the peaks (AFI). The median of the 4 mice in each group is shown 
with standard error. Data are normalized on total protein using Streptavidin-PE as mentioned.  The zonal 
markers confirm a good separation of the zones and the cytochrome P450s respond to TCPOBOP 
treatment as expected.  
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3.8.2 Issue with unspecific recognition 
An additional band was observed for some analytes at about 40 kDa which showed complete pericentral 
zonation and a signal decay over the time course. Therefore, this band showed similar behavior than GS 
(glutamine synthetase) and exactly overlaid the bands for GS. This band was observed for Cyclin A, IDH2, 
IRAK4, HDAC1, PKA C alpha and PTCH2 but was not observed in experiments using fresh frozen liver 
lysates. The molecular weight resolution of the DigiWest method allowed identification of those 
additional bands and kept analyzability of the bands at the proper molecular weight. Interestingly, when 
some of these antibodies were used for validation of the results in immunohistochemical staining (IHC) 
by Elke Zabinsky, the antibodies showed a staining pattern resembling the GS stain but only when 
formalin fixed (FFPE) sections were used. The GS-like stain was not visible on fresh-frozen sections. So 
probably the formalin treatment created cross-reactivity for GS that was recognized by several 
antibodies. The same phenomenon was observed for some more antibodies showing an additional band 
at about 50 kDa which showed pericentral zonation and an induction in the time course. The additional 
band was observed for the antibodies recognizing Cox1, Cox2, DKK1, E2F4 and Elk1.   
 
 
FIGURE 24 ADDITIONAL BANDS OBSERVED FOR SOME ANTIBODIES 
Shown is the staining of glutamine synthetase on FFPE and fresh-frozen liver sections. Some analytes 
showed additional bands at 40 kDa which were completely zonated and showed similar behavior than 
GS. HDAC1 is one of these. The GS-like staining pattern only appeared on FFPE sections, the same was 
observed for cyclin A. PTCH2 showed the 40 kDa additional band but also a completely zonated band at 
the correct molecular weight (120 kDa). The FFPE-stain should represent an overlap of these two bands 
while on the fresh-frozen section the signal should be PTCH2-specific.  
 
The molecular weight resolution of the DigiWest method allowed differentiation of the bands and kept 
analyzability for those analytes. Besides these additional bands there some more analytes which showed 
additional bands at ‘wrong’ molecular weights. In some cases these additional bands could be allocated 
to specific isoforms or variants of the proteins but in some cases they could not be allocated and were 
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discarded. The antibody recognizing RXRα showed an additional band which might represent RXRβ or 
might be an additional band and the antibody recognizing RAD23B showed an additional band which 
might represent RAD23B isoform 2 or RAD23A. The 40 kDa and 50 kDa bands observed for some analytes 
mentioned above were discarded. 
 
3.8.3 Liver zonation  
The first part of data analysis focused on proteins that showed a zonated distribution in the untreated 
animals. For this analysis all signals were normalized on the median of the pericentral zone of the control 
group and log2 transformed. Therefore, the following data represent the differences in the periportal 
zone (median) relative to the pericentral zone (median). The median was chosen because it is more 
stable to outliers and there is some variation in between the individual animals.  
T-tests were performed for statistical analysis using the MEV software package for all analytes that gave 
analyzable signals on both zones. The following analytes are not shown because they were only detect-
able in one zone: E-cadherin (periportal only), PTCH2 (pericentral only) and Cyclin A (periportal only). To 
represent the complete data set in one graph, the volcano plot representation was chosen. 
 
 
FIGURE 25 ZONATED ANALYTES 
Volcano plot: Shown are all analytes which gave analyzable signal on pericentral and periportal samples 
from the control group. The data contained in this plot are derived from more than 1500 Western-Blot 
lane equivalents.  The log2 fold difference of the periportal zone relative to the pericentral zone is shown 
on the x-axis and the statistical significance represented by the p-value of the t-test on the y-axis. 
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Significant analytes (Log2 fold difference >1, p<0.05) are shown in black, non-significant ones in gray. 
Several of the analytes which show significant zonation are highlighted.  
 
The following table contains all significantly zonated analytes from this analysis.  
Analyte Ratio GS-/GS+ Log2 Fold p-Value 
Cyclin A Periportal NA NA 
E-Cadherin Periportal NA NA 
GAS-2 19.42 4.28 1.62E-06 
SDS (serine dehydratase) 16.53 4.05 2.63E-05 
FTCD 10.16 3.34 1.72E-06 
HAL (histidine ammonia lyase) 8.31 3.05 0.00013 
PP2A C - pY307 8.29 3.05 0.00014 
PP1 gamma 5.15 2.37 0.0023 
PAK 1/2 - p S144/S141 5.06 2.34 0.00019 
GLS2 (Glutaminase 2) 5.06 2.34 0.0065 
DUSP4  4.69 2.23 3.04E-06 
RPS6 - pS240/244 4.54 2.18 0.00027 
NF-κB p100/p52 - p100 4.01 2.00 0.039 
PDGF Receptor beta 3.24 1.70 0.0038 
ASL (argininosuccinate lyase) 3.19 1.67 0.011 
RAD23B (hHR23b) - Isoform 1 2.92 1.55 0.0057 
PGC1 alpha - pS571 2.90 1.54 0.030 
p53 2.85 1.51 0.016 
c-Jun 2.84 1.51 0.0072 
HNF-4 - pS313 2.81 1.49 0.00017 
AMPK alpha 2.28 1.19 0.017 
ILK1 - pThr173 2.21 1.14 2.50E-06 
ILK1 - pS246 2.15 1.11 1.95E-06 
PTPN7 (LC-PTP, HEPTP) - 52 kDa Isoform 3 2.15 1.10 0.00099 
PKC alpha/beta II - pT638/641 2.11 1.08 0.00055 
GAPDH 2.11 1.08 0.00014 
PTPN7 (LC-PTP, HEPTP) - 40 kDa Isoform 1 2.05 1.04 0.00023 
MEK1/2 - p Ser217/221 0.446 -1.17 0.025 
N-Cadherin 0.441 -1.18 0.0036 
RAD23B (hHR23b) - Isoform 2 (or RAD23A) 0.427 -1.23 0.034 
c-myc 0.419 -1.25 0.0015 
DPP3 (Dipeptidyl-peptidase 3) 0.412 -1.28 0.0015 
INSL4 0.410 -1.29 0.0049 
HSP70 0.373 -1.42 0.00045 
GLUT-1 0.129 -2.95 2.58E-05 
Cyp2E (Cyp2E1) 0.0246 -5.35 3.18E-05 
Glutaminsynthetase 0.0030 -8.39 4.39E-08 
PTCH2 Pericentral NA NA 
TABLE 2 ANALYTES WHICH SHOWED STATISTICALLY SIGNIFICANT ZONATION IN THE CONTROL GROUP  
This table shows all significantly zonated analytes with a ratio periportal to pericentral > 2 (log2 >1) and a 
p-value < 0.05. 38 analytes hit these criteria. Shown is the median of the periportal (GS-) relative to 
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pericentral (GS+) samples with Log2 fold difference and p-value (t-test) sorted by fold difference. The 
analytes which were only detectable in one zone are included. 
 
Several of the statistically significant analytes are enzymes known to be zonated. But the set also 
contains some kinases, phosphatases and transcription factors involved in cellular signaling. Some 
analytes showed a high variance between the animals within one group resulting in larger p-values and 
less significance; some seem to be very stably expressed.  
These results confirm some published knowledge on zonation of enzymes. SDS (serine dehydratase) is 
known to be periportllay zonated (Ogawa & Kawamata, 1995), Cyp2E1 is known to be pericentrally 
zonated (Kai O. Lindros, 1997) as is GLUT-1 (Bilir et al., 1993). FTCD (glutamate formiminotransferase) 
and HAL (histidine ammonia lyase) are zonated periportally and others have  been described based on 
mRNA data (Braeuning et al., 2006).  
For a more familiar visualization of the DigiWest data, a collection of significantly zonated analytes was 
used to generate Western-Blot mimics.  
 
 
FIGURE 26 COLLECTION OF ZONATED ANALYTES AS WESTERN-BLOT MIMICS 
A collection of statistically significantly zonated analytes represented as Western-Blot mimics. The images 
are based on the background subtracted DigiWest data without normalization. Normalization on protein 
amount was performed after quantification of the bands/peaks. The analytes with complete zonation 
which were not contained in the statistical analysis (E-Cadherin, PTCH2 and Cyclin A) are also included. 
 
GS and E-Cadherin are known zonation markers and show perfect localization in the periportal and 
pericentral hepatocytes. PTCH2 is a Hedgehog receptor which has not yet been described as being 
Results Mouse liver zonation and zonal response to TCPOBOP treatment 
64  
zonated. HNF4α protein which is also included in the Western-Blot mimics did not show significant 
zonation but the phosphorylation of HNF4α at Ser313 showed a periportal zonation. 
GAS-2 has been shown to be zonated on mRNA level (Braeuning et al., 2006) which fits the observation 
on protein level. GAS-2 is an inhibitor for the protease calpain and was  shown to stabilize p53 (Benetti et 
al., 2001) which is in agreement with the localization of the p53 protein in this dataset.  
Several phosphatases, kinases and phosphorylations are found to show a zonal distribution. A prominent 
phenomenon is that several serine and threonine phosphorylations show periportal zonation which is 
part of the discussion. 
 
3.8.4 Zonation and drug response: a short overview 
The data set contains the TCPOBOP treatment time course and the zonation. Depending on the analysis, 
data were either normalized on the median of the zone specific control group or on the median of all 
controls (periportal and pericentral). The following figure represents the whole data set (median values 
of the groups) for a first overview. Data for each zone were normalized on the median of the 
corresponding control group and log2-transformed. 
 
 
FIGURE 27 OVERVIEW OF THE COMPLETE TIME COURSE DATA-SET  
Shown are the log2-fold changes (median values) relative to the control (normalized on the median of the 
corresponding control group) for all analytes in the time course representing the whole data set.  
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Besides some analytes showing strong effects, the data show a global tendency of a slight decrease over 
the time course. This phenomenon might be based on hypertrophy during TCPOBOP treatment and will 
be part of the discussion. 
 
Two microarray analysis techniques capable of time course analysis for groups of samples were 
employed for detecting drug effects over time. For analysis of the whole data set, the data were 
normalized on the median of all controls (pericentral and periportal) and log2 transformed.  In a first 
analysis, LIMMA (Linear Model for Microarray Analysis) was employed which uses two conditions, in this 
case the periportal and the pericentral location. The 4 time points (control, 24, 48 and 72 hours 
TCPOBOP treatment) were used for time course analysis. P-values for each condition and each time 
point could be calculated and the cut-off was set to p < 0.05. The results are lists giving significant 
analytes for each time point and condition. The data shown in the following figure are the significant 
analytes detected for all time points and both conditions (overall significant). 
 
 
FIGURE 28 LIMMA ANALYSIS OF THE WHOLE DATA SET 
Shown are the overall significant analytes (all time points, both conditions (zones)) from LIMMA analysis 
with p<0.05 in a heat map. The data are clustered by Pearson correlation. Some analytes were skipped 
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because there were no or not enough data for one or more time points for one of the conditions and the 
test needs data for both conditions and all time points.  
 
For statistical significance the overall significant analytes from the LIMMA analysis have to show 
significant changes over the time course and between the zones. Several analytes show similar changes 
in the periportal and the pericentral zones and are therefore not contained in this analysis. This test is 
not perfectly suited for this data set as the two zones do not exactly represent two conditions to be 
compared like treatment and control. Time course effects are not represented well on the heat map 
representation, still the subset of significant analytes clustered in the correct groups and only the 48 
hours and 72 hours treatment time points are not clustered correctly in the time course. Although the 
heat map shows only the group of overall significant analytes between all time-points and both 
conditions, there are still 25 analytes which show significant time course and zonation effects.  
 
As DigiWest represents a new method, there are no established standards for data representation. 
Depending on the aspect of the data which should be highlighted, there are different representations 
favorable.  
A collection of some analytes is represented as Western-Blot mimics in the next figure. This representa-
tion is useful as it is very similar to Western-Blots and familiar to scientists who are used to Western-Blot 
images. It focuses on molecular weight and also highlights variations between the samples or animals. 
The data represent paired samples as from each animal a periportal and a pericentral zone was isolated. 
As mentioned, background subtracted raw data are used for these representations without 
normalization on total protein. 
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FIGURE 29 SELECTION OF WESTERN-BLOT MIMICS REPRESENTING THE WHOLE SAMPLE SET 
Shown is a selection of some analytes on all 32 samples in different representations. Shown are c-Myc, 
HSP70, Ihh and MCM2. a) Western-Blot mimics generated from background subtracted raw data. b) 
Same data shown as diagrams representing the integrated signal intensities (AFI) normalized on total 
protein, median with standard error. c) Same data again, shown as log2 fold change relative to control 
for each zone with standard error. 
 
It is known that c-Myc is induced upon TCPOBOP treatment in the mouse liver (Blanco-Bose et al., 2008; 
Donthamsetty et al., 2011). But it was not known yet that this effect is completely restricted to the peri-
central zone, there is no change detectable in the periportal zone. HSP70 has not yet been described in 
context with TCPOBOP but as it is a stress related protein this is not surprising. HSP70 induction is also 
restricted to the pericentral zone but there is a lower induction in the periportal zone.  
Ihh (indian Hedgehog) is a ligand from hedgehog signaling and is induced in periportal and pericentral 
zones. Hedgehog signaling plays an important role in liver development and regeneration and induction 
of Ihh has been reported after partial hepatectomy and under conditions which might induce apoptosis 
(Ochoa et al., 2010; Omenetti, Choi, Michelotti, & Diehl, 2011).  
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MCM2 (Minichromosome maintenance protein 2) has been observed on mRNA level to be induced by 
TCPOBOP (Leoni et al., 2011). It is induced in both zones to a similar extend.  
 
The molecular weight resolution allows identification of additional bands which could be isoforms but 
can also be additional bands. All analytes which are described as isoforms here could be isoforms as 
there are known isoforms with the appropriate molecular weight but they could also be additional bands 
from other proteins which cross react with the antibody.  
 
 
FIGURE 30 SELECTION OF ANALYTES SHOWING POTENTIAL ISOFORMS 
Shown are RAD23B and PTPN7 as examples of observable isoforms. UV excision repair protein RAD23 
homolog B has 2 known isoforms (in humans) but it is also possible that the observed additional band 
might represent RAD23A. The phosphatase PTPN7 has 3 known isoforms (in humans). a) Western-Blot 
mimics of RAD23B and PTPN7. b) Integrated signals for the individual isoforms in [AFI] with standard 
error. RAD23B isoform 1 is zonated periportally and does not respond to TCPOBOP treatment while 
isoform 2 (or RAD23A) is pericentrally zonated and induced by TCPOBOP. The 3 isoforms of PTPN7 also 
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show different behavior. Isoform 1 is periportally zonated and down regulated by TCPOBOP while isoform 
2 is pericentrally zonated and induced. Isoform 3 shows high variation within the groups with a tendency 
to induction in the pericentral zone and down regulation in the periportal zone.  
 
As mentioned before these isoforms could also represent additional bands. There is no knowledge about 
the meaning or regulatory differences for these potential isoforms at this time. The UV excision repair 
protein RAD23 homolog B is involved in DNA repair. It might be possible that the 2 bands correspond to 
RAD23B and RAD23A. The hematopoietic tyrosine phosphatase PTPN7 is a mitogen-activated protein 
kinase phosphatase which can inactivate Erk and p38 (Nika et al., 2006). There is nothing known yet 
about the potential functions of the different isoforms. 
 
 
 
 
 
 
 
 
 
 
3.8.5 Zonation and drug response: pericentral effects 
In this analysis only the pericentral areas were analyzed to further investigate the TCPOBOP treatment 
time course. Data were normalized on the median of the control group of the pericentral samples. BETR 
(Bayesian Estimation of Temporal Regulation) was used as microarray analysis technique which is also 
implemented in MEV. BETR takes sample and time point information into account to detect differential 
expression in time-series data (Aryee, Gutiérrez-Pabello, Kramnik, Maiti, & Quackenbush, 2009). Signifi-
cance was calculated based on a p-value <0.05 resulting in 66 significant analytes.  
To identify analytes with similar response to TCPOBOP treatment, the significant analytes were clustered 
by Pearson correlation.  
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FIGURE 31 BETR TIME COURSE ANALYSIS OF THE PERICENTRAL AREAS  
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The heat map shows all 66 analytes which were significant (p < 0.05) in the BETR analysis clustered by 
Pearson correlation. The analyte tree on the left represents the similarity of the analyte behaviors. All 
samples are clustered in the correct order. 
 
There are many interesting changes on protein level in the pericentral areas and all samples cluster in 
the correct order. The time course effects are not well visualized in the heat map. Therefore, small 
diagrams were generated showing the log2-fold change relative to control and standard error within the 
groups. The same 66 analytes were used and grouped based on Pearson correlation corresponding to 
the analyte tree of the heat map in figure 31.  
 
 
FIGURE 32 UP-REGULATED ANALYTES IN PERICENTRAL AREAS 
Up-regulated analytes in pericentral areas based on BETR analysis. Data are medians of the groups 
shown in log2 fold change relative to the control group with standard error. Analytes are grouped by 
Pearson correlation corresponding to the analyte correlation tree of the previous heat map.  
Besides the analytes shown as examples in the short overview section there are several more analytes 
which are induced upon TCPOBOP treatment.  
 
 
 
As TCPOBOP induces hepatocyte hyperplasia with a proliferation peak at 24 to 48 hours (Donthamsetty 
et al., 2011) it is expected that some analytes show peaks at these time points.  
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FIGURE 33 ANALYTES WITH MAXIMA AT 24 OR 48 HOURS TREATMENT IN PERICENTRAL AREAS 
Data represented in log2 fold change with standard error. RPS6 (S6 ribosomal protein) phosphorylation, 
PP2A C (protein phosphatase 2 catalytic sub unit) phosphorylation and Akt Thr308 phosphorylation show 
a peak at 24 hours TCPOBOP treatment. PI3-kinase p85 shows a peak at 48 hours treatment.  
 
S6 ribosomal protein phosphorylation is associated with increased proliferation and protein synthesis 
(Stewart & Thomas, 1994). Akt (PKB) is phosphorylated at Thr308 by PDK1 and has been shown to be 
involved in liver regeneration (Haga et al., 2009). Akt and S6 kinase, the kinase phosphorylating S6 ribo-
somal protein, are both phosphorylated by PDK1 and are both dephosphorylated by the phosphatase 
PP2A (Bononi et al., 2011; Shiojima & Walsh, 2006). The phosphorylation of PP2A catalytic subunit at 
Tyr307 inhibits phosphatase activity (J. Chen, Martin, & Brautigan, 1992) which fits to the observation of 
the phosphorylation peaks. PI3-kinase shows a peak at 48 hours. 
There are more analytes which show peaks at either 24 or 48 hours, but their changes were not found to 
be statistically significant. As can be observed in figure 27 representing the whole time course data-set, 
there are several analytes which show a slight and not significant peak at the 24 hour time point. 
 
 
 
 
 
 
 
 
 
A large number of analytes showed down-regulation in the pericentral zone during the TCPOBOP time 
course. 
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FIGURE 34 DOWN-REGULATED ANALYTES IN PERICENTRAL AREAS 
Down-regulated analytes on pericentral side based on BETR analysis. Data are shown in log2 fold change 
relative to the control group with standard error. Analytes are grouped by Pearson correlation 
corresponding to the analyte tree of the heat map in figure 31.  
 
Most of the phosphorylations with significant changes are down-regulated during the time course and 
also a large number of proteins. There are also some phosphorylations which are pericentrally zonated 
and some which do not decrease but they are not statistically significant. There are several possibilities 
which might explain this. It could be due to hypertrophy and increase in cell size and the induction of 
drug metabolizing enzymes during the time course which might lead to a decrease of phosphorylated 
proteins relative to the total protein in the samples. Phosphatases could also play a role. This observa-
tion is part of the following discussion. 
Results Mouse liver zonation and zonal response to TCPOBOP treatment 
74  
The following figure shows some of the significantly changed analytes from the previous figures as 
Western-Blot mimics. 
 
 
FIGURE 35 COLLECTION OF WESTERN-BLOT MIMICS  
Shown is a selection of significantly changed analytes from the previous BETR analysis of the pericentral 
zone represented as Western-Blot mimics based on the background-subtracted raw data.  
 
Taken together, there are many changes observed in protein expression and phosphorylation in the 
pericentral areas of the mouse livers during the TCPOBOP treatment time course. Some of them will be 
part of the discussion. 
 
 
 
 
 
3.8.6 Zonation and drug response: periportal effects 
The BETR analysis performed for the pericentral zones was also performed for the periportal zones. Data 
were normalized on the median of the periportal control group and log2 transformed. BETR analysis with 
a p-value <0.05 was performed. 36 analytes showed significant changes in this time course analysis. 
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FIGURE 36 BETR TIME COURSE ANALYSIS OF THE PERIPORTAL AREAS 
The heat map shows all 36 significant analytes (p<0.05) form the BETR analysis of the periportal zones 
again clustered by Pearson correlation to cluster analytes with similar behavior. The sample groups are 
almost completely clustered according to the time course; only the 48 hours and 72 hours TCPOBOP 
treatment groups are not properly clustered. 
 
The observation that the 48 hours and 72 hours TCPOBOP treatment groups are not separated properly 
is based on the fact that most analytes do not show a continuous increase or decrease over time but 
they reach a plateau at 48 hours or in some cases go through a maximum effect followed by reduction.  
Again, the Pearson correlation tree was used to identify analytes with similar behavior and diagrams 
showing the log2 fold change relative to the control group (medians with standard error) were 
generated and arranged according to the correlation tree of the heat map in figure 36. 
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FIGURE 37 UP-REGULATED ANALYTES IN PERIPORTAL AREAS 
Analytes which are up-regulated during TCPOBOP treatment time course in periportal areas based on 
BETR significant analytes. Data are shown in log2 fold change with standard error. Analytes are grouped 
by Pearson correlation corresponding to the analyte tree.  
 
As mentioned, in the periportal zones there are not these clear increases or decreases over the time 
course than observed for the pericentral zones. Several of the up-regulated analytes observed in the 
periportal zones were also found up-regulated in the pericentral zones. An analyte which was not 
statistically significant in the pericentral zone is EZH2 which seems to be unaffected by TCPOBOP in the 
pericentral zones but is up-regulated in the periportal zones. EZH2 is a histone methyltransferase and 
part of the chromatin remodeling polycomb repressive complex 2 (PRC2). It is meant to be associated 
with hepatocyte proliferation and differentiation (Aoki et al., 2010).  
 
FIGURE 38 DOWN-REGULATED ANALYTES IN PERIPORTAL AREAS 
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Analytes which are down-regulated during TCPOBOP treatment time course on periportal side based on 
BETR significant analytes. Data are shown in log2 fold change with standard error. Analytes are grouped 
by Pearson correlation corresponding to the analyte tree.  
 
As already seen for the pericentral zones there are several phosphorylations which are statistically 
significantly down-regulated. This observation is addressed in the discussion. 
Interestingly, the analytes showing maxima at 24 or 48 hours TCPOBOP treatment which were significant 
in the analysis of the pericentral areas are not statistically significant in the periportal areas. The 
observed maxima were also found in the periportal areas but they were less distinctive.  
The following figure shows some of the analytes which were found to be significantly changed during the 
TCPOBOP time course in the periportal areas, represented as Western-Blot mimics. 
 
 
FIGURE 39 COLLECTION OF WESTERN-BLOT MIMICS 
Shown are some of the analytes which show significant changes during the TCPOBOP time course in the 
periportal areas represented as Western-Blot mimics based on the background subtracted raw data. The 
phosphorylation of RPS6 also shows the peak at 24 hours after treatment but it was not found to be 
statistically significant by the BETR analysis. MCM2, PGC-1α and EZH2 show an induction in the time 
course. RXRα also shows an induction for the main band at 50 kDa while it also shows an additional band 
at 55 kDa which could represent RXRβ and does not show induction in the time course. 
 
The number of analytes showing statistically significant changes in the TCPOBOP treatment time course 
in the periportal and pericentral areas shows that TCPOBOP has strong effects on cellular signaling. Some 
of the observed changes were found to a similar extend in periportal and pericentral zones while some 
effects were found to be restricted to one zone. The stronger effects in the time course were found in 
the pericentral zones. Some of the observations will be addressed in the following discussion. 
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3.8.7 Validation of the DigiWest results by immunohistochemistry 
Some of the statistically significant analytes were stained on mouse liver sections for validation of the 
results. The IHC stains were performed by Elke Zabinsky in the group of Michael Schwarz. The observed 
periportal zonation of several phosphorylations was of special interest to confirm the DigiWest 
measurements. For each IHC stain, a GS stain was performed on a sequential section for identification of 
periportal and pericentral zones and a secondary antibody control was performed additionally to confirm 
signal specificity. All sections were formalin fixed and paraffin embedded except for the PTCH2 staining 
which showed the described cross reactivity with GS on formalin fixed sections. Therefore, a fresh frozen 
section was used. 
 
 
FIGURE 40 VALIDATION OF RESULTS BY IMMUNOHISTOCHEMISTRY 
Immunohistochemical staining was performed for some analytes which showed statistically significant 
zonation in the DigiWest analysis. The periportal marker protein GS was stained on a sequential section 
for identification of the periportal and pericentral zones and a secondary antibody control was performed 
for validation of the signal specificity. The phosphorylation of the protein phosphatase PP2A C at Tyr307 
shows the periportal zonation as observed in the DigiWest results. The same is true for the phosphory-
lation of S6 ribosomal protein (RPS6) which was additionally confirmed in a fluorescent stain. PTCH2 
shows, as mentioned before, the observed pericentral zonation on fresh frozen and FFPE sections but on 
FFPE sections it shows cross-reactivity with GS. E-Cadherin is a known periportal marker. 
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The immunohistochemical stains confirmed the zonation of some proteins and phosphorylations 
observed in the DigiWest results. This is of special interest because several serine and threonine 
phosphorylations showed a periportal zonation which raised concern that this observation might have 
been an artefact. These images verify the results and prove the reliability of the DigiWest data. The 
following discussion also provides a reasonable explanation for the periportal zonation of the observed 
serine and threonine phosphorylations based on cellular signalling and zonation of phosphatases. 
All antibodies used for IHC to validate the DigiWest data did either confirm the DigiWest results or did 
not show any staining as most of the antibodies used for DigiWest were not suited for IHC. None of the 
antibodies which were used for IHC showed conflictive results.  
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4 Discussion 
Proteins play a pivotal role in cellular processes in health and disease. Changes in protein abundance and 
in the degree of posttranslational modifications indicate changes in the status of cells on the molecular 
level. Thereby, analysis of proteins improves our understanding of physiological and pathophysiological 
mechanisms. To gain insight into the complex interplay found in cellular signaling and to analyze the 
adaption of a cell or a living being to influences like drug treatment, it is necessary to look at as many 
factors as possible. Analysis using mass spectrometry has the advantage of being unbiased and allows de 
novo identification of changes in protein abundances or even in posttranslational modifications of 
proteins. Yet, the protein mixtures obtained from whole cells or tissues are often too complex for mass 
spectrometry analysis and laborious preprocessing steps are required to get this information. There are 
methods for specific depletion or enrichment like Kinobeads to reduce complexity to an analyzable level. 
Antibody based immunoassays are often better suited for the analysis of complex samples but the 
selection of antibodies brings in a bias. Nevertheless, immunoassays play a pivotal role in research and 
diagnostics. In research, Western-Blot is still a gold standard for semi-quantitative protein detection. 
Efforts in protein microarray technology resulted in an increased sample and analyte throughput but 
often combined with a loss of data quality. As in practice antibodies are often not perfect and show 
unspecific signal, the information of molecular weight generated by Western-Blot and identification of 
specific signal proved to be crucial.  
Different methods have been developed that do provide an increased sample and analyte throughput 
and molecular weight information. The microwestern array, which spots the samples into a gel and runs 
them for approximately 9 mm before blotting onto a membrane, is a good example. Six samples are 
analyzed in parallel and up to 96 antibodies can be analyzed in one assay. Thereby, they address the 
sample and analyte throughput and introduce some limited information on molecular weight. The focus 
of this approach is on antibody throughput (Ciaccio, Wagner, Chuu, Lauffenburger, & Jones, 2010). 
Another method that needs to be mentioned is the Simple Western technology. This method uses 
capillary electrophoresis and by running up to 96 samples simultaneously, a high parallelization is 
achieved. Denaturing SDS-PAGE using gel containing capillaries separates proteins followed by immo-
bilization by photo-activated capture chemistry. Antibody incubation is performed in the capillaries 
followed by chemiluminescent readout. The 96 capillaries can also be used to separate the same sample 
several times and incubation with different antibodies (Nguyen, Squaglia, Boge, & Fung, 2011; O’Neill et 
al., 2006). 
DigiWest Discussion 
81 
The DigiWest method uses another approach with a focus on generation of high resolution molecular 
weight information, analyte throughput and on easy and reliable signal quantification. DigiWest 
represents a digitalized Western-Blot which allows generation of hundreds of identical replicas of a 
Western-Blot. It is a novel approach which combines advantages of Western-Blot and microarrays and 
thereby also provides new possibilities in protein research. 
 
4.1 DigiWest 
4.1.1 Development of the DigiWest method 
A main part of this work was development of the DigiWest method, a system that utilizes standard 
Western-Blotting as integral part of its workflow. After gel electrophoresis and blotting, proteins are 
biotinylated on the blot and the lanes on the blots containing the separated proteins are cut into 96 
strips, each 0.5 mm high, representing molecular weight fractions. All proteins contained in each fraction 
are eluted from the membrane strips and loaded onto Luminex beads. A collection of 384 distinct color-
coded, magnetic Luminex bead-sets coated with NeutrAvidin is employed to load the eluted proteins. 
Each of the 96 molecular weight fractions is loaded onto a distinct bead-set and the 384 bead-sets allow 
loading of 4 initial Western-Blot lanes onto distinct bead-sets. After loading with proteins, the bead-sets 
are pooled into a DigiWest bead-mix. The information on the molecular weight fraction and its position 
on the initial Western-Blot are maintained in the color code of the beads. A bead-mix generated from 
one Western-Blot is sufficient for hundreds of antibody incubations in microtiter plate based assays. The 
signals obtained on each bead-set, for each antibody-incubation, are used to digitally reconstruct the 
initial Western-Blot. This is where the name is derived from.  
This novel idea could be patent protected and the whole workflow realizing this approach had to be 
developed from scratch. Important aspects throughout the method development process were 
robustness and applicability in a routine workflow. A good quality and reproducibility of the initial 
blotting procedure including sample preparation and gel loading is mandatory. The use of a commercial 
system (NuPAGE) gave acceptable reproducibility and blotting homogeneity. The obtained 
reproducibility of the DigiWest method was comparable to regular Western-Blots with only a marginal 
increase of variation. Therefore the method is very robust. Cutting the lanes into 96 molecular weight 
fractions and the resulting distribution of the proteins on the fractions can lead to variation of the shape 
of the peaks in diagram representation, integration of the peak areas still results in robust signal 
intensities. This can be seen in the spike-in experiment where the peaks for the intrinsic ERK2 have very 
different shapes depending on the exact position of the cuts (Figure 17). An aspect which plays a role 
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here is that gels run slightly faster in the middle compared to the borders which leads to a slight shift 
when lanes are compared which are not directly adjacent. Biotinylation of the proteins on the 
membranes is very reproducible because the blots are biotinylated in a whole and all potentially 
interfering contaminants are washed off before biotinylation. Elution of the proteins from the molecular 
weight fractions in 96 well plates is a critical step and quantitative elution is required for reproducible 
results. An elaborate optimization was performed resulting in a simple protocol. The different 
NeutrAvidin coated bead sets represent the binding matrix for the biotinylated proteins. It is mandatory 
that all 384 bead-sets have the same biotin binding capacity to ensure reproducible loading of the 
biotinylated proteins. Irregularities in binding capacities could appear as a bias in the DigiWest results. A 
semi-automated coupling procedure employing the KingFisher magnetic particle processor resulted in 
high reproducibility of NeutrAvidin coupling and a CV below 3% for their biotin binding capacity was 
achieved for the used 384 bead-sets.  
The assay buffer which is used for the antibody incubations has a strong impact and a new buffer was 
created based on a commercial ELISA buffer and supplemented with milk powder. This buffer showed a 
good performance for the vast majority of antibodies. A polymer based buffer was also developed which 
can be used to further increase signals. 
Development of the DigiWest method resulted in a robust system with the main source of technical 
variance derived from the initial Western-Blots. The spike-in experiment shown in this thesis illustrates 
the high data quality and reproducibility that can be obtained with DigiWest. In this experiment, a 
constant amount of HepG2 cell lysate spiked with different amounts of GST-ERK2 was loaded onto the 
gel. The DigiWest bead-mixes were derived from 18 lanes which were distributed over 3 blots. The 
Western-Blot, which was performed to compare the results, was one blot with 15 lanes. The CV of the 
Western-Blot for intrinsic ERK2 was 6.44% and the CV for the DigiWest results using the same antibody 
was 9.57%. The increased CV is derived from the whole workflow including distribution over several 
blots. Similar DigiWest experiments containing fewer lanes which were processed using only one blot 
resulted in even lower CVs.   
In this thesis only the commercial NuPAGE 4-12% Bis-Tris gels were used but as the DigiWest specific part 
of the method starts after proteins are blotted onto the membrane, all gel-separation systems which 
allow blotting of the proteins onto a membrane can be employed.  
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4.1.2 Data quality and performance 
The data quality is also an important aspect. Molecular weight fractions of 0.5 mm result in 96 fractions 
covering the molecular weight range from more than 400 to about 10 kDa using the commercial mini 
gels. Reduction of the fraction size not only leads to a better resolution with shapelier peaks but also 
increases sensitivity and robustness. Smaller fractions lead to higher densities of the analytes on the 
individual Luminex bead-sets and distribution over more bead-sets also increases the overall binding 
capacity and reduces the background signal. The resolution of 96 fractions is good enough to 
differentiate for example ERK1 and ERK2 with 44 and 42 kDa. The two bands are often not completely 
separated as two peaks but appear as a double peak. The same is true for classical Western-Blots when 
the grayscale values are plotted into a diagram. So the limit for distinguishable peaks can be assumed to 
be about 5% difference in molecular weight and is comparable to standard Western-Blots. 
A comparison of about 100 antibodies on Western-Blots and DigiWest showed a high similarity in the 
obtained band pattern (Appendix 1). Most antibodies showed the same additional bands for both 
methods. Differences between the two methods are mainly restricted to intensity and appearance of 
additional bands. Similar differences can be observed when Western-Blots are performed using BSA or 
milk powder as blocking reagents. Here, Western-Blots were performed using BSA as blocking reagent 
and for DigiWest a buffer was used which contains milk-powder. 
The spike-in experiment showed that the linear range for DigiWest covers at least 3 orders of magnitude 
with good signal linearity. This experiment also proved that DigiWest allows absolute quantification of 
analytes if a known standard is used. The direct comparison of the DigiWest to the high-end infrared 
fluorescence based Licor Odyssey scanner proved that both systems have about the same sensitivity and 
signal linearity. The obvious advantage of the DigiWest method is the fact that the same amounts of 
sample and the same initial gel electrophoresis and blotting resulted in a bead-mix sufficient for 100 
antibody incubations while the Western-Blot allowed only one antibody incubation.  
 
4.1.3 Applicability of DigiWest 
The innovation of the DigiWest method is that starting from one blot it provides hundreds of Western-
Blot replicas. This allows detection of hundreds of analytes even on limited material like LCM samples. 
This was demonstrated in the experiment on mouse liver zonation where 200 antibody incubations were 
performed on LCM derived samples. The method is scalable in respect to the number of analytes and 
generation of a DigiWest bead-mix sufficient for 1000 antibodies or more is feasible, the main limitation 
for up-scaling is the amount of sample that can be loaded onto a lane on the initial gel. The bead-mixes 
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can be stored and used for follow-up assays. A scheduled stability test is still missing but bead-mixes 
were routinely used for additional assays after 6 months without observable disintegration. 
The DigiWest method is also very economical in respect to buffer and antibody consumption compared 
to Western-Blots. DigiWest assays are run in microtiter plates and only 30 µl antibody dilution are 
needed per well. The DigiWest bead-mixes can be handled using pipettes or magnetic bead handling 
equipment allowing fast processing and providing the opportunity of automation solutions.  
As mentioned in the introduction, a disadvantage of reverse phase protein microarrays is that they 
require advanced and complicated workflow and equipment. The DigiWest is based on the wide spread 
commercial Luminex platform. The workflow is obviously more complex than a classical Western-Blot 
but compared to the workflow of RPPMs, which includes pipetting robots and spotting robots, the Digi-
West workflow is still pretty simple and besides Western-Blotting equipment and a Luminex instrument 
it needs only low-cost and low-tech equipment as long as no automation is required. Only for bead-
coating and bead-plate preparation some robotic high-tech instruments were employed.  
Taken together, DigiWest proved to be a robust method which creates hundreds of Western-Blot 
replicas with a good sensitivity, reproducibility and signal linearity. The experiments presented in this 
thesis show that it is possible to perform 200 Western-Blot-like analyses even from limited LCM samples 
and the Kinobead pulldowns show that it is also possible to analyze samples derived from affinity 
enrichment methods.   
 
4.1.4 Properties of DigiWest 
Transfer of the Western-Blot onto the bead-based Luminex platform results in completely changed 
properties. The bead-mixes can be seen as a kind of ‘liquid Western-Blot’ and allow assays in microtiter 
plates. The beads allow fast washing steps while for Western-Blots long washing steps are required, 
usually 5 times 5 or even 10 minutes. This is because Western-Blot membranes are a tree dimensional 
mesh with a thickness of 100 to 200 µm and an average pore size of typically 0.2 or 0.45 µm. Contrary to 
the typical saying ‘proteins are blotted onto a membrane’ they are actually blotted into a membrane, it is 
also possible to blot proteins through a membrane when blotting is performed for prolonged times. As 
proteins are blotted into a membrane and binding to the membrane is mainly based on hydrophobic 
interactions, accessibility and flexibility of the proteins are limited. On the DigiWest beads, proteins are 
immobilized on the surface of the beads with a flexible spacer. This results in increased flexibility and 
accessibility of the proteins and might explain the good sensitivity of the DigiWest method.  
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Another important property is that each aliquot of a bead-mix is – at least statistically – identical and 
each bead sets contains an unknown but defined mixture of proteins from a small molecular weight 
range. This allows global normalization strategies for example on the amount of loaded protein by on-
bead protein determination using streptavidin-PE or by a marker analyte like β-Actin. An intrinsic 
molecular weight marker can be calculated based on the position of the peaks from a selection of 
analytes with different molecular weights to get a precise molecular weight marker. The digital Luminex 
data allow easy and fast quantification of the peaks without image processing as necessary for Western-
Blot images. As DigiWest represents hundreds of Western-Blot replicas, it brings the Western-Blot 
towards a proteomic tool which allows system biology approaches from initial Western-Blots. The digital 
data can also be used to create images which look similar to real Western-Blots to represent data in a 
familiar way. Such Western-Blot mimics are shown several times in this thesis. An advantage of Western-
Blot mimics compared to classical Western-Blots is that the digital data can be arranged as desired to 
represent the samples in the favored order and they allow combination of samples from several blots. 
These features are not only distinctive differences to the classical Western-Blot but also to all other tech-
nologies for detection of molecular weight separated proteins. Besides the original idea of generating 
replicas of a Western-Blot, these properties can be exploited for new approaches for research as 
indicated in the outlook in chapter 4.4.  
 
4.1.5 Issues and suggestions 
An aspect which was not investigated in depth is the influence of biotinylation. The biotinylation reagent, 
which is reactive towards primary amino groups and therefore mainly modifies lysine residues, might 
have an influence on antibodies which bind a lysine-containing epitope. Some antibodies were selected 
known to have a lysine-residue in their epitope and they showed a specific peak at the correct molecular 
weight. As almost all antibodies which showed a specific band in a classical Western-Blot also showed a 
specific peak in the DigiWest data, biotinylation does not seem to be an issue and it is expected that only 
a fraction of the lysine residues is biotinylated. But biotinylation might have an effect on some 
antibodies. 
As biotinylation is performed on primary amino groups, the number biotins on a protein should be 
dependent on the number of available amino groups which should lead to a bias in protein loading. 
Proteins which provide more primary amino groups might also provide more biotins and should 
therefore be more abundant on the DigiWest beads.  
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But, the main application of Western-Blots and therefore also of DigiWest is relative quantification and 
the relative abundance of a protein in a sample compared to another sample is determined. The 
influences of biotinylation should be the same for the same protein and antibody in each sample and 
therefore it should not represent an issue for relative quantification.  
For absolute quantification, the biotinylation step could present an issue. In the experiment for absolute 
quantification presented in this thesis, the intrinsic protein ERK2 is quantified by usage of GST-ERK2 as 
standard, spiked into the samples. The GST-tag might have an influence on protein loading as it provides 
additional primary amino groups. A better setup for absolute quantification might be to use an untagged 
protein and process it on separate lanes of the gel. As mentioned, it is also expected that only a fraction 
of the lysine residues is biotinylated which might reduce the effect.  
 
It is also expected that the proteins fold into secondary and tertiary structures after elution from the 
membrane which are not expected to represent the native conformations. Western-Blot antibodies are 
optimized for detection of denatured proteins and the expected folding of the proteins does not seem to 
be an issue as almost all antibodies which worked in Western-Blot also worked for DigiWest indicating 
that the epitopes are accessible. Without objective investigation, the direct comparisons of Western-
Blots and DigiWest give the impression that DigiWest shows less unspecific signal. 
 
The workflow might need some further improvements towards a higher grade of automation. Cutting of 
the membranes employing a cutting plotter represents an intermediately optimized step of the work-
flow. It might be helpful to have a cutting tool which is optimized for this application. 
 
Another aspect is the throughput in respect to the number of samples. At the moment 96 bead sets are 
used for each sample and 4 samples can be pooled into one DigiWest bead-mix. It is possible to increase 
the number of samples per bead-mix to 5. For more samples it is necessary to generate more bead-
mixes. It is also necessary to keep empty lanes between the samples on the gel for cutting the 
membranes after blotting. This results in a limitation of 6 samples on a 15 well gel. The experiments in 
this thesis, especially the mouse liver LCM experiment using 32 samples, proved that it is possible to use 
several gels and several bead-mixes but the number of samples cannot unlimitedly be increased.  
Therefore, DigiWest completely fulfills the initial idea of hundreds of replicas of a Western-Blot but it 
also in parts inherits the property of limited sample numbers from Western-Blot. 
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4.2 Lapatinib resistance in H292 cell line 
The receptor tyrosine kinases EGFR (Her1) and Her2 are overexpressed in several types of tumors and 
therefore drugs targeting these receptors are frequently used in cancer treatment. A major issue with 
EGFR and Her2 inhibitors in cancer treatment is that tumors can acquire resistance to these drugs. This 
often leads to a relapse after an initially successful treatment. There seem to be several potential 
resistance mechanisms depending on the tumor type (C. R. Chong & Jänne, 2013).  
In an experiment performed in cooperation with Benjamin Ruprecht (laboratory of Bernhard Küster, 
TUM) we investigated the changes occurring during resistance development of the lung cancer cell line 
H292 to the EGFR/Her2 inhibitor Lapatinib. As the targets of Lapatinib are receptor tyrosine kinases and 
several downstream signaling pathways are kinase cascades or involve kinases (Yarden & Sliwkowski, 
2001) they represented a promising starting point for investigation. A Lapatinib resistant H292 cell line 
was generated in the laboratory of Bernhard Küster and Kinobeads were used to enrich kinases from the 
cell lysates of Lapatinib resistant and parental H292 cells. The kinase enriched fractions were analyzed by 
mass spectrometry. Statistical analysis resulted in a panel of 24 kinases which showed significant differ-
ences in protein abundance between the two cell lines and thereby were likely to be connected to the 
observed Lapatinib resistance. 
Using the same kinase enriched material these 24 kinases were analyzed using the DigiWest approach. 
Mass spectrometry and DigiWest results showed good correlation (correlation coefficient 0.98) although 
they represent completely different methods for protein quantification. DigiWest was used to further 
investigate the Kinobead pulldowns and also the initial whole cell lysates were analyzed for kinase 
content and differences in phosphorylations.  
The set of 24 significantly changed kinases contained 5 members of the Eph receptor tyrosine kinase 
family which are receptors for the Eph receptor-interacting (Ephrin) family of proteins (Pasquale, 2010). 
EphA2 (Myk2) and EphB4 (Myk1) were found down-regulated whereas EphA4, EphB3 and EphB6 were 
found up-regulated in the Lapatinib resistant cell line. Ephrins and Eph receptors provide complex 
signaling mechanisms which are not yet fully understood. They are involved in intercellular signaling and 
capable of signaling in both directions, from the cell with the Eph receptor and towards the cell with the 
receptor. Their role in cancer seems to be context dependent resulting in opposing outcomes in different 
tumors or cell lines. EphA2 and EphB4 have been observed being up or down regulated together but 
depending on the context, up-regulation resulted in increased or decreased cell motility and proli-
feration (Pasquale, 2010; Xi, Wu, Wei, & Chen, 2012). The Src family member Fyn which was found to be 
up-regulated in the identified set of kinases could also be involved in Ephrin signaling as Src tyrosine 
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kinase family members are involved in Eph signaling (Pasquale, 2010). Some kinases involved in cell cycle 
regulation were also found to be deregulated.  
The DigiWest analysis of the whole cell lysates unveiled that the Lapatinib resistant cell line 
overexpresses EGFR more than 3-fold and Her2 more than 2-fold compared to the parental cell line 
which might be an adaption to the permanent presence of the inhibitor.  
Another interesting observation is a kind of switch in dual-specific phosphatases (DUSPs). DUSP6 (MKP3) 
is massively down regulated in the resistant cell line while DUSP9 (MKP4) is up regulated. Both these 
phosphatases are involved in regulation of MAP kinase cascades which are downstream of the Lapatinib 
targets EGFR (Her1) and Her2 (Owens & Keyse, 2007; Yarden, 2001).  
An Ingenuity pathway analysis performed by Benjamin indicated that p53 should be down-regulated in 
the Lapatinib resistant H292 cell line. As p53 is not a kinase, a DigiWest assay was performed on the 
whole cell lysates which confirmed the down-regulation of p53. This is in-line with published data which 
investigated resistance mechanisms for other EGFR/Her2 inhibitors in lung cancer cell lines including 
H292 based on clonal selection for resistant cells. They found that in this case the resistance mechanism 
is based on loss of p53 (S. Huang et al., 2011). We can show that p53 is also the key player for Lapatinib 
resistance in H292 cells and that p53 is down-regulated in reversibly resistant cells without clonal 
selection and without loss of p53. Therefore, loss of p53 might be a result of the selective pressure of 
permanent presence of Lapatinib and might give a survival advantage to these cells.  
 
The combination of mass spectrometry and DigiWest combined with Ingenuity pathway analysis proved 
to be a powerful team. The mass spectrometry analysis and the pathway analysis were especially helpful 
in respect to a guided analyte selection for the DigiWest approach. And the analysis of the whole cell 
lysates combined with the Kinobead pulldowns gave the opportunity to analyze non-kinases. The 
experiment also shows that DigiWest can be used for analysis of co-immunoprecipitation-like affinity 
enriched samples. 
The obtained data are only indicative for a mechanism that leads to Lapatinib resistance and follow-up 
experiments are missing. Nevertheless, the identification of p53 as key player in Lapatinib resistance in 
H292 lung cancer cells by an in-depth bioinformatics analysis of the generated data, combined with the 
experimental proof that p53 is down regulated in the resistant state, is an important observation. At this 
point we cannot completely exclude that the long term culture in Lapatinib containing medium could 
have resulted in partial clonal selection but the cells seemed to lose their induced resistance when 
cultured in Lapatinib free medium.  
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4.3 Mouse liver LCM 
The liver is the major organ for blood homeostasis and has a wide range of metabolic functions including 
drug metabolism and therefore it is especially susceptible to toxic drug effects. Many studies on toxic 
drug effects and also on the effects of non-genotoxic carcinogens focus on the liver. As the liver is a 
complex organ with the lobules as building blocks which provide different metabolic competences within 
the different zones, it is helpful to look at the different functional zones individually to gain a better 
understanding of the function of the liver and of drug effects. It is known that several enzymes including 
drug-metabolizing enzymes underlie zonation (Kai O. Lindros, 1997; S. P. S. Monga & Cagle, 2010).  
Here, the DigiWest approach was employed to investigate the different functional zones of liver lobules 
on protein level with a focus on cellular signaling. A comprehensive protein analysis was performed for a 
drug treatment time course with zonal resolution to obtain knowledge on signaling and drug response 
processes in periportal and pericentral hepatocytes. 
In this experiment, which was performed in cooperation with Albert Braeuning from the Institute of 
Toxicology at University of Tübingen in the Laboratory of Michael Schwarz, the effects of the non-
genotoxic carcinogen TCPOBOP were investigated. TCPOBOP is a phenobarbital-like tumor promoter and 
an agonist of the nuclear receptor CAR which induces hepatomegaly and liver hypertrophy followed by 
liver tumors in mice (Donthamsetty et al., 2011; S. P. S. Monga & Cagle, 2010). 
Liver sections from TCPOBOP treated mice (controls and 24, 48 and 72 hours TCPOBOP treated groups) 
were generated and LCM was performed to isolate tissue from pericentral and periportal zones. A 
DigiWest analysis was performed with more than 200 antibodies.  
A major question was feasibility of this approach as the resulting material was limited and less than 
usually used for a single Western-Blot. Another restraint was that proteins had to be formalin fixed to 
preserve posttranslational modifications during staining and LCM and reversion of formalin fixation 
impairs protein quality and yield. The experiment proved that it is possible to perform 200 DigiWest 
analyses from this limited material. It should be noted that in total about 660 antibodies were tested on 
appropriate material and not all potentially interesting analytes could be covered by the 204 antibodies 
which were employed in the main experiment.  
To visualize the liver zones for laser capture microdissection, the sections were stained for the 
pericentral marker protein glutamine synthetase (GS) using a mouse derived GS specific antibody. 
Preparation of the sections was performed by Elke Zabinsky at the Institute of Toxicology. For LCM, areas 
positively stained for GS (1-2 cell layers) were collected as pericentral zones and areas of 1-2 cell layers 
surrounding GS negative vessels were collected as periportal zones. Therefore, the areas represent only 
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the proximal periportal and pericentral zones. The DigiWest analysis of the LCM derived samples 
resulted in a 470 fold enrichment of GS in the pericentral compared to the periportal areas. The 
periportal marker protein E-cadherin was not detectable in the pericentral areas. This indicates that the 
collected material presents pure preparations of periportal and pericentral areas from the mouse liver 
sections. Some other proteins known to be zonated were also investigated and showed the expected 
results. Different cytochrome P450 family members which were analyzed and are known to be induced 
by TCPOBOP also showed the expected inductions.  
An aspect which is not discussed here but which should be kept in mind is that hepatocytes make only 
60% of the cells and 80% of the volume of a liver. Therefore, some of the observed differences and 
changes might not be hepatocyte specific. 
 
4.3.1 Reflection of potential issues 
It is a common observation that some antibodies show additional bands and often it is not clear whether 
these represent protein isoforms or other proteins with similarity to the epitopes. There was an 
additional band observed for some antibodies which was at the molecular weight of GS (about 40 kDa) 
which exactly overlaid the bands for GS and showed the same zonation and decrease over the time 
course and another additional band at about 50 kDa showing pericentral zonation and induction in the 
time course. The DigiWest method allows identification of additional bands and only bands at the proper 
molecular weights were used for signal quantification. Interestingly, the use of some of the affected 
antibodies in IHC on tissue sections showed a staining pattern resembling the GS stain but only on 
formalin fixed sections. IHC on fresh-frozen sections did not show this staining. So probably the formalin 
treatment caused cross reactivity with GS and another protein for some antibodies.  
During data analysis it turned out that most of the investigated serine and threonine phosphorylations 
which showed statistically significant zonation were periportally zonated. Since during LCM the peri-
portal areas were collected first, followed by isolation of the pericentral areas, this observation caused 
some concerns. But in pre-experiments, in which the pericentral areas were collected first, these phos-
phorylations showed the same periportal zonation for these analytes which indicated that no artefacts 
were created. The immunohistochemical stains performed by Elke for some analytes and also some of 
the periportally zonated phosphorylations confirmed the DigiWest results. The following discussion 
provides a possible explanation for the periportal tendency of phosphorylations based on a cellular 
signaling mechanism.  
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A decrease for several analytes was observed over the TCPOBOP treatment time course. A possible 
explanation could be hypertrophy during TCPOBOP treatment and therefore a reduction of the number 
of cells in the samples. In a liver with enlarged hepatocytes, more structural and metabolic proteins 
relative to signaling proteins might be present. Drug metabolizing proteins that are induced may 
contribute to the observed relative decrease. The obtained data were normalized on the total protein 
amount. For LCM, an area of about 3.7 mm² (a volume of about 0.037 mm³) was collected for each 
sample and the total protein amount in this volume did not change during TCPOBOP treatment. 
Therefore, the samples represent a defined amount of protein and also a defined volume of liver tissue. 
The number of cells was not determined but the TCPOBOP induced hypertrophy should result in a 
decrease in cell number during the time course when a defined volume is examined. The normalization 
on the protein amount did not show any tendency which might have resulted in a bias. The effects on 
cellular signaling resulting from this potential effect cannot be assessed. 
 
4.3.2 Liver zonation and regulation of metabolism 
A major function of the liver is to maintain blood homeostasis. This includes regulation of content of 
glucose, lipids and other metabolites and nutrients and adaption to different situations. Many of the 
enzymes required for these functions underlie zonation. The composition of the blood entering the liver 
through the portal vein underlies strong variations. The content and composition of nutrients depends 
on the feeding state and also the circadian rhythm and many of the detoxifying enzymes are induced by 
presence of xenobiotics. To adapt to these variations, the enzymatic equipment of the liver varies not 
only within the zones but also depending on feeding, circadian rhythm and presence of hormones, 
xenobiotics and other metabolites. For successful blood maintenance the liver is equipped with sensory 
systems. Many of the sensors are nuclear receptors which, upon activation by ligands or signaling events, 
induce expression of metabolic enzymes (Arias, 2009; Dufour & Clavien, 2009; Schibler, Ripperger, & 
Brown, 2003).  
Cellular signaling underlying liver zonation and metabolic adaption is complex and integrates many 
signals from different sensory systems. Some details and key players are uncovered. It is known that 
inversion of the blood flow in the liver leads to inversed zonation of several but not all zonated enzymes. 
That means that blood flow itself and the resulting gradients in oxygen, nutrients, hormones and others 
play a role (Thurman & Kauffman, 1985).  
Studies from the Eighties shed some light on metabolic characteristics of the liver zones. A comprehen-
sive review on metabolic zonation of the liver summarizing the knowledge from that time is available 
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from Rolf Gebhardt (R Gebhardt, 1992). Oxygen uptake was found to be about 2-fold higher in periportal 
regions when compared to pericentral regions (Matsumura & Thurman, 1984). Plasma concentration of 
Insulin was found to be about 2-fold higher in the portal vein compared to the central vein (BALKS & 
JUNGERMANN, 1984) and a periportally zonated binding of the epidermal growth factor (EGF) using I125-
labelled EGF was observed (Chabot, Walker, & Pelletier, 1986; St Hilaire, Hradek, & Jones, 1983).  
 
4.3.2.1 Known signaling pathways involved in liver zonation 
A gradient in β-catenin signaling plays an important role in liver zonation (S. P. S. Monga & Cagle, 2010). 
Periportal hepatocytes express APC which is a negative regulator of β-catenin. Pericentral hepatocytes 
do not express APC causing accumulation of active β-catenin (Benhamouche et al., 2006). E-Cadherin 
which is only expressed in the periportal zone traps β-catenin to the membrane and prevents nuclear 
translocation (Orsulic, Huber, Aberle, Arnold, & Kemler, 1999). In the nucleus, β-catenin acts as a co-
activator and can interact with transcription factors of the TCF/LEF family. These transcription factors 
bind Wnt-response-elements and lead to β-catenin-mediated gene transcription (Benhamouche et al., 
2006; S. P. S. Monga & Cagle, 2010).  
The antibodies used for the DigiWest data set contained antibodies for β-catenin, active (non-
phosphorylated) β-catenin and phosphorylated β-catenin but no significant zonation was observed. This 
is in line with the fact that the zonation of β-catenin cannot be measured or detected in IHC (personal 
communication from Albert Braeuning) and is because β-catenin predominantly localizes at the 
membrane and in the cytoplasm (S. P. Monga, Pediaditakis, Mule, Stolz, & Michalopoulos, 2001). 
DigiWest is not capable of distinguishing nuclear and cytoplasmic or membrane-bound β-catenin which 
might explain that β-catenin did not show zonation in the analysis. The hypothesis of the role of 
β-catenin in liver zonation is based on knock-out models resulting in livers which do not show zonation 
for important zonation markers and resemble either a pericentral gene expression pattern for these 
markers when APC is knocked out or a periportal pattern when β-catenin is knocked out (Benhamouche 
et al., 2006; S. P. S. Monga & Cagle, 2010).  
MAP kinase signaling is also meant to play an important role in liver zonation. This hypothesis is based on 
the observation that β-catenin mutated tumors resemble more pericentral gene and marker protein 
expression while tumors harboring an activating mutation in Ha-Ras or B-Raf resemble more periportal 
gene and marker protein expression. Experiments on transgenic mice further support this hypothesis 
(Braeuning, Ittrich, Köhle, Buchmann, & Schwarz, 2007; Braeuning, Menzel, et al., 2007; Hailfinger, 
Jaworski, Braeuning, Buchmann, & Schwarz, 2006). For the phosphorylation of ERK1/2 there was no 
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zonation observed with a very slight and not significant periportal tendency. The DigiWest results 
showed 2-fold pericentral zonation of phosphorylated MEK1/2 which is not in line with this hypothesis 
and is a contentious point. This phosphorylation would be expected to be periportally zonated as it is 
downstream of EGF receptor and upstream of ERK and as MAPK signaling is postulated to be periportally 
zonated (Braeuning, Ittrich, et al., 2007; Kolch, 2005). A similar discrepancy has been described for 
female rats where phosphorylated ERK was found to be pericentrally zonated (Hvid et al., 2011). Again 
the intracellular distribution which cannot be accessed by DigiWest might play a role. 
 
4.3.2.2 New insights into liver zonation: Hedgehog signaling 
The first part of the data analysis considered the zonation found in the untreated livers of the control 
group. Known zonation markers (GS and E-cadherin) and several enzymes known to underlie zonation 
showed the expected results. In respect to cellular signaling some new findings were made that point to 
a role of hedgehog-signaling in liver zonation. The group of Rolf Gebhardt described Hedgehog signaling 
being pericentrally zonated in the liver based on the observation of Ihh (indian Hedgehog) zonation (Rolf 
Gebhardt & Matz-Soja, 2014; Matz-Soja et al., 2014; Matz-Soja, Hovhannisyan, & Gebhardt, 2013) 
although in the publication from 2013 they mention a periportal zonation.  
Here I show that PTCH2, which is a hedgehog signaling receptor, is completely pericentrally zonated. The 
IHC staining of PTCH2 on fresh-frozen mouse liver sections performed by Elke Zabinsky validated the 
zonation. Ihh, one of the known ligands of the Ptch receptors, was also part of the DigiWest analysis. It 
was barely detectable in the control group and the obtained signals did not show a significant zonation. 
A strong induction of Ihh to a similar extend in both zones was observed after TCPOBP treatment in the 
time course. The IHC staining performed by Elke showed that after TCPOBOP treatment Ihh is zonated in 
the mid-lobular zone and less expressed in the pericentral and periportal zones. In the untreated liver 
Ihh was located in ‘spots’ in between the hepatocytes which might represent other kinds of cells and did 
not show zonation. The mid-lobular zonation of Ihh explains that in the DigiWest results Ihh did not show 
zonation as only the proximal periportal and the pericentral zones were investigated. Hedgehog signaling 
will be discussed in some more detail in the section for the TCPOBOP treatment. Staining of Ihh is shown 
in figure 43. 
 
4.3.2.3 New insights into liver zonation: HNF4α 
The nuclear receptor HNF4α is seen as an important player in the liver as it occupies 12% of hepatic 
promoters yet it does not show zonation (Gougelet et al., 2014; K O Lindros, Oinonen, Issakainen, Nagy, 
Discussion Mouse liver LCM 
94  
& Thorgeirsson, 1997; S. P. S. Monga & Cagle, 2010). However, HNF4α plays a role in expression of 
pericentral and periportal genes, the interaction of HNF4α with Lef1 is required for expression of the 
pericentral marker GS while HNF4α alone seems to repress GS expression. It was found that HNF4α 
alone might be sufficient for expression of several periportally expressed genes (Colletti et al., 2009; S. P. 
S. Monga & Cagle, 2010). Important crosstalk has also been found for Tcf-4 and HNF4α. Tcf-4 interacting 
with β-catenin binds to Wnt-responsive elements of β-catenin induced genes while Tcf-4 binds to HNF4 
responsive elements of genes repressed by β-catenin (Gougelet et al., 2014). HNF4α is phosphorylated at 
Ser313 (uniprot and phosphosite plus databases) yet this phosphorylation site is referred to as Ser304 in 
their references (Hong, Varanasi, Yang, & Leff, 2003; Zhongyan Wang, Salih, & Burke, 2011). The 
phosphorylation site is located in the interaction domain of HNF4α and prevents formation of homo-
dimers; the kinase responsible for this phosphorylation is AMPKα (Hong et al., 2003).  
The DigiWest analysis found HNF4α not being zonated but phosphorylation of HNF4α at Ser313 showed 
a more than 2-fold enrichment on the periportal side. The activating phosphorylation of AMPKα at 
Thr172 was also found to be periportally zonated (1.7 fold). If the HNF4α phosphorylation in the 
interaction domain would also prevent interaction of HNF4α with Lef1, Tcf-4 and other transcription 
factors, this could explain the observation that HNF4α plays a role in expression of both pericentrally and 
periportally expressed genes either as HNF4α alone on the periportal side or interacting with other 
transcription factors on the pericentral side, or at least with differing interaction partners dependent on 
the phosphorylation. This observation needs further investigation. 
 
4.3.2.4 New insights into liver zonation: phosphatases  
Some phosphatases showed a zonated distribution. The dual-specific phosphatase DUSP4 was found to 
be 4.7-fold periportally zonated in the DigiWest results. DUSP4 expression is known to be induced by 
activated AMPK and seems to be required for inhibition of gluconeogenesis (Berasi et al., 2006).  
An about 5-fold periportal zonation of PP1γ, the catalytic subunit of PP1, was found. PP1 is, as is PP2A, a 
holoenzyme comprised of catalytic and regulatory subunits. PP1 and the PP1γ subunit do not only 
underlie the circadian rhythm (Schmutz et al., 2011) but it is also involved in regulation of glycogen 
metabolism by dephosphorylating and activating glycogen synthase. To regulate glycogen metabolism it 
is anchored to the glycogen particles via a glycogen-targeting regulatory subunit. These subunits were 
not investigated. It is known that in the liver the glycogen-targeting subunit PPP1R3G is upregulated 
upon fasting and downregulated upon feeding while other glycogen-targeting regulatory subunits of PP1 
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are downregulated upon fasting (Luo et al., 2011). Zonation of PP1γ alone is not sufficient to draw a full 
picture. 
 The data on zonation of proteins and protein phosphorylations in the control group show that the 
inhibitory phosphorylation of PP2A C, the catalytic subunit of PP2A, is more than 8-fold enriched in the 
periportal zone and as a consequence of this inhibition, several targets of PP2A and targets thereof show 
a periportal zonation for serine and threonine phosphorylation. PP2A is one of the major 
serine/threonine phosphatases in mammalian cells (Virshup & Shenolikar, 2009). Besides Src and Lck, 
Insulin and EGF receptors have been identified as kinases which can phosphorylate PP2A (J. Chen et al., 
1992). Src phosphorylation at Tyr527 and Tyr416 did not show zonation and Lck phosphorylation at 
Tyr505 showed a pericentral zonation. Therefore, the inhibitory phosphorylation might be derived from 
EGF and Insulin receptor. 
 
4.3.2.5 New insights into liver zonation: phosphorylation of proteins  
Besides the analytes mentioned already, several serine and threonine phosphorylations showed a 
periportal zonation. This can be explained by the inhibitory phosphorylation of PP2A at Tyr307. IHC 
stainings were performed to confirm the zonation. PP2A can dephosphorylate AMPK (S. P. Davies, Helps, 
Cohen, & Hardie, 1995) and also Akt and S6 kinase (T. Wang et al., 2010), the kinase phosphorylating 
RPS6, which are both phosphorylated by PDK1 (Bononi et al., 2011; Shiojima & Walsh, 2006). 
Phosphorylation of RPS6 in the liver increases massively after feeding in an insulin dependent manner 
(Lu et al., 2012). 
Active PP2A dephosphorylates and thereby inhibits AMPK which was shown to promote HSP70 
expression (T. Wang et al., 2010). This might provide the explanation for the observed pericentral 
zonation of HSP70. As PP2A is inhibited in the periportal zone, the activating phosphorylation of AMPKα 
and RPS6 are higher and the activating phosphorylation of Akt at Ser473 is also expected to be higher in 
the periportal zone. Akt phosphorylation at Thr308 was measured and did not show significant zonation, 
phosphorylation of Ser473 could not be investigated. 
AMPK is meant to be an energy sensor of the cell and can be phosphorylated at Thr172 in response to 
calcium flux, different kinds of cellular stress and several hormones (Kahn, Alquier, Carling, & Hardie, 
2005; Mihaylova & Shaw, 2011; Towler & Hardie, 2007). HNF4α is not only a target of AMPK but 
integrates many signals resulting in several phosphorylations and acetylations and HNF4α is involved in 
different protein complexes (Daigo et al., 2011; Um et al., 2011; Xue & Kahn, 2006). It is also involved in 
regulation of circadian transcription (Reddy et al., 2007).  
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A study on AMPK activity in periportal and pericentral hepatocytes isolated from rat livers by Witters et 
al. showed 2-fold pericentral zonation of AMPK activity in fasted rats which almost vanished after 
refeeding (Witters, Gao, Kemp, & Quistorff, 1994). This is not in line with the DigiWest results which 
show periportal zonation in ad libitum fed mice, but data comparison is difficult as the time consuming 
process of cell perfusion and isolation may have led to changes in phosphorylation in this study. 
PAK1/2 phosphorylation at Ser144/Ser141 showed an 8-fold periportal zonation. The role of PAK1/2 (p21 
activated protein kinase) in the liver is not yet completely clear but it seems to play a role in glucose 
homeostasis. PAK1 is involved in insulin secretion in β-cells and also seems to be involved in insulin 
signaling in the liver (Y.-T. A. Chiang et al., 2014; Zhanxiang Wang, Oh, Clapp, Chernoff, & Thurmond, 
2011). PAK2 was identified as an AMPK substrate (Banko et al., 2011). Several serine residues in PAK2 are 
phosphorylated by AMPK although the direct substrate of AMPK is possibly Ser20 which induces 
autophosphorylation at several sites including Ser144/Ser141. This phosphorylation is meant to 
significantly contribute to activation (C. Chong, Tan, Lim, & Manser, 2001; Molli, Li, Murray, Rayala, & 
Kumar, 2009). The phosphorylation of Integrin linked kinase ILK1 at Ser246 and Thr173 is directly 
connected to this observation. Both of these phosphorylation sites on ILK have been shown to be 
substrates of PAK. Phosphorylation on Ser246 and Thr173 seems to inhibit nuclear localization of ILK 
(Acconcia, Barnes, Singh, Talukder, & Kumar, 2007; Hannigan, McDonald, Walsh, & Dedhar, 2011).  
All these observations and connections mentioned above are represented in figure 41 for illustration. 
This might draw a clearer picture. 
  
4.3.2.6 New insights into liver zonation: Nuclear receptors and coregulators 
PPARγ is a nuclear receptor involved in regulation of lipid and glucose metabolism. Phosphorylation of 
PPARγ at Ser112 can be caused by MAP-kinases and CDKs, the function of this phosphorylation is not 
clear yet (Ahmadian et al., 2013). PPARγ was found to be periportally zonated in the DigiWest results. 
Phosphorylation of PPARγ at Ser112 showed the same zonation as did the PPARγ coactivator PGC-1α 
phosphorylation at Ser571. The coregulator PGC-1α is again a protein that integrates signals from many 
sources and plays a critical role in glucose, lipid and energy homeostasis. It is meant to be a master 
regulator of mitochondrial biogenesis and can interact with a variety of nuclear hormone receptors 
including HNF4α (Jäger, Handschin, St-Pierre, & Spiegelman, 2007; Lin, Handschin, & Spiegelman, 2005; 
Oberkofler et al., 2002). Insulin signaling involving the kinase Akt has been shown to induce the 
inhibitory PGC-1α phosphorylation at Ser571 (Ser570 in mouse) (X. Li, Monks, Ge, & Birnbaum, 2007; W. 
Wang & Wong, 2010). PGC-1α is phosphorylated by S6 kinase at Ser568 and Ser572 (Lustig et al., 2011), 
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the phosphorylation which was measured at Ser570 (in mouse) is derived from Akt (X. Li et al., 2007), 
which attenuates binding to HNF4α and inhibits gluconeogenesis while these phosphorylations seem to 
have no impact on mitochondrial biogenesis or β-oxidation of fatty acids (Lustig et al., 2011). The 
observed phosphorylation of RPS6 indicates higher S6 kinase activity in the periportal zone and therefore 
the phosphorylations at Ser568 and Ser572 might also show periportal zonation.  
4.3.2.7 Insulin signaling and liver zonation 
Insulin signaling regulates glucose and lipid homeostasis and is associated with several signaling 
pathways including regulation of cellular growth. As most investigations are performed utilizing cultured 
cells and insulin is part of the endocrine system, it seems to be clear that not all of the observed 
pathways and signaling events are relevant for the physiological functions of insulin (Saltiel, 1996). 
Although the insulin receptor is a tyrosine kinase, its activation results in up- and down-regulation of 
several serine and threonine phoshorylations indicating important roles for kinases and also 
phosphatases (Saltiel, 1996). PDK1 was identified as potential missing link (Cohen, Alessi, & Cross, 1997) 
and the link from insulin receptor to Akt was filled by PI3K (Vanhaesebroeck & Alessi, 2000). The 
phosphatases which might be involved were forgotten as the question of how the tyrosine kinase activity 
of insulin receptor is translated into serine and threonine phosphorylations seemed to be solved. 
Although there has been intense effort in deciphering insulin signaling and many players were identified, 
insulin signaling is still not fully understood (Cohen, 2006).  
 
The study on liver zonation was not designed for investigation of insulin signaling. Nevertheless the data 
on cellular signaling with a focus on phosphorylation in liver zonation provide insights into physiological 
insulin signaling in the liver. Besides a periportal zonation of PDK1 (1.7-fold) several serine and threonine 
phosphorylations and also several phosphatases were found to underlie zonation. These include the 
serine/threonine phosphatases PP1 and PP2A.  
The high degree of inhibitory phosphorylation of PP2A observed in the DigiWest results should result in 
much higher PP2A activity in the pericentral zone and might explain the observed tendency of periportal 
zonation for several serine and threonine phosphorylations as PP2A is one of the major serine and 
threonine phosphatases in mammalian cells and has a broad range of substrates (Virshup & Shenolikar, 
2009; Westermarck & Hahn, 2008).  
The following figure represents a possible connectivity for most of the analytes which were discussed 
above. The core component is the periportal zonation of the inhibitory phosphorylation of PP2A which 
might be derived from activated insulin and EGF receptors.  
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FIGURE 41 OVERVIEW OF THE OBSERVATIONS FOR ZONATED SIGNALING IN THE LIVER 
Shown is a detail of a liver lobule with some of the known characteristics highlighted.  The illustration is 
adopted from Angélique Gougelet and Sabine Colnot (Gougelet & Colnot, 2012) and in smaller parts from 
Albert Braeuning (Braeuning et al., 2006). The data represent most of the data mentioned in the 
discussion above. There are small bar diagrams with standard error for all given analytes with the 
periportal data shown in blue and the pericentral data in red. Data are normalized to the higher value. 
The ratios of periportal to pericentral (not in log2) are given. 
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The lower part shows a possible connection of the observations in respect to cellular signaling. As the 
mice were not starved, insulin is expected about 2-fold higher in the periportal zones as is EGF signaling. 
Insulin itself and the receptors were not analyzed. Activated insulin and EGF receptors on the periportal 
side can phosphorylate protein phosphatase 2 (PP2A) at the inhibitory Tyr307. Inhibited PP2A cannot 
dephosphorylate AMPKα, S6 kinase or Akt resulting in increased activity of these kinases. On the 
periportal side, insulin also leads to activation of PDK1 which phosphorylates Akt at Ser473 (which could 
not be measured) and S6 kinase, which can also be phosphorylated by Akt, which then phosphorylates 
the transcriptional coactivator PGC-1α at Ser571 (Ser570 in mouse). Neighboring phosphorylation sites at 
Ser568 and Ser572 of PGC-1α which are phosphorylated by S6 kinase might also be periportally zonated 
but were not measured and are not included in the illustration. Besides PAK 1/2, AMPK phosphorylates 
HNF4α at the inhibitory Ser residue in the interaction domain. Activated PAK1/2 can phosphorylate ILK1 
at the 2 phosphorylation sites.  
On the pericentral side, where insulin and EGF are reduced and PDK1 is also less expressed, PP2A shows 
less inhibition resulting in less active AMPK, S6 kinase and Akt which results in less phosphorylation of the 
targets. As the phosphorylations which inhibit or change interaction of HNF4α and PGC-1α with other 
proteins are reduced, this might result in protein interaction and formation of transcription regulating 
complexes.  
On the periportal side the phosphorylations of HNF4α, PGC-1α and PPARγ might inhibit their interactions 
with each other or other proteins like Lef1 or might lead to a switch in interaction partners.  
 
The core component of this proposed connectivity is the periportally zonated inhibitory phosphorylation 
of PP2A resulting in active AMPKα and RPS6 and probably also active Akt. The periportal zonation of 
PDK1 might support this. The central role of the inhibition of PP2A is of special interest as this could 
mean that the specificity of the cellular signal and regulation of the downstream phosphorylations is 
more derived from the phosphatase.   
 
4.3.2.8 Consequences for metabolic zonation 
Active AMPK induces DUSP4 expression and leads to suppression of gluconeogenesis via down regulation 
of PEPCK and glucose-6-phosphatase, the rate limiting and hormonally controlled enzymes in gluconeo-
genesis (Berasi et al., 2006). The protein interactions of PGC-1α with PPARγ and with HNF4α also play an 
important role in glucose metabolism. As mentioned, the phosphorylations of these proteins are meant 
to inhibit their interactions although for PPARγ it is not fully clear. If not inhibited, PGC-1α is meant to 
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activate a fasting response including gluconeogenesis, fatty-acid β-oxidation, ketogenesis and bile-acid 
homeostasis by coactivating key hepatic transcription factors (Lin et al., 2005). Interaction of PGC-1α 
with HNF4α is also required for gluconeogenesis and expression of the rate limiting enzymes PEPCK and 
glucose-6-phosphatase (Rhee et al., 2003). AMPKα and its target PAK1/2 are meant to play an important 
role in membrane translocation of the insulin responsive glucose transporter GLUT4 resulting in 
increased glucose uptake (Y. A. Chiang & Jin, 2014; Viana et al., 2006). 
As the mice in this study were fed ad libitum and no starved mice were investigated, it is not clear how 
the observed phosphorylations might depend on the feeding state and whether the adaptions to 
changes in feeding and related hormones would affect the periportal or the pericentral hepatocytes. But 
as the initial triggers of the proposed connectivity are meant to be insulin and EGF, the signaling might 
adjust in the way that the phosphorylations are reduced in the periportal zones. Depending on the 
contribution of EGF this could also be a minor change.  
 
4.3.2.9 Conclusions  
The blood entering the liver through the portal vein underlies high variations in content and composition 
of nutrients and also metabolism regulating hormones whereas the blood leaving the liver through the 
central vein needs to be in the physiological range. Therefore, it might make sense that the regulatory 
phosphorylations of critical regulators for energy metabolism are periportally zonated. Phosphorylation 
of AMPKα, HNF4α, PPARγ, PCG-1α and also PAK1/2 and RPS6 could provide links for regulation of 
metabolism to these variations and to the circadian rhythm. It is not clear whether the inhibitory PPARγ 
phosphorylation is linked to activated AMPKα or not, but it is known that activated AMPK can inhibit 
PPARγ transcriptional activity (Sozio, Lu, Zeng, Liangpunsakul, & Crabb, 2011).  
The proposed connectivity puts PP2A into a central role. As mentioned, this phosphatase is a major 
serine and threonine phosphatase with a broad range of substrates. The inhibitory phosphorylation of 
PP2A shows a strong peak at 24 hours after TCPOBOP treatment which is also observed for the 
phosphorylation of RPS6 and phosphorylation of Akt at Thr308 but not for phosphorylation of AMPK and 
several other proteins. This implies an important role for the regulatory subunits of PP2A which were not 
part of this analysis. PP2A is a holo-enzyme that contains regulatory subunits which influence substrate 
specificity and lead to precisely regulated phosphatase activity (Virshup & Shenolikar, 2009). The 
measured inhibitory phosphorylation is on the catalytic subunit. 
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Besides the discussed observations, other interesting differences between periportal and pericentral 
areas of the analyzed liver sections were found. Table 2 in the results section summarizes all analytes 
showing statistically significant zonation (more than 2-fold, p < 0.05).  
This study was designed to investigate changes in cellular signaling in the TCPOBOP treatment time 
course. For investigation of differences in cellular signaling in respect to feeding state and insulin it 
would have been helpful to add different feeding states like starved mice or mice fed with different diets 
like high fat, high carbohydrate and high protein diets. For investigation of circadian rhythm 
dependencies the day/night cycle might be incorporated. Therefore, further investigations are 
necessary. 
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4.3.3 TCPOBOP time course – effects with zonal resolution 
TCPOBOP is a prototypical non-genotoxic carcinogen and the most potent phenobarbital-like inducer. It 
binds the nuclear receptor CAR and induces expression of genes associated with xenobiotic 
detoxification and proliferation. Hepatomegaly and liver hypertrophy are observed within the first two 
days after administration resulting in an increase of liver mass by 2 to 3 fold. This is meant to be a 
physiological process as a larger liver provides higher drug metabolizing capacity. This mitogenic process 
needs to be tightly controlled and terminated in time (Donthamsetty et al., 2011). CAR agonists like 
phenobarbital and TCPOBOP specifically promote β-catenin mutated hepatocellular carcinoma 
(Braeuning et al., 2011)(personal communication Albert Braeuning). It is still not clear why 
phenobarbital-like non-genotoxic carcinogens specifically promote tumors harboring an activating β-
catenin mutation. 
In this experiment, protein expression was investigated in separated proximal periportal and pericentral 
areas from mouse liver sections for a time course of 3 days after TCPOBOP injection. The DigiWest 
method allowed measuring protein expression and phosphorylation using about 200 antibodies resulting 
in a wide-ranging, yet biased, selection of analytes. Aim of this experiment was to gain deeper insights 
into changes in cellular signaling induced by TCPOBOP.  
As shown in the results section, there are many changes occurring after TCPOBOP administration. Some 
analytes show the same or similar behavior in pericentral and periportal zones but some TCPOBOP 
induced effects are focused or even restricted to just one zone.  
As this is the first time that cellular signaling was investigated in mouse livers with zonal resolution and in 
a study with a drug-treatment time course, the data set is difficult to interpret. The large data-set would 
need further analysis using systems biology approaches and pathway mapping. Therefore, the following 
section just highlights some observations. 
 
4.3.3.1 Stress response and oxidative stress upon TCPOBOP treatment 
The inhibitory phosphorylation of PP2A shows a massive peak 24 hours after treatment (about 40-fold 
increase in the pericentral zone and about 6-fold in the periportal zone reaching a similar level in both 
zones) indicating a substantial disturbance of cellular signaling. The high standard error at the 24 hour 
time point might indicate that the effect peaks sharply and the maximum is not met perfectly in the one 
day resolution of the time course. A peak showing an appropriate hyper-phosphorylation at the 24 hours 
TCPOBOP treatment time point was also observed for Akt pThr308 and RPS6 pSer240/244 but it was not 
observed for other substrates of PP2A like AMPKα which indicates an important role for the regulatory 
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subunits of PP2A and their regulation of substrate specificity. Akt pThr308 is involved in liver 
regeneration (Haga et al., 2009) and RPS6 pSer240/244 is associated with increased proliferation and 
protein synthesis (Stewart & Thomas, 1994). Phosphorylation of ERK1/2 at Thr202/Tyr204 also showed a 
slight peak at 24 hours but less than factor 2. The representation of the whole data-set in figure 27 in the 
results part indicates that several analytes show a slight peak at the 24 hours treatment time-point. 
Increased PP2A phosphorylation in response to oxidative stress has been described (Jin Jung et al., 
2013). The inhibitory PP2A phosphorylation has been described to mediate a stress survival response in 
retinal cells showing a massive peak in response to reactive oxygen species which was not observable 
when reactive oxygen species were scavenged (Finnegan, Mackey, & Cotter, 2010). Therefore the 
observed peak in PP2A phosphorylation could be based on oxidative stress.  
The induction of c-Myc, HSP70 and DPP3 in the TCPOBOP treatment time course were found to be 
restricted to the pericentral zone. Induction of c-Myc by TCPOBOP has been described and was meant to 
be a key mediator of direct liver hyperplasia (Blanco-Bose et al., 2008). c-Myc expression is induced 
during liver regeneration and upon treatment with several chemicals (Donthamsetty et al., 2011; Hickling 
et al., 2010; Makino, Hayashi, & Sugimura, 1984) but it has been shown that deletion of c-Myc does not 
impair liver regeneration (F. Li et al., 2006). c-Myc has manifold functions including induction of 
apoptosis and regulation of metabolism (Dang, 1999). Myc dependent apoptosis has been shown to 
result from oxidative stress and to be prevented by glutamine (Xu, Nguyen, Lo, & Czaja, 1997; Yuneva, 
Zamboni, Oefner, Sachidanandam, & Lazebnik, 2007). The pericentrally zonated GS might therefore 
support survival of the stressed pericentral cells. 
HSP70 is induced by several kinds of stress including oxidative stress and it is also induced during liver 
regeneration. It protects cells against stress-induced apoptosis (Konishi et al., 1995; Mosser, Caron, 
Bourget, Denis-Larose, & Massie, 1997; Wolf et al., 2014).  
DPP3 (Dipeptidyl-peptidase 3) was shown to bind Keap1 and replace Nrf2 which prevents Nrf2 
ubiquitination and activates Nrf2-dependent transcription (Hast et al., 2013). Nrf2 plays an important 
role in defense against reactive oxygen species and induces an antioxidant response (W. Chen et al., 
2009). Nrf2 is meant to redirect metabolism of glucose and glutamine into anabolic pathways  (Mitsuishi 
et al., 2012).  
The restriction of the induction of c-Myc, HSP70 and also DPP3 to the pericentral zone might indicate 
that the pericentral zone is more affected by oxidative stress upon TCPOBOP treatment.  
The antibody directed against RAD23B, which is a protein involved in DNA damage repair (Friedberg, 
2001), showed periportal zonation and no significant changes in the time-course. But the antibody 
detected an additional band which could represent isoform 2 of RAD23B or it could represent RAD23A. 
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This additional band showed pericentral zonation and induction in the treatment time-course with a 
stronger pericentral effect. This might indicate increased DNA damage in the pericentral zone which 
might result from the oxidative stress. But as it could also be an additional band this needs further 
investigation. 
 
 
FIGURE 42 SOME OF THE TCPOBOP INDUCED EFFECTS MENTIONED IN THE DISCUSSION 
Shown are some of the analytes showing significant changes in the TCPOBOP time course mentioned in 
the discussion so far. The data are shown in diagrams representing the AFI values (relative fluorescence 
units) with standard error for the pericentral zone in red and for the periportal zone in blue. The smaller 
diagrams represent the same data but as log2-fold changes relative to the control (normalized on median 
of control) with standard error. The phosphorylations of PP2A at Tyr307, RPS6 at Ser240/244 and Akt at 
Thr308 show a strong peak at 24 hours TCPOBOP treatment with a high standard error at this time point. 
The phosphorylation of ERK1/2 at Thr202/Tyr204 shows a slight and not statistically significant peak. c-
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Myc, HSP70, DPP3 and the additional band obtained with the antibody directed against RAD23B which 
could represent isoform 2 or RAD23A all show a pericentral zonation with an induction during the time-
course while they show no or less induction in the periportal zone.  
 
4.3.3.2 Proliferative and other effects 
MCM2 (Minichromosome maintenance protein 2) has been observed on mRNA level to be induced by 
TCPOBOP (Leoni et al., 2011). The DigiWest data show that it is induced in both zones upon TCPOBOP 
treatment. MCM2 plays an important role in cell proliferation and is often used as proliferation marker 
(Blow & Hodgson, 2002). 
Activation of Hedgehog signaling was shown to play an important role in liver regeneration after partial 
hepatectomy and under conditions which might induce apoptosis (Ochoa et al., 2010; Omenetti et al., 
2011). The DigiWest data show a massive increase of the Hedgehog ligand Ihh (about 100-fold) in the 
TCPOBOP treatment time course in both zones. As the hedgehog receptor PTCH2 was found to be 
pericentrally zonated, there could be a pericentrally zonated activation of hedgehog signaling induced by 
TCPOBOP. PTCH1 could not be measured and therefore it is not clear how it is expressed in the liver. The 
differences between PTCH2 and PTCH1 are not known yet, the two hedgehog receptors seem to provide, 
at least in parts, redundant functionality (Alfaro, Roberts, Kwong, Bijlsma, & Roelink, 2014).  
Immature ductal cells and stellate cells have been reported to produce hedgehog ligands in response to 
injury-associated factors. This enriches the injured liver with hedgehog ligands and stimulates hedgehog 
responsive cells. Mature hepatocytes are not meant to be hedgehog responsive (Choi, Omenetti, Syn, & 
Diehl, 2011). It has also been reported that apoptotic stimuli trigger mature hepatocytes to produce Ihh 
(Choi et al., 2011; Jung et al., 2010) which might connect to the proposed  oxidative stress and apoptosis 
related functions of c-Myc and HSP70 and might be part of a stress survival response. 
The IHC staining for Indian hedgehog showed thin areas in between the hepatocytes positive for Ihh 
which could be stellate cells. After TCPOBOP treatment, the whole liver showed a strong staining for Ihh 
including the hepatocytes with a stronger staining in the mid-lobular zone (see figure 43 b)). The finding 
that PTCH2 is expressed in the pericentral zone might indicate that pericentral hepatocytes could be 
hedgehog responsive. As hedgehog signaling is often associated with differentiation and precursor cells, 
the hepatocytes might, at least slightly, dedifferentiate to reactivate their mitotic abilities. The zonation 
of the hedgehog receptor PTCH2 and the consequences of the induction of the ligand Ihh on hedgehog 
signaling need further investigation including the downstream proteins Smo, Gli1-3 and target proteins 
to investigate the hedgehog responsiveness. 
Discussion Mouse liver LCM 
106  
The glucose transporter GLUT1 was found to be pericentrally zonated in the liver which is in line with 
literature (Bilir et al., 1993). In the TCPOBOP treatment time-course, GLUT1 is induced in both zones with 
a stronger induction in the periportal zone resulting in the same level in both zones. This could indicate a 
higher energy demand upon treatment.   
RXRα is induced upon TCPOBOP treatment. It shows a slower but stronger induction in the periportal 
zone. RXRα is a nuclear receptor predominantly expressed in the liver where it plays important roles in 
regulation of metabolism and gene expression. It has the ability to hetero-dimerize with numerous other 
nuclear receptors and thereby controls specific gene transcription (Evans & Mangelsdorf, 2014; Zhan et 
al., 2012). It also hetero-dimerizes with CAR and PXR.  
 
 
FIGURE 43 HEDGEHOG LIGAND IHH AND RECEPTOR PTCH2 IN THE TCPOBOP TREATMENT TIME-COURSE 
a) The data obtained for PTCH2 and Ihh represented as diagrams in AFI (relative fluorescence units) with 
standard error. PTCH2 was only detectable in the pericentral zone and shows a decrease in the time-
course. Ihh is about 100-fold induced in the time-course in both zones (red is periportal and blue is 
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pericentral). The smaller diagrams show the log2-fold changes relative to the control group with standard 
error. Data were normalized on the median of the corresponding control group. 
b) IHC staining of PTCH2 and Ihh. The stainings were performed by Elke Zabinsky. PTCH2 staining is 
shown on a fresh-frozen liver section of a control mouse and shows a pericentral zonation. Ihh was 
stained on formalin fixed, paraffin embedded sections from a control mouse and a mouse treated with 
TCPOBOP for 72 hours. In the control mouse, Ihh staining shows a pattern which seems to be cells in 
between the hepatocytes which could be stellate cells. The zones cannot be assigned for the sections. The 
staining does not show a clear zonation. In the TCPOBOP treated liver all the hepatocytes show Ihh 
staining with a midlobular zonation. The intensities of the pictures cannot be compared as the 
microscope automatically searched for the ideal contrast. The staining was also performed using 
fluorescence and the zones are indicated by pv (portal vein) and cv (central vein). In the 10x 
magnification, the pattern in the control mouse is not so clear but Ihh is also located in between the 
hepatocytes. In the TCPOBOP treated mouse again all hepatocytes show Ihh staining and the stronger 
staining in the midlobular zone is clearly visible. 
 
4.3.3.3 PP2A is involved in TCPOBOP induced CAR activation 
The nuclear receptor CAR which is activated by phenobarbital and TCPOBOP is retained in the cytoplasm 
and upon drug induced activation, it translocates into the nucleus (Kawamoto et al., 1999). Dephos-
phorylation of CAR at Ser202 seems to be necessary for nuclear translocation which is performed by 
PP2A (Hosseinpour, Moore, Negishi, & Sueyoshi, 2006). It was shown that the CAR-HSP90 complex, 
which is located in the cytoplasm, recruits PP2A upon Phenobarbital treatment which might induce CAR 
translocation to the nucleus (Yoshinari, Kobayashi, Moore, Kawamoto, & Negishi, 2003). The observed 
zonation of PP2A phosphorylation in the DigiWest results should result in low periportal and high 
pericentral PP2A activity.  
PP2A itself has been described as tumor suppressor and inhibitors of PP2A have been described as tumor 
promoters (Fujiki, Sueoka, & Suganuma, 2013; Haystead et al., 1989; Westermarck & Hahn, 2008). As 
mentioned, for retinal cells the inhibitory PP2A phosphorylation has been described to mediate a stress 
survival response. They observed a massive peak in PP2A phosphorylation within 15 minutes as response 
on reactive oxygen species (Finnegan et al., 2010). 
Therefore, the observation on the inhibitory phosphorylation of PP2A is interesting, showing a strong 
peak after 24 hours of TCPOBOP treatment. This effect shows a strong variation in between the animals 
resulting in high standard deviations which might result from a very sharp peak which cannot be resolved 
in the 4 time points. Yet after 24 hours, in the pericentral zone a minimum increase of 10.6-fold 
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(maximum of control group compared to minimum of 24 hours treatment group) and a maximum 
increase of 155-fold (minimum of control group compared to maximum of 24 h treatment group) were 
seen. The median increase for the peak at 24 hours is 40-fold for the pericentral zone and 6-fold for the 
periportal zone. The amount of phosphorylated PP2A reaches a similar level in both zones at 24 hours. 
This should result in a massive inhibition of PP2A after 24 hours and as PP2A is a major serine and 
threonine kinase it represents a massive disturbance in cellular signaling which might have wide ranging 
effects. As inhibitors of PP2A have been described as tumor promoters, the proliferation peak induced at 
24 to 48 hours after TCPOBOP treatment and the resulting increase in liver mass which has been seen as 
a physiological process meant to increase the detoxifying capacity of the liver (Donthamsetty et al., 
2011),  might possibly be a pathophysiologic effect based on an overdrive of a stress survival response 
and the massive inhibition of PP2A.  
 
4.3.3.4 Wnt-signaling might be down-regulated  
Expression of the zonation marker glutamine synthetase has been shown to be regulated by β-catenin 
and might be a target of the Wnt/β-catenin pathway (Cadoret et al., 2002) and overexpression of 
glutamine synthetase is associated with β-Catenin mutations in mouse liver tumors (Loeppen et al., 
2002). Besides the massive zonation of glutamine synthetase, the DigiWest results show a decrease of 
GS over the TCBPOBOP treatment time course of about 2-fold (72 hours compared to control) for 
periportal and pericentral zones. β-catenin itself and Wnt3a, the only Wnt protein measured in this 
experiment, also show a decrease during the time. This might indicate that β-catenin signaling could be 
reduced during TCPOBOP treatment. But as mentioned, several analytes and phosphorylations show a 
decrease over the time course. As the samples represent a defined volume of liver tissue this might be 
associated with the increase in cell size and the analytes might hence still be present in the same number 
in the cells but due to the volume increase their concentration might decrease. The effect on cellular 
signaling resulting from this phenomenon cannot be accessed. 
 
4.3.4 Conclusions from the mouse liver LCM experiment 
The main part of this work was development of the DigiWest method. Therefore, an important aspect is 
the technical side. The DigiWest approach successfully allowed analysis of laser-capture microdissected 
material. The additional bands which appeared for some antibodies in a formalin-dependent manner 
underline the value of the molecular weight resolution which the DigiWest approach provides. The 
estimated about 2.5 µg of protein per sample which are barely enough for a single Western-Blot were 
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used for 204 antibody incubations and allowed a comprehensive analysis of the proximal periportal and 
pericentral zones from mouse livers. An additional advantage of the LCM based approach was the 
possibility to analyze phosphorylation of proteins which is impaired by perfusion-based approaches. 
The analysis of the proximal liver zones in the untreated control group gave new insights into cellular 
signaling in the liver zones and highlighted the role of serine and threonine phosphorylations, kinases 
and phosphatases. 
The analysis of the TCPOBOP treatment showed that there are manifold changes upon TCPOBOP 
treatment. The proper interpretation of all these changes demands for advanced bioinformatics and 
systems biology approaches. Even without these analyses the results show that there are substantial 
differences between the periportal and the pericentral zones indicating that oxidative stress might be 
restricted to the pericentral zone and the inhibitory phosphorylation of PP2A and the massive peak 
thereof at 24 hours might indicate a massive disturbance in cellular signaling upon TCPOBOP treatment. 
The data also unveiled the pericentral zonation of the hedgehog receptor PTCH2 which, combined with 
the strong induction of Ihh, might result in activation of hedgehog signaling. 
Several of the results need further investigations as they represent new observations which have not yet 
been described. The experiment proved that the DigiWest method can be used for comprehensive 
analyses of limited LCM samples.  
Although several pre-experiments were performed, all the data on mouse liver shown in this thesis were 
derived from one single DigiWest experiment which additionally underlines the value of the method. 
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4.4 Conclusions and outlook 
The DigiWest method generates hundreds of replicas of a Western-Blot. It results in a bead-mix which 
contains the size-separated proteins from the initial Western-Blot and retains the molecular weight 
information in the color code of the beads. A bead-mix is sufficient for hundreds of antibody incubations 
while the results are highly comparable to classical Western-Blots. Thereby, it bridges the gap between 
Western-Blot and microarrays and brings the Western-Blot towards a systems-biology tool. As the 
DigiWest method mainly uses Western-Blotting equipment and the now wide-spread Luminex 
technology, it represents an interesting method which could be implemented in other laboratories 
without major investments.  
Tissues represent the ‘natural environment’ of cells and therefore the most relevant material for 
research but they are not very popular as they are heterogeneous and contain for example different 
types of cells, stroma and blood vessels obstructing proper analyses. This can be solved by isolation of 
cells by LCM but most methods for protein analysis are not capable of or struggle with analysis of LCM 
samples. As demonstrated with the mouse liver LCM experiment, the DigiWest method can be used for 
comprehensive analyses of LCM isolated samples. In experiments which are not shown in this thesis, 
where hematoxylin and eosin (H&E) stained sections were used without formalin fixation and cells were 
isolated using the Arcturus system, the analysis worked even better. Therefore, DigiWest could promote 
analysis of tissue and LCM samples as it allows hundreds on analyses from limited material.  
The DigiWest method completely changes the properties of the ‘blot’. The bead-mixes can be handled 
like a liquid and pipetted or magnetic bead handling equipment can be employed providing the 
possibility for automation. Washing steps are fast as the proteins on the beads are better accessible for 
washing buffers but also for antibodies and other reagents. Assays are performed in microtiter plates 
and each aliquot of a bead-mix is statistically identical and contains the same proteins on the same bead-
sets. These features are not only distinctive differences to the classical Western-Blot but also to all other 
technologies for detection of molecular weight separated proteins. Besides the original idea of genera-
ting replicas of a Western-Blot, these properties can be exploited for new approaches for research.  
The nature of identical replicates can be used for pattern analysis for example using human serum 
samples instead of antibodies. Incubation of serum samples on DigiWest bead-mixes loaded with 
pathogen lysates can be used for analysis of reactivity of the serum antibodies towards the pathogen 
proteins. The resulting patterns on the size-resolved proteins can be used for classification of e.g. 
patients that are/were infected and non-infected. Using the pattern instead of an absolute signal could 
result in better classification compared to ELISA or similar approaches. The feasibility of this approach 
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has already been shown in a successful experiment performed by Anette Döttinger in our group using 
human sera and bacteria lysates. A similar approach might be possible for cancer diagnostics. Human 
tumor samples could be used to analyze reactivity of serum contained antibodies in a pattern analysis 
which might even allow differentiation of tumor types based on the patterns. 
The Kinobead pulldowns shown in this thesis are similar to co-immunoprecipitations (co-IPs) which can 
therefore also be analyzed by DigiWest in a more comprehensive way which might allow analysis of large 
protein complexes and their dynamics under different conditions. 
Another application which has not yet been tested could be experiments similar to Far-Western-Blot for 
protein interaction analysis or similar approaches. The better accessibility and flexibility of the proteins 
might bring a further advantage compared to Western-Blot besides the higher output. 
It is also possible to perform enzymatic reactions on the DigiWest bead-mixes. The immobilized proteins 
could for example be dephosphorylated by phosphatases to test the phosphorylation specificity of 
antibodies. Therefore, an aliquot of a DigiWest bead-mix can be enzymatically dephosphorylated and 
used to compare the antibody specific signal to the signal obtained on an aliquot of the original bead-
mix. DigiWest bead-mixes are generally ideal for antibody characterization as they allow fast and 
automatable assays with high reproducibility and high throughput. DigiWest might also be useful for 
RPPM as it could be used for prescreening of antibodies on the samples of interest and might thereby 
increase the reliability of the RPPM results. 
DigiWest provides a new possibility to bring Western-Blot applications and variations to a higher output 
and the unique features of DigiWest provide the possibility to develop new ideas.  
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5 Methods 
5.1 Sample preparation 
5.1.1 Samples for method development 
The samples used during method development were already lysed in CLB1 and protein content was 
determined in a Bradford assay. Samples were prepared in commercial NuPAGE LDS sample buffer 
according to the manufacturer’s instructions. Preparations were composed of 1/4th volume 4x LDS 
sample buffer, 1/10th volume 10x NuPAGE Reducing Agent, the desired amount of sample and the 
remaining volume ddH2O. Sample preparations were incubated on a Thermomixer comfort or a 
Mastercycler gradient for 10 minutes at 70°C prior to application to the gels.  
 
5.1.2 GST-ERK2 spike-in experiment 
HepG2 lysate was spiked with GST-ERK2 in a 1:4 dilution series. The preparations contained 10 µg HepG2 
lysate and 20 ng, 5 ng, 1.25 ng, 0.31 ng, 78 pg or 19.5 pg of the GST-ERK protein per 12 µl.  
HepG2 lysate (in CLB1 lysis buffer, 6.08 mg/ml protein) was prepared in LDS sample buffer according to 
the manufacturer’s instructions. 1320 µl were prepared containing 1100 µg protein. 12 µl (10 µg protein) 
were applied to the gel for each lane.  
Therefore:  677 µl H2O, 330 µl of 4x LDS sample buffer, 132 µl of 10x reducing agent and 181 µl sample 
were mixed. 
GST-ERK2 was obtained from Millipore (#14-536) with a concentration of 1.463 mg/ml. 3 µl were mixed 
with 6 µl H2O resulting in a concentration 487.7 µg/ml.  
294 µl of the HepG2 preparation was mixed with 1.005 µl diluted GST-ERK2 (490 ng) resulting in 20 ng 
GST-ERK2 per 12 µl. The remaining HepG2 preparation (1026 µl) was adjusted with 3.5 µl H2O. The GST-
ERK2 spiked and the un-spiked HepG2 preparations were used to prepare a 1:4 dilution series. 200 µl of 
the HepG2 preparation were mixed with 66.67 µl of the GST-ERK2 spiked HepG2 preparation resulting in 
5 ng GST-ERK2 per 12µl. This preparation was used for the next dilution step. 6 dilutions (from 20 ng to 
about 20 pg per 12 µl, overall dilution factor of 1024) were prepared. Samples were denatured at 70°C 
for 10 minutes. 12 µl were applied per lane.  
For DigiWest, 3 replicates of each dilution were used resulting in 18 lanes. They were distributed over 3 
blots (empty lanes between the protein-loaded lanes were needed for cutting the membrane). For 
Western-Blots, the 3 higher concentrations were applied in duplicates, the 3 lower concentrations in 
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triplicates resulting in 15 lanes per blot. 4 Western-Blots were prepared, 2 were blotted onto PVDF 
membranes, 2 on nitrocellulose membranes.  
 
5.1.3 LCM of mouse liver sections  
The TCPOBOP treatment study was performed by Albert Braeuning as described (Braeuning et al., 2011) 
and the sections were prepared by Elke Zabinsky at the Institute of Toxicology. Frozen mouse liver tissue 
was cut into 10 µm sections, placed on slides (MembraneSlide 1.0 PEN, Zeiss). Sections were formalin 
fixed and stained with a mouse-derived anti-glutamine synthetase (GS) antibody. These sections were 
stored at -80°C till used. The mouse liver tissue sections were derived from 16 animals, 4 replicates of 
each treatment condition. They were either treated with corn oil or with TCPOBOP for 24, 48 and 72 
hours. Some more sections from mouse livers with corn oil and 48 hours TCPOBOP treatment were 
prepared for pretests. 
For laser capture microdissection, the stained sections were stored on dry ice. One section per day was 
equilibrated to room temperature and placed on the PALM MicroBeam. Areas around the central veins 
(GS stained areas) and areas around non-stained blood vessels which should represent portal triads were 
collected. About the same width as seen for GS staining was chosen (1-2 cell layers). An area of about 3.7 
mm² was collected on AdhesiveCap 200 opaque (Zeiss) for central vein and portal vein regions. Each 
sample was collected on 6 caps with an area of about 0.6 mm² per cap. The caps containing the collected 
areas were stored at room temperature till the LCM of the section was completed (8 hour in average). 
The collected samples were then placed on dry ice and later stored at -80°C. So the 16 sections for the 
main experiment resulted in 32 samples each composed of 6 caps.  
For lysis, the areas from each sample were pooled into 0.5 ml vials by adding 10 µl of 100% ethanol to 
each cap and transfer into the vials. The vials containing about 60 µl ethanol and the LCM material were 
stored at -80°C. The next day they were dried in a speed-vac. The lysis buffer had the following 
composition. 500 µl lysis buffer: 275 µl TPER, 125 µl 4x LDS, 100 µl Reducing Agent. 15 µl of this buffer 
was added to each sample and incubated for 1 hour at 95°C, 1200 rpm on a Thermomixer comfort. 
Samples were stored at -80°C and used as is for gel electrophoresis. 
 
5.1.4 H292 cell lysates and Kinobead pulldowns 
These samples were provided by Benjamin Ruprecht, TUM, laboratory of Bernhard Küster. Samples were 
provided in 2x LDS sample buffer containing 2x Reducing Agent. Cell lysates were diluted in the same 
buffer to a concentration of 25 µg protein per 15 µl volume. Preparation of the Kinobead pulldowns was 
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performed as follows: 13 µl pulldown (in 2x LDS) + 5 µl of LDS buffer containing Reducing Agent (80 µl 4x 
LDS + 20 µl Reducing Agent). Samples were incubated at 50°C for 30 minutes following Benjamin’s 
instructions. 
 
5.2 Electrophoresis and blotting 
5.2.1 Electrophoresis (SDS PAGE) 
The commercial NuPAGE gel electrophoresis system was used for all gel electrophoresis experiments 
mentioned. Gels were NuPAGE 4-12% Bis-Tris Protein Gels. They contain a gradient from 4 to 12% poly-
acrylamide. All gels used were 1 mm thick, the number of lanes varied depending on the experiment. 
Gels were unpacked, rinsed with ddH2O and placed in the corresponding chambers. NuPAGE MES SDS 
running buffer was prepared using 40 ml 20x buffer and adding ddH2O to a volume of 800 ml per 
chamber. The inner chamber was supplemented with 500 µl NuPAGE Antioxidant. 5 µl SeeBlue Plus 2 
pre-stained protein standard was used as molecular weight marker. For DigiWest experiments the 
marker was applied twice, usually in the outer left and the outer right lanes.  
Samples were loaded and gels were run at 150 V for 90 minutes on ice. For DigiWest experiments every 
second lane was left empty. This was necessary for cutting the membranes after blotting. For the H292 
cell lysates and Kinobead pulldowns NuPAGE MOPS buffer was used and gels were run at 100 V for 3.5 
hours on ice following Benjamin’s instructions. 
Gels for protein determination were usually just run for 20 to 45 minutes.  
 
5.2.2 Western-Blotting 
Blotting onto membranes was based on the wet blotting method. Again the commercial NuPAGE system 
was used. Blotting modules were the XCell SureLock Mini-Cells. NuPAGE Transfer buffer was used. 
Transfer buffer was (per blotting module) 25 ml 20x NuPAGE Transfer buffer, 50 ml methanol, filled to 
500 ml with ddH2O. Transfer setup was as follows: 3 transfer sponges soaked with transfer buffer, 2 
Whatman papers soaked with transfer buffer, gel, membrane soaked with transfer buffer, 2 soaked 
Whatman papers, 2 soaked sponges. Transfer conditions were: 30 V, 200 mA, 60-75 minutes. In earlier 
experiments transfer was performed on ice, later at room temperature. 
Membranes were, depending on the experiment, nitrocellulose or PVDF membranes. Membranes and 
Whatman papers had a size of 7.5x8.5 cm. For DigiWest experiments PVDF membranes were used which 
were pre-wetted in 100% methanol for 20-30 seconds.  
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5.2.3 Ponceau S staining 
After blotting, a Ponceau S stain was performed for quality control and in case of DigiWest experiments 
for labelling of the lane positions. Nitrocellulose membranes were stained directly. PVDF membranes 
were washed/blocked in PBST for about 15 minutes prior to staining. Membranes were stained in 
Ponceau S solution for 5 minutes and washed in ddH2O till the proteins were visible. In case of DigiWest 
experiments a pencil was used to label the protein lane positions. Images of each blot were taken using 
the Fuji LAS-4000. Blots were destained in TBST till no Ponceau S was visible anymore. For DigiWest 
experiments blots were destained and washed in PBST for 30 minutes with several rounds of buffer 
exchange. 
5.2.4 Immuno-detection 
For Western Blot incubations, blots were blocked in either 3% BSA or 3% milk powder in TBST for about 1 
hour. Antibody dilutions were prepared in either 1% BSA or 1% milk powder in TBST. Blots were placed in 
15 ml or 50 ml tubes and incubated with the primary antibody overnight on a wobble roller at 4°C. For 
small blots in 15 ml tubes, 2.5 ml antibody dilution were used, for whole blots in 50 ml tubes 4 ml. Blots 
were washed 5 times for 5 minutes in TBST. For 15 ml tubes 5 ml TBST were used for washing, for 50 ml 
tubes 10 ml were used. Secondary antibodies were prepared in the same buffer than the primary anti-
bodies and incubated for 1 hour at room temperature, in case of fluorescently labelled antibodies in the 
dark. After washing 5 times for 5 minutes blots were prepared for readout.  
For fluorescent LICOR Odyssey readout blots were dried between Whatman paper and readout was 
performed using the dry blots. Blots were pre-scanned with different laser power settings to find the 
optimal setting (highest intensity without saturated pixels) for high resolution readout. 
For chemiluminescent readout using the Fuji LAS-4000 the SuperSignal West Pico chemiluminescent 
substrate was used. Working solution was prepared freshly following the manufacturer’s instructions. 
Blots were incubated for 5 minutes in the chemiluminescent substrate then placed on the LAS-4000 tray, 
soaked with the chemiluminescent substrate, covered with a glass plate and exposed on the LAS-4000 in 
an incremental series. The image with the longest exposure time without any saturation was chosen for 
further processing. 
 
5.2.5 Western-Blot quantification 
Western Blot quantification was performed using the Fuji MultiGauge software.  
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5.3 Luminex bead preparation (final workflow conditions) 
5.3.1 Coating of MagPlex beads with NeutrAvidin 
Coupling conditions were optimized over time. The following conditions represent the latest coupling 
conditions which were used for the main 384-plex DigiWest bead-mixes. 
Coupling of NeutrAvidin to Luminex MagPlex bead-sets was performed employing a KingFisher 96 auto-
mated magnetic particle processor. 400 bead sets were coated with NeutrAvidin. These bead sets were 
used to compose a 384-plex consisting of 4 times 96 bead sets. The KingFisher 96 was equipped with a 
96 head for deep well plates. The coupling procedures took place in KingFisher 96 KF plates using tip 
combs for deep well plates. 
MagPlex magnetic Luminex beads were delivered in vials containing 1 ml bead suspension with a 
concentration of 12.5 million beads/ml. Beads were vortexed vigorously for 30 seconds and placed in an 
ultrasonic bath for 10 seconds. Beads were vortexed again directly before pipetting them into the bead 
plates. To reduce stickiness of the KingFisher consumables, all buffers were supplemented with Triton X-
100 (see buffer compositions).  
500 µl of each bead set were used. The first round of bead-coating was performed for 16 bead sets 
followed by four rounds of 96 bead sets each. 2 bead plates were used to provide the beads to the 
KingFisher. 5 µl of a 2.5% Triton X-100 solution in ddH2O were pipetted to each well followed by 250 µl 
bead suspension. 2 more plates were filled with 200 µl/well activation buffer (100 mM phosphate buffer, 
pH 6.2, 0.01% Triton-X100).  
In the first program, the KingFisher pooled the 2 bead plates and used the 2 activation buffer plates for 
washing followed by release of the pooled beads in the second activation buffer plate. 
The coupling procedure worked as follows: 
The KingFisher was equipped with 8 plates providing all buffers and solutions necessary. Beads were 
transferred to the activation plate which was prepared directly before the program was started. The 
activation plate contained 150 µl/well activation mix (5 mg/ml EDC and 5 mg/ml sulfo-NHS in activation 
buffer). The activation of the carboxylated Luminex beads to sulfo-NHS esters was performed for 20 
minutes (4 rounds of 1 minute mixing and 4 minutes incubation). The next 2 plates contained 200 µl/well 
coupling buffer (50 mM MES, pH 5.0, 0.01% Triton X-100) for washing followed by the coupling plate 
which contained 150 µl/well of 500 µg/ml NeutrAvidin in coupling buffer. Coupling was performed for 2 
hours (12 rounds of 1 minute mixing and 9 minutes incubation). After coupling, the beads were washed 
in 2 plates containing 200 µl/well CBS (‘carboxy block store’, 1% BSA in PBS, 0.05% sodium azide, 0.05% 
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Tween-20 (in later coupling procedure the Tween-20 was omitted)). The beads were finally released in a 
plate containing 200 µl CBS. 
Beads were pipetted into 1.5 ml vials, wells were washed once with 200 µl CBS. The vials were placed in 
a magnet stand, buffer was removed and 1 ml CBS was added to each bead-set. 
 
5.3.2 Quality control 
500 µl CBS were pipetted into a 1.5 ml vial which was placed on a magnet stand. Bead sets were 
vortexed vigorously before use. 5 µl of each bead set were pipetted into the 1.5 ml vial. When the vial 
was full, some buffer was removed. After 5 µl of all 400 bead sets were pipetted into the vial, the buffer 
was removed and 1 ml CBS was added.  
5.3.2.1 Bead count 
500 µl of this 400-plex bead-mix was transferred to a new vial for loading control. The remaining 500 µl 
bead-mix were placed on a magnet stand, buffer was discarded and 1250 µl CBS were added. 8 
replicates of 100 µl of this bead-mix were added to an assay plate. Readout was performed on a Luminex 
FlexMap 3D with the settings: count to 10000 and 50 µl volume. The count to 10000 cannot be reached 
so the instrument measures all beads in the solution till the volume limit is reached. The number of 
beads which were measured of each set can be used to back-calculate the bead concentration of each 
set. The calculated concentrations were used to adjust the 400 bead sets to a concentration of 4000 
beads/µl. 
5.3.2.2 Biotin binding capacity 
The 500 µl bead-mix from above was placed in a magnet stand and buffer was removed. Beads were 
resuspended in 180 µl CBS. A biotinylated c-Myc peptide was used for testing the biotin binding capacity. 
The peptide had the sequence biotin-Doa-Doa-EQKLISEEDL. 40 µl of a 1 mg/ml solution were added to 
the bead-mix. Loading of the peptide onto the beads was performed for 2 hours on a Thermomixer at 
900 rpm, 25°C. Beads were washed 5 times with 500 µl CBS and resuspended in 300 µl CBS.  
Anti-c-Myc antibody (clone 9E10) was used for the loading control assay. A dilution series of anti-c-Myc-
antibody was prepared (1 µg/ml, 0.2 µg/ml and 0.04 µg/ml) in CBS and a blank (CBS).  
50 µl/well CBS were pipetted into an assay plate. 10 µl/well of the peptide-loaded bead-mix were added 
to 16 wells, preincubated for some minutes, placed on a magnet plate and buffer was discarded. 50 µl of 
the antibody dilution were added to the beads with 4 replicates each. Antibody was incubated for 2 hour 
on a Thermomixer at 750 rpm, 23°C. After 3 times washing with 100 µl PBST on a magnet plate, anti-
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mouse-PE secondary antibody was added (50 µl/well, 2.5 µg/ml in CBS) and incubated for 1 hour at 
750 rpm, 23°C. After washing 3 times with PBST on a magnet plate, 100 µl/well PBST were added for 
readout on a Luminex FlexMap 3D. 
5.3.2.3 DigiWest bead plate composition 
The bead sets used were the Luminex MagPlex bead sets 001 to 400. Some of the bead sets had to be 
excluded due to a technical problem leading to a shift of some bead sets out of their classification region 
in one corner of the 3-dimensional classification space. So these bead sets were excluded from the 384-
plex DigiWest bead-mix. Some more bead sets were excluded due to their performance in the biotin 
binding capacity test. The selected 384 bead sets had a biotin binding capacity with a CV below 3% and 
were adjusted to a concentration of 4000 beads/µl. They were arranged in 4 blocks with 96 bead sets 
according to their bead set ID.  
5.3.2.4 Bead plate preparation 
200 µl/well of the 4 x 96 bead sets were pipetted into 4 96 well V-shape plates. These plates were used 
as master-plates to generate DigiWest bead plates containing a defined number of beads per well. This 
was done employing a BioMek FX pipetting robot which was equipped with a 96 pipetting head. 96 well 
V-shape plates were filled with 50 µl/well CBS and placed in the BioMek FX together with the master 
plate. Usually 40000 beads/well (10 µl) or 20000 beads/well (5 µl) were pipetted by the robot into each 
plate. Plates were labelled and vacuum sealed. These plates were stored at 4°C in the dark till used. 
 
5.4 DigiWest (final workflow conditions) 
5.4.1 Membrane processing 
After Ponceau S staining and washing in PBST for 30 minutes with several rounds of buffer exchange, 
membranes were biotinylated. For each blot an aliquot NHS-PEG12-Biotin (50 mM, 20 µl in DMSO) was 
diluted in 20 ml PBST resulting in a concentration of 50 µM and added to the membrane. The reaction 
was performed at room temperature on a shaker for 1 hour at speed 30/minute and an angle of 6° in the 
dark. Blots were washed with PBST 3 times for 1 minute and dried between 2 Whatman papers. 
Dried membranes were placed on a template printed on 120 g/m² paper and fixed with tape. The used 
templates were self-made Adobe Illustrator files. Membranes were covered with a piece of 120 g/m² 
paper. The template with the protected membrane was placed on a Silhouette cutting mat and placed in 
a Silhouette SD cutting plotter. Each lane containing separated proteins (every second) was cut into 96 
horizontal strips which were usually 6 mm wide and 0.5 mm high.  
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5.4.2 Protein Elution 
Elution buffer was 8 M urea, 1% Triton X-100 in 100 mM Tris-HCl buffer pH 9.5 (final concentration due 
to the volume of the urea was about 60-65 mM). 
Each lane was folded or cut in the middle as the wells of 96 well plates have a diameter below 6 mm. The 
96 strips were picked using a forceps and sorted into 96 well plates resulting in 1 plate per lane. 10 
µl/well of the elution buffer was added. Plates were sealed with plate sealing tape and incubated on 
either Thermomixer comfort or a TiMix 5 control equipped with 2 decks for 16 plates at 1200 rpm for 90 
minutes at room temperature.  
 
5.4.3 Protein loading onto Luminex beads 
Before bead loading, 90 µl of 5% BSA in PBST with 0.05% sodium azide was added to each well of the 
plates containing membrane snippets and eluted proteins to dilute the denaturing elution buffer. In 
earlier experiments a 3% BSA solution was used. Plates were placed on a shaker for some seconds. Bead 
plates were prepared ready to use and stored at 4°C till used as described. A KingFisher 96 PCR magnet 
head was used manually. A KingFisher 96 tip comb for PCR magnets was pre-blocked in the 3% or 5% BSA 
solution from above for some minutes. Then a KingFisher 96 PCR head and the comb were used to 
transfer the beads from the DigiWest bead plates to the plates containing the diluted and eluted 
proteins. Plates were sealed with a plate sealing tape and incubated on either Thermomixer comfort or 
TiMix 5 control over night at room temperature at either 750 rpm or 650 rpm.  
5.4.3.1 Blocking of remaining biotin binding sites 
An aliquot of the NHS-PEG12-Biotin was mixed with 500 µl TBST and incubated overnight at room 
temperature (left on the workbench). The inactivated biotinylation reagent was used to block the 
remaining biotin binding sites on the Luminex beads. The biotinylation reagent was diluted with TBST to 
a volume sufficient for 4 to 6 plates. 5 µl of the diluted biotin was added to each well and incubated for 1 
hour at room temperature.  
5.4.3.2 Pooling the beads to a DigiWest bead-mix 
A PickPen 8-magnet tool and corresponding silicone tips were used to pool the beads into one bead-mix. 
All 4 plates containing the 384-plex representing 4 Western-Blot lanes were pooled. In several 
experiments the beads from the 4 plates were pooled into one plate using a KingFisher 96-well magnet 
prior to the PickPen pooling procedure. The beads were then transferred into 1.5 ml vials, washed 3 
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times with 500 µl CBS employing a magnet stand and then resuspended in CBS to a concentration of 
40 beads/set/µl.  
 
5.4.4 DigiWest assays 
The assay layouts were individually designed for each experiment mainly depending on the number of 
samples and the resulting number of DigiWest bead-mixes. 
DigiWest assays were performed in 96 well half-area plates (Corning). The assay buffer for the final 
workflow was blocking reagent for ELISA (Roche) supplemented with 0.2% milk powder, 0.05% Tween-20 
and 0.02% sodium azide. Antibodies were diluted in assay buffer. Antibodies were usually used in a 
concentration about 5 times higher than recommended for Western-Blots and not more than 1 µg/ml. 
For example antibodies from Cell Signaling which are recommended to be diluted 1:1000 were used in a 
1:200 dilution.  
Plates were filled with 50 µl assay buffer per well. The DigiWest bead-mix or bead-mixes were added, 
usually 5 µl of the bead-mixes containing 40 beads/ID/µl resulting in 200 beads/ID/well. Beads were pre-
incubated in assay buffer for some minutes. Plates were placed on magnet plates and buffer was 
discarded. 30 µl/well of the antibody dilutions were added, plates were sealed with plate sealing tape 
and incubated overnight on a Thermomixer comfort at 750 rpm and 15°C. The next day the plates were 
washed twice with PBST (100 µl/well) on a magnet plate. PE-labelled secondary antibodies were diluted 
1:200 in assay buffer (2.5 µg/ml). 30 µl were added per well and incubated for 1 hour at 750 rpm, 23°C. 
Plates were washed twice and 100 µl/well PBST was added for readout. 
Readout settings on the Luminex FlexMap 3D were count to 50 beads per set, 90 µl volume and due to 
the bigger size of the MagPlex beads compared to the MicroPlex beads an increased gate. Depending on 
the bead recovery in the first assay of each DigiWest bead-mix or bead-mixes the count was lowered to 
40 or 35 beads which represent the absolute minimum for stable assays.  
 
5.4.5 Data analysis 
As DigiWest is a completely new method there was no data analysis software. Therefore I created an 
Excel based analysis tool. This tool is described in detail in the method development section. 
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5.4.6 Western-Blot mimics 
For generation of the Western-Blot mimics the background subtracted Luminex data were used. 
Background subtraction was performed either using the species specific blank or the bead-set specific 
background. The background subtracted data were normalized to values between 0 and 1 and loaded 
into the TM4 Microarray Software Suite (MEV) which created gray-scale maps using a black and white 
color scheme with 0 represented in white and 1 in black. The images were saved and a Gaussian diffusor 
was applied in Photoshop with a radius of half the element height.  
 
5.5 Protein determination 
5.5.1 Coomassie (Bradford) 
A Bradford (Coomassie) Protein Assay Kit was used according to the manufacturer’s instructions. A BSA 
standard was prepared in the same buffer as the corresponding samples. In cases when the samples 
were diluted for the assay, the standard was prepared in the same dilution. The standard concentrations 
usually covered the range from 1000 µg/ml to 25 µg/ml and a blank. 5 µl of the standards, blank and 
samples were pipetted to a 96 well F-bottom plate (Greiner) in duplicates or triplicates. 200 µl of the 
Coomassie reagent was added. The plates were placed on a shaker for 30 seconds and then incubated 
for 10 minutes at room temperature. Readout was performed on a FLUOstar OPTIMA.  
  
5.5.2 BCA (bicinchoninic acid) 
A BCA Protein Assay Kit was used according to the manufacturer’s instruction. The BSA standard was 
prepared as described for Coomassie protein determination. 
 
5.5.3 In gel 
For very limited samples which were directly prepared in LDS sample buffer or in Laemmli buffer it was 
necessary to perform the protein determination in gel as no protein assay was compatible with these 
buffers and sensitive enough. 
Krypton stain was used for in gel protein stain. A sample which was related to the samples of interest 
was used as standard. For example for mouse liver LCM samples a mouse liver lysate was used. The 
standard sample was used in 4 different concentrations based on best guess for the samples of interest 
in a 1:2 dilution series. The standards and aliquots of the samples were run on a gel as described in the 
electrophoresis section. 
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Either Krypton Flourescent Protein Stain or Krypton Infrared Protein Stain was used according to the 
manufacturer’s instruction. Usually the standard procedure or an intermediate between standard and 
rapid procedure was used. Readout was performed on the Odyssey scanner (Licor) for the infrared 
variant or on the Typhoon Trio (GE Healthcare) for the ‘fluorescent’ variant. 
For quantification the MultiGauge software was used. In contrast to Western-Blot quantification not a 
single band was chosen for quantification but a wide range representing the whole or the majority of the 
lanes. 
  
5.6 Gel staining 
5.6.1 Krypton 
See in-gel protein determination. 
 
5.7 Statistical analysis 
For statistical analysis the TM4 Microarray Software Suite (MEV) was used which has the R statistical 
language packets implemented (Saeed et al., 2006). The experiment-specific tests are described in the 
results part. In general, data were normalized on the median or mean of the corresponding control 
group and log2 transformed prior to statistical analysis. The settings for the individual tests are also 
described in the results part. 
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6 Materials 
6.1 Reagents and consumables 
6.1.1 Buffers and solutions 
Basic buffers 
  
Buffer Name Composition Supplier 
PBS (Dulbecco‘s) PBS 10x, BP399 Thermo Fisher Scientific, Walthab, MA, USA 
PBS (Dulbecco‘s)   PAA Laboratories, Pasching, Austria  
TBS  10 mM Tris, 150 mM NaCl in ddH2O pH 7,4    
Tris/HCl 100 mM Tris, adjusted with HCl in ddH2O, pH 9.5   
   
Composed buffers 
  
Buffer Name Composition Supplier 
Activation Buffer 100 mM phosphate, pH 6.2, 0.01% Triton X-100, ddH2O   
Antioxidant NuPAGE Antioxidant Life Technologies, Carlsbad, CA, USA  
Assay buffer 
0.05% Tween 20, 0.2% milk powder, 0.05% sodium azide, in 
BRE 
  
Blocking Reagent for Elisa (BRE) Blocking Reagent for Elisa, 11112589001 Roche, Rotkreuz, Risch, Switzerland 
Bradford Reagent Pierce Coomassie Assay Reagent  Thermo Fisher Scientific, Waltham, MA, USA  
CLB1 lysis buffer Zeptosens Reverse Array Lysis Buffer CLB1  Bayer Technology Services, Leverkusen  
Coupling Buffer 50 mM MES, pH5.0, 0.01% Triton X-100, ddH2O   
Elution buffer 8 M urea, 1% Triton X100 in 100 mM Tris/HCl pH 9.5   
Gel-Staining Krypton protein stain Thermo Fisher Scientific, Walthab, MA, USA 
  Krypton infrared protein stain Thermo Fisher Scientific, Walthab, MA, USA 
LDS sample buffer NuPAGE LDS Sample Buffer  Life Technologies, Carlsbad, CA, USA  
Lowry reagent DC Protein Assay Kit  Bio-Rad Laboratories, Hercules, CA, USA  
PBST  0,1 % (v/v) Tween 20 in PBS    
Ponceau S solution 0.1% (w/v) Ponceau S, 1% acetic acid, ddH2O   
Protein ladders  Odyssey Protein Molecular Weight Marker;  LI-COR Biosciences, Lincoln, NE, USA;  
  SeeBlue Plus2 Pre-Stained Standard  Life Technologies, Carlsbad, CA, USA  
Reducing agent NuPAGE Sample Reducing Agent  Life Technologies, Carlsbad, CA, USA  
Running buffers NuPAGE MES SDS Running Buffer  Life Technologies, Carlsbad, CA, USA  
  NuPAGE MOPS SDS Running Buffer  Life Technologies, Carlsbad, CA, USA  
Storage buffer (CBS) 1% BSA, 0.05% sodium azide, (0.05% Tween 20), in PBS   
Streptavidin-PE  Streptavidin-R-Phycoerythrin  Dianova, Hamburg 
TBST  0,1 % (v/v) Tween 20 in TBS    
T-PER T-PER Tissue Protein Extraction Reagent Thermo Fisher Scientific, Walthab, MA, USA 
Transfer buffer NuPAGE Transfer Buffer  Life Technologies, Carlsbad, CA, USA  
Western blotting substrate SuperSignal West Pico Chemiluminescent Substrate  Thermo Fisher Scientific, Waltham, MA, USA  
 
6.1.2 Chemicals and reagents 
Product  Supplier 
Acetic acid Carl Roth, Karlsruhe  
Biotin-c-myc peptide (custom) NMI Peptides, Reutlingen 
BSA (Fraktion V, protease free)  Carl Roth, Karlsruhe  
DMSO  Sigma-Aldrich, St. Louis, MO, USA  
EDC Thermo Fisher Scientific, Walthab, MA, USA 
Glycerol  Sigma-Aldrich, St. Louis, MO, USA  
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Product  Supplier 
GST-ERK2 fusion protein Millipore / Merck, Darmstadt 
HCl Sigma-Aldrich, St. Louis, MO, USA  
KCl  Sigma-Aldrich, St. Louis, MO, USA  
Krypton Protein Stain Thermo Fisher Scientific, Walthab, MA, USA 
Krypton Infrared Protein Stain Thermo Fisher Scientific, Walthab, MA, USA 
MES Sigma-Aldrich, St. Louis, MO, USA  
Methanol  Carl Roth, Karlsruhe  
MgCl2  Merck, Darmstadt  
Milk powder Carl Roth, Karlsruhe  
Na2HPO4  Carl Roth, Karlsruhe  
NaCl  Sigma-Aldrich, St. Louis, MO, USA  
NaH2PO4  Carl Roth, Karlsruhe  
NaHCO3  Merck, Darmstadt  
NaN3 (Sodium azide) Sigma-Aldrich, St. Louis, MO, USA  
NaOH  Carl Roth, Karlsruhe  
NHS-LC-LC-Biotin Thermo Fisher Scientific, Walthab, MA, USA 
NHS-PEG12-Biotin Thermo Fisher Scientific, Walthab, MA, USA 
Ponceau S  Carl Roth, Karlsruhe  
PVA (different chain lengths)) Sigma-Aldrich, St. Louis, MO, USA 
PVP (PVP-360) Sigma-Aldrich, St. Louis, MO, USA  
PVP (different chain lengths) ICN Biomedicals, Aurora, Ohio, USA 
 Sigma-Aldrich, St. Louis, MO, USA 
SDS Sigma-Aldrich, St. Louis, MO, USA  
sNHS Thermo Fisher Scientific, Walthab, MA, USA 
Tris  Carl Roth, Karlsruhe  
Triton X-100  Sigma-Aldrich, St. Louis, MO, USA  
Triton X-100  VWR, Radnor, PA, USA 
Tween 20  Merck, Darmstadt  
Urea Sigma-Aldrich, St. Louis, MO, USA  
 
6.1.3 Secondary antibodies 
Antigen Species Label Supplier Product # 
anti-Goat IgG (H+L) Donkey HRP Jackson Dianova 705-035-147 
anti-Goat IgG (H+L) Donkey  IRDye 800CW  LI-COR Biosciences 926-32214  
anti-Goat IgG (H+L)  Donkey  RPE (PE) Jackson Dianova 705-116-147  
anti-Mouse IgG (H+L) Goat HRP Jackson Dianova 115-035-062 
anti-Mouse IgG (H+L) Donkey  RPE (PE) Jackson Dianova 715-116-151 
anti-Mouse IgG (H+L) Goat RPE (PE) Jackson Dianova 115-116-146 
anti-Mouse IgG (H+L) Donkey  IRDye 800CW  LI-COR Biosciences 926-32212  
anti-Rabbit IgG (H+L) Donkey HRP Jackson Dianova 711-035-152 
anti-Rabbit IgG (H+L) Donkey  RPE (PE) Jackson Dianova 711-116-152 
anti-Rabbit IgG (H+L) Donkey  IRDye 800CW  LI-COR Biosciences 926-32213  
anti-Rat IgG (H+L) Donkey HRP Jackson Dianova 712-035-153 
anti-Rat IgG (H+L) Donkey  RPE (PE) Jackson Dianova 712-116-153 
anti-Rat IgG (H+L) Goat  IRDye 800CW  LI-COR Biosciences 926-32219  
anti-Sheep IgG (H+L) Donkey  RPE (PE) Jackson Dianova 713-116-147 
Streptavidin   RPE (PE) Jackson Dianova 016-110-084 
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6.1.4 Primary antibodies 
Antigen P-Sites Species Distributor Product # Lot # 
14-3-3 sigma   gt R&D AF4424 ZLC01-07051 
4E-BP1   rb Epitomics 1557-1 YC111401 
4E-BP1 – phospho Ser65 rb Cell Signaling 9451 14 
ABL2   rb Epitomics 5431-1   
ABL2 (phosphorylated) antibody    rb Biorbyt orb34396   
Acetyl-CoA Carboxylase – phospho Ser79 rb Cell Signaling 3661 10 
ADAM12   rb abcam ab137468 GR128068-2 
AHR   sheep R&D AF6697 CFAL0111021 
Ahr   rb Biomol SA-210   
Akt   rb Cell Signaling 4685   
Akt   rb Cell Signaling 4691 11 
Akt   rb Cell Signaling 9272 11 
Akt – phospho Ser473 rb Cell Signaling 4060 5 
Akt – phospho Thr308 rb Cell Signaling 9275   
Alcohol dehydrogenase beta subunit (Aldh1A1)   rb Epitomics 2052-1 YE0226012 
AMPK alpha   rb Cell Signaling 2532 3 
AMPK alpha – phospho Thr172 rb Cell Signaling 2535 13 
Anti-Folate Binding Protein (Folate Receptor, FOLR1)   rb Epitomics ab125030   
Anti-SIK3   rb Epitomics ab88495   
A-Raf   rb Cell Signaling 4432 2 
ASK1   rb CST 8662   
ASK1 Phospho Ser83 rb CST 3761   
ASK1 Phospho Thr845 rb CST 3765   
ASL (argininosuccinate lyase)   rb Atlas/Sigma HPA016646 R06318 
ATF3   rb Sigma HPA001562 A70381 
ATM   rb Cell Signaling 2873 3 
ATM – phospho Ser 1981 ms Millipore MAB3806 2015985 
Aurora A – phospho Thr288 rb Cell Signaling 3079 3 
Aurora A (AIK)   rb Cell Signaling 4718   
Aurora A/B/C – phospho T288/T232/T198 rb Cell Signaling 2914 3 
Aurora A/B/C – phospho T288/T232/T198 rb Cell Signaling 2914 3 
Aurora B (AIM1)   rb Cell Signaling 3094 2 
Axin1   rb Cell Signaling 3323 1 
Bad   rb Cell Signaling 9292 6 
Bad – phospho Ser112 ms Cell Signaling 9296 2 
Bax   rb Cell Signaling 2772 6 
Bcl2   rb Cell Signaling 2870 2 
Bcl-xL   rb Cell Signaling 2764 4 
beta-Actin   ms Sigma A1978 012M4821 
beta-Catenin   rb Biosource AHO0462 25439-06S 
beta-Catenin – phospho Ser675 rb Cell Signaling 9567 1 
beta-Catenin – phospho Thr41/Ser45 rb Cell Signaling 9565 2 
beta-Catenin – phospho Ser552 rb Cell Signaling 9566 2 
beta-Catenin (non-pospho Ser33/37/Thr41; active)    rb Cell Signaling 8814 3 
Bmf   rb Cell Signaling 4692 1 
b-Raf   rb Upstate 07-583   
b-Raf – phospho Ser445 rb Cell Signaling 2696   
BRCA1   rb Cell Signaling 9010 2 
BRCA1 – phospho Ser1524 rb Cell Signaling 9009 2 
C/EBP alpha   rb Cell Signaling 8178 0001 
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Antigen P-Sites Species Distributor Product # Lot # 
Caseinkinase 1 alpha   rb Cell Signaling 2655 1 
Caseinkinase 1 delta   ms Abcam ab85320 GR3957 
Caseinkinase 1 epsilon   rb Invitrogen 487600 070629237D1 
Caseinkinase 1 epsilon   ms Nanotools 0172-100   
Caseinkinase 2 alpha   rb Cell Signaling 2656 1 
Caspase 3   rb Cell Signaling 9662   
Caspase 7   rb Cell Signaling 9492   
Caspase 8   ms Cell Signaling 9746   
Caspase 9   ms Cell Signaling 9508   
Caveolin-1   rb Cell Signaling 3238 3 
CD36   rb Epitomics 5777-1 YI081203CS 
cdc2 – phospho Tyr15 rb Cell Signaling 4539   
cdc2 (CDK1)   ms Cell Signaling 9116   
CDK6   ms CST 3136P   
CDK6 (126hosphor-Tyr13) antibody    rb Biorbyt orb15013   
CDK6 (126hosphor-Tyr24) antibody    rb Biorbyt orb15014   
CDKN2B (p15 INK4B, CDN2B, MTS2)   rb Cell Signaling 4822   
c-Jun   rb Cell Signaling 9165 2 
c-Jun – phospho Ser63 rb Cell Signaling 2361 1 
c-Jun – phospho Ser73 rb Cell Signaling 9164 3 
c-Kit   rb Epitomics 1522-1 GR90061-1 
c-myc   rb Cell Signaling 9402 3 
c-myc clone 9E10, Helmholtz Zentrum München  ms E. Kremmer custom  
c-myc - phospho Thr58/Ser62  rb Epitomics 1203-1 C04017 
c-myc - phospho Thr58/Ser62 rb Epitomics 1203-1 GR104962-1 
Cofilin   rb Cell Signaling 5175 0001 
Cofilin - phospho Ser3 rb Cell Signaling 3313 4 
Cox1   rb Cell Signaling 9896 1 
Cox2   rb Cell Signaling 4842 2 
c-Raf   rb Cell Signaling 9422 2 
c-Raf - phospho Ser259 rb Cell Signaling 9421 4 
CREB   rb Cell Signaling 9197 1 
CREB - phospho Ser133 rb Cell Signaling 9198 10 
CREB - phospho Ser133 rb Cell Signaling 9191 8 
Crk (p38)   rb Epitomics 1779-1 YD032001 
Crk (p38) - phospho Tyr221 rb Epitomics 2132-1 YE060603 
CXCR4   rb Calbiochem PC389 D00086510 
Cyclin A   rb abcam ab53054 332779 
Cyclin A2   rb Epitomics 1547-1 C10191 
Cyclin B1   ms Cell Signaling 4135 4 
Cyclin B1 - phospho Ser133 rb Cell Signaling 4133 1 
Cyclin D1   ms Cell Signaling 2926 7 
Cyp2B  rb Dr Wolf, gift   
Cyp2C8   rb Puracyp Hu-A004 RaPh/B#6 
Cyp2E1   rb StressGen     
Cyp3A4, 3A1, 3A11   ms Millipore MAB10041 PSO1482596 
Cytokeratin 18   ms Cell Signaling 4548 1 
Cytokeratin 7   rb Epitomics 2181-1 YE040203 
Cytokeratin 8   ms Santa Cruz sc-8020   
Cytokeratin 8 - phospho Ser23 rb Epitomics 2147-1 YE062501 
Dicer1   ms Millipore MABN461 Q2095733 
DKK1   rb Biorbyt orb27676   
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DPP3 (Dipeptidyl-peptidase 3)   rb Epitomics S1902 39757 
DUSP1 - phospho - (MKP-1) Ser296/318 rb Abcam ab78898   
DUSP1 (MKP1)   rb Millipore 07-535   
DUSP10 (MKP-5)   rb Cell Signaling 3483   
DUSP4    rb abcam ab72593 713785 
DUSP5 (VH3)   rb Sigma D8819   
DUSP6 (MKP3, MKP-3, PYST1)   rb Epitomics 2138-1 YE061201C 
DUSP9 (MKP4, MKP-4)   rb ProteinTech 14484-1-AP 05-May-09 
Dvl2   rb Cell Signaling 3224 1 
Dvl3   rb Cell Signaling 3218 1 
E2F-3   ms Millipore 05-551 NG1911119 
E2F4   rb biorbyt orb10571 A1502 
E-Cadherin   rb Cell Signaling 3195   
E-Cadherin - phospho Ser838/Ser840 rb Epitomics 2239-1   
eEF2   rb Cell Signaling 2332 5 
eEF2 - phospho Thr56 rb Cell Signaling 2331 7 
EGFR   rb Cell Signaling 4405 1 
EGFR - phospho Tyr845 rb Cell Signaling 2231 7 
EGFR - phospho Tyr1068 rb Cell Signaling 2234 13 
EGFR - phospho Tyr992 rb Cell Signaling 2235 7 
EGR1   rb Cell Signaling 4153 3 
eIF2 alpha   rb Cell Signaling 9722 7 
eIF2 alpha - phospho Ser51 rb Cell Signaling 3597 4 
eIF4E   rb Cell Signaling 2067 1 
eIF4E - phospho Ser209 rb Cell Signaling 9741 4 
Elk-1   rb Cell Signaling 9182 3 
Elk-1 - phospho Ser383 rb Cell Signaling 9181 4 
EphA2   rb CST 6997P   
EphA2 Phospho Tyr594 rb CST 3970   
EphA2 Phospho Ser897 rb CST 6347   
EphA2 Phospho Tyr588 rb CST 7423   
EphA2 Phospho Tyr772 rb CST 8244   
EPHA4 (phospho-Tyr596) antibody    rb Biorbyt orb126908   
EphA4 antibody    rb Biorbyt orb38212   
EphB3 antibody    rb Biorbyt orb38239   
EphB4 antibody    rb Biorbyt orb38241   
EphB6   rb abcam ab70181 855934 
EphB6 antibody    rb Biorbyt orb38245   
Ephrin B Phospho Tyr324/329 rb CST 3481   
Erk1/2 (MAPK p44/42)    rb Cell Signaling 4695 14 
Erk1/2 (MAPK p44/42) - phospho Thr202/Tyr204 rb Cell Signaling 4370 7 
Ets-1   ms Bonn     
Ezh2   rb Cell Signaling 5246 5 
Ezrin / Radixin / Moesin   rb Cell Signaling 3142 3 
Ezrin / Radixin / Moesin - phospho Thr567/564/558 rb Cell Signaling 3149 11 
FAK   rb Cell Signaling 3285 9 
FAK - phospho Tyr397 rb Cell Signaling 8556 1 
FAK 1   rb Epitomics 2146-1 YE052404C 
FAK 1 - phospho Tyr861 rb Epitomics 2153-1 YE070902 
FAK 1 - phospho Tyr576/Tyr577 rb Epitomics 2183-1 YE080103C 
FDPS (farnesyl diphosphate synthase)   rb Atlas/Sigma HPA028200 R27252 
Frizzled-1   rb abcam ab71342 GR121802-1 
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FTCD   rb biorbyt orb36816 E5977 
Fyn   rb Cell Signaling 4023 2 
Fyn   rb CST  4023P   
Gab1   rb Cell Signaling 3232 3 
GADD45B   rb Epitomics 5833-1 GR80581-12 
GAPDH   rb Abcam ab9485   
GAS2   rb Epitomics 3347-1 YH053106C 
GCN5L2   rb Cell Signaling 3305 4 
GLDC   rb biorbyt orb40195 E9357 
GLS2 (Glutaminase 2)   rb Atlas HPA038608 H89921 
GLUT-1   rb Millipore 07-1401 2373314 
Glutaminsynthetase   rb Sigma G2781 061K4811 
GSK3 alpha/beta - phospho Ser21/9 rb Cell Signaling 9331 15 
GSK3 beta   rb Cell Signaling 9315 11 
GSK3 beta   rb Cell Signaling 9332 4 
GSK3 beta - phospho Ser9 rb Cell Signaling 9336 3 
HAL (histidine ammonia lyase)   rb Atlas/Sigma HPA038547 R35558 
Ha-ras   rb Upstate 05-775 26823 
Her2   rb Dako A0485 00018437 
Her2 - phospho Tyr877 rb Cell Signaling 2241   
Her2 - phospho Tyr1221/Tyr1222 rb Cell Signaling 2243 8 
Her2 - phospho Tyr1248 rb Biosource 44904 0104 
hHR23b   rb abcam ab86781 957974 
HIF1 alpha   rb Cell Signaling 3716 2 
HIF1 beta (ARNT)   rb Cell Signaling 3718 1 
Histon Deacetylase 1 (HDAC1)   rb Cell Signaling 2062 1 
Histon Deacetylase 2   rb Epitomics 1603-1 YC-12-16-06 
Histon Deacetylase 3 (HDAC3)   rb Epitomics 1580-1 YC120108 
Histon H3   rb Cell Signaling 9715 0 
Histon H3 - acetyl Lys9 rb Cell Signaling 9649 9 
Histon H3 - acetyl Lys9 rb Cell Signaling 9671 2 
Histon H3 - dimethyl Lys4 rb Epitomics 1347-1 C07063 
Histon H3 - phospho Ser10 rb Cell Signaling 9701 13 
Histon H4 - acetyl Lys8 rb Epitomics 1796-1 YD062903 
HNF-4 alpha (HNF-4A)   gt Santa Cruz sc-6556   
HNF-4 alpha (HNF-4A) - phospho Ser313 rb biorbyt orb5454 A3963 
HSP 70   rb Cell Signaling 4876 2 
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)   rb Cell Signaling 8137 1 
IDH2   ms abcam ab55271 GR98694-1 
Ihh  rb abcam Ab52919 GR61013-15 
IkappaB alpha   ms Cell Signaling 4814 4 
IkappaB alpha   rb Cell Signaling 9242 5 
IkappaB alpha - phospho Ser32 rb Cell Signaling 9241 7 
IKKε   rb CST 2905   
IKKε Phospho Ser172 rb CST 8766   
ILK1   rb Cell Signaling 3862 2 
ILK1 - phospho Thr173 rb biorbyt orb6213 A4945 
ILK1 - phospho Ser246 rb biorbyt orb6214 A4946 
INSL4   rb abcam ab75061 633606 
Integrin beta1   ms Transduction Lab. I41720 4 
IPP-2 (PPP1R2, IPP2, PP1 Inhibitor 2) - phospho Thr72 rb abcam ab27850 686457 
IRAK4   rb Cell Signaling 4363 2 
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IRAK4 - phospho  Thr345/Ser346 rb Cell Signaling 11927 1 
IRE1 alpha   rb Cell Signaling 3294 4 
JNK/SAPK   rb Cell Signaling 9252   
JNK/SAPK   rb Cell Signaling 9258 7 
JNK/SAPK - phospho Thr183/Tyr185 rb Cell Signaling 4668 7 
JNK/SAPK - phospho Thr183/Tyr185 rb Cell Signaling 9251 8 
KSR1   rb abcam ab52196 791002 
KSR1 - phospho Ser392 rb Cell Signaling 4951 2 
LATS2   rb CST 5888   
Lck - phospho Tyr505 rb Cell Signaling 2751 5 
LIMK1   rb CST 3842   
LIMK1 Phospho Thr508 / Thr505 rb CST 3841   
LRP6   rb Cell Signaling 3395 1 
LRP6 - phospho Ser1490 rb Cell Signaling 2568 3 
LRRK2   rb CST 5559   
LRRK2 Phospho Ser910 rb Epitomics 5098-1   
LRRK2 Phospho Ser935 rb Epitomics 5099-1   
Mcl-1   rb Cell Signaling 5453 1 
Mcl-1 - phospho Ser159/Thr163 rb Cell Signaling 4579 1 
MCM2   rb Cell Signaling 3619 3 
MEK1   rb Cell Signaling 9124   
MEK1 - phospho Thr292 rb Epitomics 2233-1 YE100906 
MEK1/2 - phospho Ser217/221 rb Cell Signaling 9121 7 
MEK1/2 - phospho Ser217/221 rb Cell Signaling 9154   
MEK2   rb Cell Signaling 9125 1 
MERTK   rb abcam ab95925 GR121529-1 
MKK3/6 - phospho Ser189/207 rb Cell Signaling 9236   
MKK3/MKK6 Phospho S218/T222,S207/T211 rb RnD AF4930   
MKK4   rb Epitomics 1658-1 YD021301 
MKK4 (SEK1) - phospho Ser257/Thr261 rb Cell Signaling 9156 2 
MKK6   rb Epitomics 1821-1   
MKK7   rb Cell Signaling 4172 3 
MKK7 - phospho Ser271/Thr275 rb Cell Signaling 4171 2 
MLK3 - phospho Thr277/Ser281 rb Sigma M6318 094K0766 
MLK3 ( MAP3K11)   rb Epitomics 2000-1 YE010205 
MLK3 -phospho ( MAP3K11) Thr277/Ser281 rb Cell Signaling 2811 2 
Mnk1   rb Cell Signaling 2195 1 
Mnk1 - phospho Thr197/202 rb Cell Signaling 2111 3 
MSK1   rb Cell Signaling 3489 1 
MSK1 - phospho Ser360 rb Epitomics 2154-1 YE071202 
MSK1 - phospho Ser212 rb R&D AF1036 FKC03 
mTOR   rb Cell Signaling 2983 1 
mTOR - phospho Ser2448 rb Cell Signaling 2971 9 
MUC1 (CD227)   ms Chemicon CBL264 2641911LC 
N-Cadherin   rb Cell Signaling 4061 3 
NF-κB p100/p52   rb Cell Signaling 4882 4 
NF-κB p105/p50   rb Epitomics 1559-1 YG012101C 
NF-κB p105/p50   rb Cell Signaling 3035 3 
NF-κB p65   rb Cell Signaling 3034   
NF-κB p65   rb Cell Signaling 4764 3 
NF-κB p65 - phospho Ser536 rb Cell Signaling 3033 6 
NIK   rb Cell Signaling 4994 2 
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Numb   rb Cell Signaling 2756 2 
p21/Waf1/Cip1   rb Cell Signaling 2947 5 
p27(Kip1) - phospho - (CDKN1B) Ser10 rb Epitomics 2187-1 YE081401 
p27(Kip1) (CDKN1B)   ms Cell Signaling 3698 1 
p38/MAPK   rb Cell Signaling 9212   
p38/MAPK - phospho Thr180/Tyr182 rb Cell Signaling 9211   
p53   rb Cell Signaling 2527 4 
p53   rb Cell Signaling 9282 4 
p53 - acetyl Lys305 rb Epitomics 3308-1 GR44067-4 
p53 - phospho Ser392 rb Cell Signaling 9281 4 
p53 - phospho Ser20 rb Cell Signaling 9287 5 
p70 S6 kinase   rb Cell Signaling 2708 1 
PAI-1   rb Cell Signaling 11907 1 
PAK 1/2 - phospho  Ser144/Ser141 rb Cell Signaling 2606 2 
PAK 2    rb Cell Signaling 2608 3 
PAK 4   rb Cell Signaling 3242 2 
PAK 4/5/6 - phospho S474/S602/S560 rb Cell Signaling 3241 5 
PAK1/2/3 - phospho  Ser141 rb Biosource 44-940G 0301 
PARP   rb Cell Signaling 9542 5 
PDGF Receptor beta   rb Cell Signaling 4564 1 
PDGF Receptor beta - phospho Tyr751 rb Cell Signaling 3161 5 
PDK1   rb Cell Signaling 3062 10 
PERK   rb Cell Signaling 3192 1 
PERK - phospho Thr980 rb Cell Signaling 3179S 10 
PGC-1 alpha   ms Calbiochem KP9803 D00151286 
PGC-1 alpha - phospho Ser571 rb R&D AF6650 CEBA0111101 
Phospho-Fyn(Tyr530) antibody    rb Biorbyt orb99261   
PI3-kinase p110 subunit alpha   rb Cell Signaling 4255   
PI3-kinase p85   rb Cell Signaling 4292 4 
PI3-kinase p85 alpha   rb Epitomics 1675-1 YF-05-06-11C 
PKA C alpha   rb Cell Signaling 4782 1 
PKA C alpha/beta - phospho Thr197 rb Biosource 44-988 0104 
PKA C alpha/beta/gamma - phospho Thr197 rb Cell Signaling 4781 2 
PKA Substrate - phospho Ser/Thr rb Cell Signaling 9621 4 
PKC (pan) - phospho Ser660 rb Cell Signaling 9371 3 
PKC alpha/beta II - phospho Thr638/641 rb Cell Signaling 9375 3 
PKCθ   rb CST 12206   
PKCθ Phospho Thr538 rb CST 9377P   
PKG-1   rb Cell Signaling 3248 2 
PLC gamma I   rb Cell Signaling 2822 3 
PLC gamma I - phospho Tyr783 rb Cell Signaling 2821 3 
PP1 alpha   rb Millipore 06-221 1350289 
PP1 alpha  - phospho Thr320 rb Epitomics 2167-1 YE072306 
PP1 gamma   rb Calbiochem 
539543 
 
D00114312 
PP2A C   rb Cell Signaling 2259   
PP2A C - phospho Tyr307 rb R&D AF3989   
PPAR alpha   rb abcam ab8934   
PPAR alpha - phospho Ser12 rb abcam ab3484   
PPAR gamma   rb biorbyt orb11291 B2538 
PPAR gamma - phospho Ser112 rb biorbyt orb5574 A3704 
PRL-1 (PTP4A1)   gt ProSci 46-225   
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PTCH2   rb Cell Signaling 2470 1 
PTEN   rb Cell Signaling 9552 3 
PTEN - phospho Ser380 rb Cell Signaling 9551 6 
PTPN7 (LC-PTP, HEPTP)   rb ProteinTech 15286-1-AP 01-May-09 
PTPN7 (LC-PTP, HEPTP)   rb Atlas HPA019118 R08192 
PTP-PEST (PTPN12, PTN12)   rb Bethyl A301-302A A301-302A 
PXR (NR1I2)   rb Biorbyt orb131805   
Pyk2 - phospho Tyr402 rb Cell Signaling 3291   
Pyk2 / FAK 2   rb Epitomics 1480-1   
RACK1   ms BD Biosciences 610177   
Rad51   rb Epitomics 3161-1 YH031704C 
Raptor   rb Cell Signaling 2280 10 
Raptor - phospho Ser792 rb Cell Signaling 2083 4 
Ras   rb Cell Signaling 8955 1 
RBPSUH   rb Cell Signaling 5313 1 
RKIP (PBP, PEBP, PEBP1)   rb Cell Signaling 4742 1 
RSK 1   rb Upstate 06-668   
RSK 1 - phospho Thr573 rb Epitomics 2185-1 GR72730-3 
RSK 1 (p90RSK) - phospho Ser380 rb Cell Signaling 9341   
RSK 1/2/3   rb Cell Signaling 9347 0005 
RSK 3 - phospho Thr353/356 rb Epitomics 2012-1 C04223 
RSK 4   rb Epitomics 2102-1 YE041203 
RSK 4 - phospho Ser235 rb Epitomics 2151-1 YE051803 
RXR alpha   ms R&D PP-K8508-00   
RXR alpha   rb Santa Cruz sc-553   
S6 Ribosomal Protein   rb Cell Signaling 2217 1 
S6 Ribosomal Protein - phospho Ser240/244 rb Cell Signaling 2215 9 
SDS (serine dehydratase)   rb Atlas/Sigma HPA039230 R36967 
Shh   rb Cell Signaling 2207 2 
SHP-2   rb Epitomics 1609-1 YC121206 
SIK3 (KIAA0999) antibody    rb Biorbyt orb29515   
Slug   rb Cell Signaling 9585 3 
Smad1   rb Cell Signaling 6944 1 
Smad2 - phospho Ser245/250/255 rb Cell Signaling 3104 2 
Smad2 - phospho Ser245/250/255 rb Cell Signaling 3104 2 
Smad2 - phospho Ser465/467 rb Cell Signaling 3108 7 
Smad2/3   rb Cell Signaling 3102 8 
Smad3   rb Cell Signaling 9523 5 
Smad3 - phospho Ser423/425 rb Cell Signaling 9520 10 
SPRED2   rb abcam ab50535 545611 
SPRY2 (Protein sprouty homolog 2)   rb Millipore 07-524 31940 
SPRY3 (Spry-3, Sprouty 3)   rb Sigma (ASB) AV50519 QC22737 
Src   rb Cell Signaling 2109 4 
Src - phospho Tyr527 rb Cell Signaling 2105 9 
Src Family - phospho Tyr416 rb Cell Signaling 6943 1 
STAT 1   rb Cell Signaling 9172 10 
STAT 3   rb Cell Signaling 4904 2 
STAT 3 - phospho Ser727 rb Cell Signaling 9134 5 
STAT 3 - phospho Tyr705 ms Cell Signaling 9138 2 
STAT 5   rb Cell Signaling 9310 4 
STEP (PTPN5, PTN5)   rb Cell Signaling 4817 1 
Superoxiddismutase (Cu/Zn)   rb StressGen SOD-100 102411 
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TAK1   rb Cell Signaling 4505 3 
TAK1 - phospho Ser412 rb Cell Signaling 9339 1 
TBK1 (NAK) - phospho Ser172 rb Cell Signaling 5483 1 
TCF4   rb Cell Signaling 2565 3 
Thrombospondin 2   ms BD     
Thymidin Phosphorylase (ECGF1)   rb Abnova H00001890 09091 WULZ 
Topoisomerase 1   rb Abcam ab85038 940503 
VASP - phospho Ser157 rb Cell Signaling 3111 5 
VASP - phospho Ser239 rb Cell Signaling 3114 5 
VEGFR 2 (FLK-1)   rb Cell Signaling 9698 1 
Vimentin   rb Cell Signaling 5741 1 
Wnt3A   rb Millipore 09-162 DAM1764519 
YAP   rb Cell Signaling 4912 0 
YAP - phospho Ser127 rb Cell Signaling 4911   
γ-Catenin   rb Cell Signaling 2309 1 
 
6.1.5 Primary antibodies for IHC 
Antigen P-Sites Species Distributor Product # 
E-Cadherin     From the Institute of Toxiciology   
Glutaminsynthetase     From the Institute of Toxiciology   
PP2A C - phospho Tyr307 rb R&D AF3989 
PTCH2   rb Cell Signaling 2470 
S6 Ribosomal Protein - phospho (RPS6) Ser240/244 rb Cell Signaling 5364 
Ihh (indian hedgehog)  rb Abcam (Epitomics) Ab52919 
 
6.1.6 Consumables 
Type Format Distributor 
Vials 0.5 ml, 0.65 ml, 1.5 ml, 2 ml, 15 ml, 50 ml Biozym Scientific,Hessisch Oldendorf 
    Greiner Bio-One, Frickenhausen 
    Mettler-Toledo, Columbus, OH, USA 
    neoLab, Heidelberg 
    Starlab, Hamburg 
    Thermo Fisher Scientific, Waltham, MA, USA 
    Eppendorf, Hamburg 
Beads MicroPlex, MagPlex Luminex 
Blotting paper   GE Healthcare, Chalfont St Giles, UK  
Gels 
NuPAGE Novex 4 – 12 % Bis-Tris Gels 1,0 mm, different 
formats 
Life Technologies, Carlsbad, CA, USA  
King fisher 
consumables 
Plates, combs Thermo Fisher Scientific, Waltham, MA, USA 
LCM slides MembraneSlide 1.0 PEN Carl Zeiss AG, Jena 
LCM caps AdhesiveCAp 200 opaque Carl Zeiss AG, Jena 
Membranes PVDF, nitrocellulose Millipore / Merck, Darmstadt 
    GE Healthcare, Chalfont St Giles, UK  
    BioRad, Hercules, California, USA 
    Merck, Darmstadt  
Pipette tips   VWR, Radnor, PA, USA 
    Mettler-Toledo, Columbus, OH, USA 
    Starlab, Hamburg 
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    Beckman Coulter, Brea, CA, USA 
Plates 96-well plates Thermo Fisher Scientific, Waltham, MA, USA 
    Greiner Bio-One, Frickenhausen 
    Corning , New York, NY, USA 
Plate sealing tape   Thermo Fisher Scientific, Waltham, MA, USA 
Vacuum bags   Landig + Lava GmbH , Bad Saulgau 
 
 
6.2 Equipment 
6.2.1 Instruments / lab equipment 
Application Product  Supplier 
Balance Explorer E12140  OHAUS, Pine Brook, NJ, USA  
Bead readout instruments FLEXMAP 3D, Luminex 100 Luminex, Austin, TX, USA  
Centrifuges 5415D, 5417R  Eppendorf, Hamburg, Germany 
  Universal 30F  Hettich, Tuttlingen, Germany 
Cutting plotter Silhouette SD Silhouette America, West Orem, UT, USA 
Gel electrophoresis XCell SureLock Mini-Cell  Life Technologies, Carlsbad, CA, USA  
Gel blotting XCell II Blot Module Life Technologies, Carlsbad, CA, USA  
Heating block Mastercycler gradient, Thermomixer comfort  Eppendorf, Hamburg, Germany 
Horizontal tube rotator RM5  Assistent, Sondheim, Germany 
LCM microscope Palm Microbeam Carl Zeiss AG, Jena, Germany 
Magnetic bead handling PickPen 8-channel Bio-Nobile, Pargas, Finland  
 Plate magnets for 96 well plates Luminex, TX, USA 
  DynaMag™- Spin Magnet Life Technologies, Carlsbad, CA, USA  
  KingFisher96, KingFisher Flex Thermo Fisher Scientific, Waltham, MA, USA  
Mixer Vortex Genie 2  Scientific Industries, Bohemia, NY, USA  
Pipettes PIPETMAN Neo  Gilson, Middleton, WI, USA  
Pipettes electronic Xplorer, Research pro Eppendorf, Hamburg, Germany 
Pipetting robot  Biomek FX Beckman Coulter, Brea, CA, USA 
pH meter  pH-Meter 766  Knick, Berlin, Germany 
Power source Power Ease 500  Life Technologies, Carlsbad, CA, USA  
Shakers Polymax 2040 (gels + membranes) Heidolph, Schwabach, Germany 
  DRS-12 (membranes) NeoLab, Heidelberg, Germany 
  KL-2 (gels + membranes) Edmund Bühler GmbH, Hechingen  
  Thermomixer comfort (Vials + MTP) Eppendorf, Hamburg, Germany 
  TiMix 5 control (MTP) Edmund Bühler GmbH, Hechingen  
Spectrometer  Fluostar OPTIMA  BMG Labtech, Offenburg, Germany 
Speedvac BaVaCo-M Mini-30  Bachofer, Reutlingen, Germany 
Stirrer RCT basic IKA Werke, Staufen, Germany 
Ultrasonic bath SONOREX Bandelin, Berlin, Germany 
Vacuum sealer   Landig + Lava GmbH , Bad Saulgau, Germany 
Western-Blot readout / gel documentation ODYSSEY Infrared Imaging System LI-COR Biosciences, Lincoln, NE, USA 
  ImageQuant LAS 4000 mini  GE Healthcare, Chalfont St Giles, UK  
  Typhoon Trio GE Healthcare, Chalfont St Giles, UK  
Water purification system arium 61316  Sartorius Stedim Biotech, Göttingen, Germany 
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6.3 Software 
Software Distributor 
Creative Suite CS5 (Illustrator, Photoshop, Acrobat) Adobe Systems, San Jose, CA, USA 
DigiWest Analysis tool, based on Excel self-made 
ImageJ 1.42q Wayne Rasband (NIH), NIH  Bethesda, Maryland, USA 
Mendeley Mendeley Ltd., New York, NY, USA 
Multi Gauge V 3.0 FUJIFILM, Minato, Tokio, Japan 
Odyssey V 3.0 LI-COR Biosciences, Lincoln, NE, USA 
Office 2010 (Word, Power Point, Excel) Microsoft, Redmond, WA, USA 
TM4 Microarray Software Suite, MeV Version 4.8.1 Dana-Farber Cancer Institute, Boston, MA, USA 
XLfit 5.3.1.3 IDBS, Guildford, Surrey, GB 
Xponent, different versions Luminex, Austin, TX, USA  
Diverse control software for the instruments See instruments 
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7 Abbreviations 
Abbreviation Explanation 
 
Abbreviation Explanation 
°C degree Celsius 
 
MAP-kinase mitogen-activated protein kinase 
µ micro 
 
MES 2-(N-morpholino)ethanesulfonic acid 
µl microliter 
 
MFI median fluorescence intensity 
µM micromolar 
 
mg milligramm 
µm micrometer 
 
MKP MAP kinase phosphatase 
2D two dimensional 
 
ml milliliter 
3D three dimensional 
 
mm millimeter 
Å Angstrom 
 
mM millimolar 
AFI assembled fluorescence units 
 
MOPS 3-(N-morpholino)propanesulfonic acid 
ATP Adenosine triphosphate 
 
MS mass spectrometry 
BCA Bicinchoninic acid assay 
 
MΩ mega  Ω 
BETR Bayesian Estimation of Temporal Regulation 
 
ng nanogramm 
BSA bovine serum albumine 
 
NGC non-genotoxic carcinogen 
Ca Calcium 
 
NHS N-Hydroxysuccinimide 
CAR Constitutive androstane receptor 
 
nl nano liter 
CBS carboxy block store (storage buffer) 
 
nm nanometer 
CCD Charge-coupled device 
 
nM nanomolar 
CLB1 Cell lysis buffer 1 
 
PAGE Polyacrylamide gel electrophoresis 
cm centimeter 
 
PBS Phosphate buffered saline 
co-IP co-immunoprecipitation 
 
PE Phycoerythrin 
CV Coefficient of variation 
 
PEG Polyethylene glycol 
ddH2O purified water (18.2 MΩ) 
 
pg picogramm 
DEN diethylnitrosamine 
 
pH Unit for acidity 
DNA deoxyribonucleic acid 
 
pI isoelectric point 
DUSP dual specific phosphatases 
 
PMT photomultiplier tube 
e.g.  Latin “exempli gratia” 
 
PVA Polyvinyl alcohol 
ECL Enhanced chemiluminescence 
 
PVDF Polyvinylidene fluoride 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
 
PVP Polyvinylpyrrolidone 
EGF Epidermal growth factor 
 
RPPM Reevrse phase protein microarray 
ELISA Enzyme-linked immunosorbent assay 
 
S serine 
f fempto 
 
SDS Sodium dodecyl sulfate 
FFPE formalin-fixed, paraffin-embedded  SEM Standard error of mean 
fM femptomolar 
 
Ser serine 
GPI Glycosylphosphatidylinositol 
 
sNHS sulfo-NHS 
GS Glutamine synthetase 
 
SU sub unit 
GST Glutathione S-transferase 
 
T threonine 
h hour 
 
TBS Tris-buffered saline 
HRP Horseradish peroxidase 
 
TCPOBOP substance described in the text 
IC50 half maximal inhibitory concentration 
 
Thr threonine 
i.e. id est 
 
TPER Tissue protein extraction reagent 
I125 Iodine 125 
 
Tris tris(hydroxymethyl)aminomethane 
IHC Immunohistochemistry 
 
TUM Technical University Munich 
k kilo 
 
Tyr tyrosine 
Kd Dissociation constant 
 
USA United States of America 
kDa kilo dalton 
 
UV Ultra violett 
L Liter 
 
V Volt 
LCM laser capture microdissection 
 
VBA Visual Basic for Applications 
LIMMA Linear Model for Microarray Analysis 
 
w/v weight/volume 
M molar 
 
WB Western-Blot 
m milli 
 
Y tyrosine 
M mega 
 
Ω Ohm 
mA milli ampere   
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9 Presentations, publications, awards 
Poster presentation at Keystone Symposia: Proteomics, Interactomes 
Stockholm, Sweden 2012 
Poster presentation at Cold Spring Harbor Laboratories:  Mechanisms & Models of Cancer 
Cold Spring Harbor, NY, USA 2014 
Talk at the ‘Arbeitstagung Mikromethoden in der Proteinchemie’  
Bochum, Germany 2012 
 
Young Talent Award at the ‘Arbeitstagung Mikromethoden in der Proteinchemie’  
Winner of the Serva Electrophoresis Award 
Bochum, Germany 2012 
Science2Start award of ‘BioRegio STERN’  
Winner of the 1st price together with Markus Templin 
Esslingen, Germany 2014 
 
Patent on the DigiWest Method 
DE102011109063 B3    Verfahren zum Nachweis von Biomolekülen 
CA 2842995 A1 / PCT/EP2012/062403   Method for detecting biomolecules 
 
Publications 
The DigiWest method is planned for publication 
The Mouse liver LCM data are planned for publication  
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12 Appendices 
12.1 Appendix 1: Comparison of Western-Blots to DigiWest 
Shown are comparisons of classical Western-Blots and DigiWest data as described in section 3.5.1. The 
sample which was used for the Western-Blots and for generation of the DigiWest bead-mix was a HepG2 
lysate. For each of the 104 antibodies a classical Western-Blot is shown on the left, the DigiWest data in 
a reduced diagram in the middle with the specific signal highlighted in black and a grayscale-map 
representing the DigiWest data as Western-Blot mimic on the right. 
Appendix 1: Comparison of Western-Blots to DigiWest Appendices 
155 
 
Appendices Appendix 1: Comparison of Western-Blots to DigiWest 
156  
Appendix 1: Comparison of Western-Blots to DigiWest Appendices 
157 
Appendices Appendix 1: Comparison of Western-Blots to DigiWest 
158  
Appendix 1: Comparison of Western-Blots to DigiWest Appendices 
159 
Appendices Appendix 1: Comparison of Western-Blots to DigiWest 
160  
Appendix 1: Comparison of Western-Blots to DigiWest Appendices 
161 
Appendices Appendix 1: Comparison of Western-Blots to DigiWest 
162  
Appendix 1: Comparison of Western-Blots to DigiWest Appendices 
163 
Appendices Appendix 1: Comparison of Western-Blots to DigiWest 
164  
Appendix 2: GST-ERK2 spike-in complete experiment Appendices 
165 
 
 
 
 
 
 
 
 
12.2 Appendix 2: GST-ERK2 spike-in complete experiment 
This appendix is part of the experiment shown section 3.5.3. The figure in the appendix shows all 
replicates from the spike-in experiment including the technical replicates and the repeated measure-
ments. The table shows the quantified signal from the DigiWest measurements (in [AFI], relative 
fluorescence units) and from quantification of the Western-Blot also in relative fluorescence units. 
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12.3 Appendix 3: Data from the mouse liver LCM experiment  
This table contains all DigiWest data from the Mouse liver LCM experiment. All analytes which gave 
analyzable signal at the correct molecular weight are contained. Data are given in [AFI], normalized on 
total protein amount (streptavidin-PE). ‘GS+’ is the proximal pericentral zone and ‘GS-‘ is the proximal 
periportal zone. The numbers behind the time-points represent the animal identifiers. 
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  Control GS+     Control GS-     24 h TCP GS+     24 h TCP GS-     
Analyte 
Ctrl 28 
GS+ 
Ctrl 29 
GS+ 
Ctrl 30 
GS+ 
Ctrl 31 
GS+ 
Ctrl 28 
GS- 
Ctrl 29 
GS- 
Ctrl 30 
GS- 
Ctrl 31 
GS- 
24h 50 
GS+ 
24h 52 
GS+ 
24h 53 
GS+ 
24h 55 
GS+ 
24h 50 
GS- 
24h 52 
GS- 
24h 53 
GS- 
24h 55 
GS- 
ADAM12 160 200 187 204 149 312 193 180 127 155 88 99 204 323 127 185 
AHR (Aryl Hydrocarbon Receptor) 849 1773 2029 1859 1721 2485 1298 1679 2092 2171   1583 2037 2667 1423 2216 
Akt 914 1260 986 1016 792 1048 879 873 972 1112 968 993 849 875 791 1021 
Akt - pT308   102 314 103 122 125 155 96 3510 803 1511 521 971 59 649 446 
AMPK alpha 150 73 53 72 222 161 152 169 49 72 147 135 184 222 261 367 
AMPK alpha - pT172 2010 2272 2949 2540 3791 4432 4859 3770 1710 1920 1402 1678 3734 4324 3307 3697 
A-Raf 278 322 187 152 264 172 203 189 156 198 328 333 204 231 222 262 
ASL (argininosuccinate lyase) 3344 7190 7813 7676 9454 25820 22335 25167 6867 7988 2128 2335 18989 23574 7059 7736 
Bax 48 56   41 45 51 41 59 71 63 79 100 49 42     
beta-Actin 67618 86022 40613 80899 85426 104922 41985 94533 76090 95594 63030 104972 91844 102378 93273 107177 
beta-Catenin 7454 7160 9197 5682 9525 8290 11864 6480 4805 4705 7808 7523 6660 7475 10733 10938 
beta-Catenin - p S552 1955 1949 2505 1363 2681 2409 3286 1913 1035 994 1123 1223 1656 1803 1831 2164 
beta-Catenin - p S675 1309 1409 1773 1100 1639 1515 2282 1174 845 894 1154 1157 1118 1308 1397 1533 
beta-Catenin (non-pS33/37/T41 - active) 90 94 74 84 203 150 111 63 78 67 111 119 88 131 175 214 
C/EBP alpha  - p30 1631 1803 2109 1584 2120 2423 2304 2033 1252 1041 1440 1296 1417 1317 2115 2471 
C/EBP alpha - p42 1741 1848 1789 1827 2056 2017 1921 2080 1239 916 1645 1568 1534 1497 2682 2804 
C/EBP alpha total 3372 3651 3898 3411 4176 4440 4224 4112 2491 1957 3085 2864 2951 2813 4798 5274 
Caseinkinase 1 alpha 133 157 87 153 203 150 111 211 160 146 240 195 130 180 222 206 
Caseinkinase 2 alpha 399 403 289 438 425 424 360 334 405 415 563 608 415 416 521 532 
Catenin gamma 60 51 64 33 114 105 87 56 137 48 45 55 52 67 127 144 
CDKN2B (p15 INK4B, CDN2B, MTS2) 687 1594 1283 2139 589 1567 1013 1699 1589 1974 418 421 1729 1487 473 570 
c-Jun   40 30   110 108 67 91 99 115 150 169 128 145 156 152 
c-myc 449 607 379 317 200 155 194 136 706 771 566 655 216 244 196 152 
COX1 1541 1676 2485 1940 1262 1464 1462 1174 1221 1461 1100 1310 766 899 547 624 
CREB 147 168 170 233 216 193 121 161 165 175 247 231 208 202 258 234 
CREB - pS133 329 325 386 317 398 471 392 499 378 312 312 495 364 470 596 611 
Cyclin A         1263 1081 1157 1073         1094 1211 1935 1680 
Cyp2B 5469 3363 33843 15550 7024 5248 35145 14024 37549 39485 53778 47573 44569 53022 60171 72358 
Cyp2C (Cyp2C8) 82667 62324 55550 41347 34816 34273 23910 31632 97947 100953 148538 130381 97284 103105 117129 136219 
Cyp2E (Cyp2E1) 106574 74028 81468 59633 2787 1090 4007 1311 83711 82150 138079 128454 2926 2834 2658 3061 
Cyp3A (Cyp3a4 3a1 3a11) 62903 45965 21853 12647 46661 15985 6598 1611 241864 234245 336431 270103 111524 115119 117181 103546 
DKK1 649 536 589 496 870 502 506 472 533 414 560 949 560 482 607 1037 
DPP3 (Dipeptidyl-peptidase 3) 81 91 86 81     41 29 149 151 146 174 33 29     
DUSP4  3170 2111 2518 2548 12651 11653 10576 12129 2852 1649 2346 2910 11029 11578 16102 18752 
E2F4 78516 65830 60894 38792 120194 96330 105460 72512 27885 33423 38513 54721 57463 73011 86322 133271 
E-Cadherin         7290 7381 7740 5953         7760 8880 7552 8280 
E-Cadherin - pS838/S840         14387 12464 15311 10313         13529 16817 14559 15146 
EEF2 1768 2835 3175 2305 2917 2333 2569 1590 2410 2726 1426 2281 2139 2902 1517 1940 
eEF2 pT56 21795 24216 31355 19693 25822 19026 27305 15163 21639 23723 22226 26555 19059 22830 21458 22946 
EGR1 81 98 147 87 55 64 97 66 100 132 142 103 67 61 72 59 
eIF2 alpha 9597 11969 8382 10914 9482 11589 8792 10911 12360 12762 12332 12683 11407 11753 11662 11568 
eIF2 alpha - pS51 85 201 307 297 89 156 203 214 443 286 245 375 209 160 167 209 
eIF4E 1325 1558 1057 1264 1114 1619 1204 1290 1816 2173 2865 1924 1631 1641 2027 1698 
Erk1/2 - ERK1 418 530 484 547 701 697 705 522 447 495 530 618 606 711 697 842 
Erk1/2 - ERK2 979 1081 872 935 1051 1219 840 913 912 993 1085 935 833 965 967 1032 
Erk1/2 - pT202/Y204 - ERK1 395 159 257 219 419 366 351 278 458 424 437 594 311 437 776 481 
Erk1/2 - pT202/Y204 - ERK2 755 425 650 616 793 903 334 520 1080 819 1086 1328 580 923 1309 992 
Erk1/2 - pT202/Y204 - total 1150 584 907 836 1213 1270 685 798 1538 1243 1524 1922 891 1360 2084 1473 
Erk1/2 - total 1398 1612 1356 1482 1752 1916 1544 1436 1359 1488 1615 1553 1439 1676 1662 1874 
Ets-1 322 309 403 333 299 307 254 226 271 373 552 431 227 334 192 332 
Ezh2 70 91 77 99 69 60 74 60 78 125 74 128 127 137 134 84 
Ezrin / Radixin / Moesin 78 120 61 70 122 103 108 82 73 82 91 90 83 97 117 93 
Ezrin / Radixin / Moesin - pT567/564/558 1034 432 1466 381 538 284 969 279 412 446 808 806 287 325 472 518 
FAK 140 116 200 57 191 160 358 107 66 87 54 142 129 163 212 203 
FAK - pY397 131 116 333 84 145 147 421 119   126   89 152 143   165 
FDPS - Isoform 1 591 1305 983 1363 857 1952 1183 2220 977 1641 744 798 1527 2532 779 978 
FDPS - Isoform 2 346 358 664 495 688 656 841 848 284 431 250 343 565 593 491 555 
FDPS - total 938 1663 1649 1857 1545 2608 2026 3068 1262 2072 992 1142 2092 3125 1271 1534 
FTCD 113 88 149 138 1332 1197 1547 1228 117 139 103 130 835 1113 984 1153 
Fyn 509 535 552 581 588 684 686 525 386 553 451 373 431 507 521 510 
Gab1 613 612 855 734 647 649 1022 495 498 484 447 538 775 888 667 554 
Gadd45 beta 105 342 181 488 36 221 103 179 260 312 176 184 101 214 38 43 
GAPDH 33 33     63 68 73 71 50 41     68 79 42 70 
GAS-2 102 100 123 74 1320 2283 2045 1874 282 293 332 263 3599 4036 3524 3636 
GLS2 (Glutaminase 2)   37 56 31 121 176 199 269         119 178 211 205 
GLUT-1 579 560 389 298 72 52 62 60 295 289 773 545 211 253 361 463 
Glutaminsynthetase 916859 890495 1045050 953850 5316 2746 2830 2715 758972 813109 828246 971226 1575 1557 1687 1142 
GSK3 alpha/beta - pS21/9 - alpha 105 89 119 92 172 217 135 151 139 210 164 108 194 247 133 151 
GSK3 alpha/beta - pS21/9 - beta 199 138 187 102 204 167 188 156 208 278 193 167 150 190 149 180 
GSK3 alpha/beta - pS21/9 - total 304 225 306 195 376 384 323 306 346 488 357 274 343 439 280 330 
GSK3 beta 2747 2683 2651 2330 2244 2275 1846 2038 2126 1897 2094 2523 1787 1841 1812 2098 
GSK3 beta - pS9 322 212 247 145 294 331 225 170 314 399 252 248 223 323 255 229 
HAL (histidine ammonia lyase) 124 212 87 147 710 1173 1083 1444 148 145 95 175 767 1051 455 547 
Histon Deacetylase 1 (HDAC1) 53 52   56 36 61 49 78 45 57 79 80 52 70   62 
Histon Deacetylase 3 (HDAC3) 41 43   26   36   49 37   57 50 39   68 51 
Histon H3 - acetyl K9 7212 6091 6527 6489 9078 7952 9226 8617 4763 6787 5441 5633 7263 7178 6923 8341 
HNF-4 - pS313 406 286 372 482 1415 1051 1008 1135 252 275 330 355 946 1193 1511 1221 
HNF-4 alpha 710 575 404 418 569 720 465 525 553 561 164 663 403 722 967 552 
HSP70 62 79 117 88 30 32 33 24 97 131 170 138 24 39 49 34 
IDH1 ([NADP] cytoplasmic) 2664 4384 3975 4439 1657 2706 2288 2393 4994 5234 2775 2778 2323 2769 1566 1959 
IDH2 3090 2516 1430 2090 2777 2772 3098 2893 2439 2707 5346 4719 2932 3921 4128 4242 
Ihh (indian Hedgehog) 47 22 24 31 67 51 33 45 778 813 831 883 1211 1482 1113 1544 
IkappaB alpha 41 70   40 72 66 39 65 75 36 47 125 59 38 74 103 
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  Control GS+     Control GS-     24 h TCP GS+     24 h TCP GS-     
ILK1 575 476 662 422 594 602 966 615 395 425 510 494 432 528 648 526 
ILK1 - pS246 109238 97912 101469 113290 248451 230855 218883 222680 75649 91168 96072 104791 215329 240440 292952 279271 
ILK1 - pThr173 75237 68261 69468 79468 179774 161140 158305 157565 49871 59595 60103 68849 157832 165983 215907 206005 
INSL4 1321 1220 1360 1716 466 509 1013 595 1181 1435 1869 1712 978 888   1581 
IRAK4 - Isoform 1 456 371 489 430 551 565 539 526 366 383 488 510 372 467 723 694 
IRAK4 - p T345/S346 - Isoform 2 85 120 59 86 90 107 59 90 108 124 150 135 80 90 84 92 
JNK/SAPK (p46) 135 124 89 146 77 177 150 94 128 143   178 126 113 152 154 
JNK/SAPK (p54) 156 273 180 144 209 340 203 214 262 146 315 150 210 158 271 317 
JNK/SAPK - total 290 396 269 290 287 516 354 307 390 288   330 336 272 423 471 
KRAS GTPase 157 105 121 132 91 131 105 100 92 124 132 134 76 93 85 92 
KSR1 - pS392 501 312 826 444 787 596 1200 784 529 439 878 802 564 584 1076 1198 
LCK - pY505 1748 2009 2226 1787 1149 1332 1505 1266 1543 1765 1396 1424 1021 1122 1039 1019 
MCM2 81 114 114 49 92 126 155 65 280 393 152 193 444 521 286 312 
MEK1/2 - p Ser217/221 98 70 49 143 33 36 39 52 95 105 112 80 68 56 69 40 
N-Cadherin 3467 3560 5323 3880 1327 1819 2618 1483 3687 4259 1609 2504 1474 1864 977 1007 
NF-κB p100/p52 - p100   166 71 53 200 332 372 247         139 246 117 85 
NF-κB p105/p50 - p50 1624 1599 1157 1406 1404 1382 1455 1359 1279 1370 1253 1432 1333 1535 1857 1839 
NF-κB p65 125 158 159 131 144 133 169 155 146 198 152 115 177 171 127 135 
Numb 1061 1279 1326 1086 1005 1487 1859 1053 792 943 1121 1006 950 1269 1457 1387 
p38/MAPK 129 223 191 211 146 194 143 132 197 144 139 127 130 133 102 107 
p38/MAPK - pT180/Y182 225 276 429 368 146 314 240 296 214 186 186 123 150 203 154 206 
p53 269 212 111 112 506 422 547 256 85 145 200 233 272 425 556 783 
p70 S6 kinase 269 415 366 365 239 328 285 313 337 450 337 378 309 314 258 308 
PAK 1/2 - p S144/S141 90 100 76 147 466 553 319 496 60 99 139 93 480 761 713 675 
PAK 4 178 154 239 119 206 193 243 114 100 135 118 160 113 192 176 258 
PAK 4/5/6 - pS474/602/560 96 96 154 88 136 121 132 56 67 92 78 120 80 76 104 102 
PARP 6586 5860 4920 3418 10263 9144 7872 6628 2139 2528 2205 3870 4388 5047 4620 9156 
PDGF Receptor beta 56 69 90 57 251 186 223 107 61 47   35 168 203 231 315 
PDK1 123 181 87 128 176 248 173 250 408 222 207 165 277 273 202 205 
PGC1 alpha - pS571 665 440 627 180 1987 1473 1625 614 377 1017 340 519 1537 2436 1436 1302 
PI3-kinase p85 164 181 239 155 150 146 200 91 132 173 156 224 105 131 120 126 
PI3-kinase p85 alpha 33 43 51 26 26 29 50 29 27 36 41 50   32   55 
PKA C alpha/beta - pT197 2915 2889 2611 2390 2215 2668 2818 2482 2805 2962 2335 2243 2135 2451 2366 2258 
PKA C alpha/beta/gamma - pT197 418 518 549 313 269 331 386 301 329 373 214 247 287 313 143 192 
PKA Substrate - pSer/Thr - band at 100 kDa 245 276 394 188 359 246 322 141 190 211 159 321 231 333 208 304 
PKA Substrate - pSer/Thr - band at 35 kDa 83 70 54 63 75 76   48 87 67 116 99 70 50   80 
PKC (pan) - pS660 355 452 397 332 645 796 782 492 272 368 292 307 539 590 628 647 
PKC alpha/beta II - pT638/641 1116 1228 1155 812 2507 2288 2689 1920 660 805 863 822 1829 1824 2326 2091 
PKG-1 50 116 76 63 67 157 187 106 53 71   78 82 99 149 212 
PP1 alpha   1094 646 937 746 1750 1256 1650 636 788 1525   1620 2047     
PP1 alpha - pT320 250 306 313 274 320 391 270 229 346 318 417 385 339 337 315 440 
PP1 gamma 2353 1594   1453 11586 9409 7015 7169 1463 1752 1297 1519 12549 14062 11308 12801 
PP2A C - pY307 290 280 320 197 1392 2423 4352 2305 3396 19335 30585 3805 6964 21692 25473 2782 
PPAR gamma 28486 22669 25205 18114 53638 45699 47554 41718 7577 11264 9805 15680 32692 42480 40225 49830 
PPAR gamma - pS112 1201 882 1030 744 1843 1566 1919 1461 262 428 359 614 1006 1309 1284 1752 
PTCH2 (main band) 176 479 716 1007         588 679 432 513         
PTEN 855 774 639 671 852 722 724 616 725 711 753 639 601 738 691 764 
PTEN - pS380 330 358 333 272 386 341 439 308 312 312 380 294 338 365 341 302 
PTPN7 (LC-PTP, HEPTP) - 40 kDa Isoform 1 738 730 540 553 1446 1378 1218 1255 501 762 371 540 821 1284 1010 1164 
PTPN7 (LC-PTP, HEPTP) - 45 kDa Isoform 2 511 324 409 458 265 269 194 136 1058 1267 1847 1434 101 295 139 403 
PTPN7 (LC-PTP, HEPTP) - 52 kDa Isoform 3 858 914 1185 634 1824 1917 1884 1961 814 924 1024 1168 1577 2138 1307 1534 
RACK1 20337 28321 15091 24752 19389 27268 15380 23394 25186 27333 23586 22868 25980 26146 23383 23762 
RAD23B - Isoform 1 238     261 702 756 478 838 211 269   292 731 890 732 938 
RAD23B - Isoform 1+2 (or RAD23A/B) 1109     1880 989 1474 753 1674 2718 2702   2895 1410 1780 1188 1583 
RAD23B (hHR23b) - Isoform 2 (or RAD23A) 872 1077 1046 1619 285 718 275 835 2506 2433 3054 2603 680 890 456 644 
RBPSUH 384 418 380 359 367 471 430 385 332 392 400 340 377 437 449 449 
RSK 1/2/3 56 50 54 33 86 72 87 30       54 43 51 53   
RSK 3 - pT353/356 98 158 174 139 234 290 336 197 92 120 121 209 149 211 212 201 
RXR alpha - 45 kDa (add. band, or RXR beta) 1036 1012 983 1129 1218 1362 1108 1043 1027 1189 1596 1375 1289 1233 1704 1802 
RXR alpha - 50 kDa (main band) 362 246 286 114 193 73 164 172 1100 896 1099 1173 1231 1271 1166 1658 
RXR alpha - 50+45 kDa or RXR alpha/beta 1398 1259 1267 1243 1412 1435 1272 1215 2127 2085 2695 2546 2520 2503 2869 3459 
RPS6 325 234 90 312 354 442 264 399 466 566 1153 836 522 690 1075 765 
RPS6 - pS240/244 1666 1577 1412 911 4039 7308 7503 6300 8507 22732 31127 9820 13297 25907 25270 7328 
SDS (serine dehydratase) 345 421 537 784 4736 7171 8751 9344 524 544 285 332 6552 7016 5072 5582 
SerpinE1 / PAI1 1451 1307 2388 1775 1533 1926 1251 1283 1722 1764 739 1189 1511 2509 945 1246 
SHP-2 221 406 383 392 200 330 320 278 344 374 167 243 277 317 143 147 
Smad1 109 95   88 103 108 126 63 141 98 242 187 112 90 182 231 
Smad3 37 62 87 62 77 71 123 72 56 96 48 39 68 78 55 93 
SPRED2 33 54 47 51   30 65 43 48 50 62 63 29 33 51   
SPRY2 (Protein sprouty homolog 2) 1011 1629 722 1463 230 693   947 1750 1413 988 1099 786 838 430 712 
SPRY3 (Sprouty 3) 68224 61318 53529 60061 86220 87764 65971 85132 59008 60332 80289 70731 86876 81509 114302 113846 
Src 3867 2538 3828 2785 4179 3664 4713 3147 1854 2496 4348 4371 2639 3214 4625 6009 
Src - pY527 2233 3549 3627 3225 2293 4257 3549 3292 2762 3273 1823 2014 2573 3416 1697 1804 
Src Family - pY416 69 204 337 229 100 232 415 228 183 152 147 147 173 211 128 179 
STAT 1 1281 2000 2082 1555 1443 1753 2220 1715 1731 1908 1540 1796 1616 2035 1597 1881 
STAT 3 1836 2429 2446 2003 2091 2555 2686 2111 2232 2298 2104 2296 2406 2461 2338 2470 
STAT 3 - pS727 108 142 151 128 209 171 158 133 168 172 111 152 162 211 241 121 
Strep 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 
Superoxiddismutase (Cu/Zn) 1119 1387 1872 1658 632 880 922 851 1688 1744 1334 1326 985 775 714 853 
TBK1/NAK - pS172 36 55 56 39 68 83 108 56 32 40 74 74 50 56 95 85 
TCF4 59 116 70 127   56   56 104 96 41 54 47 49     
Topoisomerase 1 2146 1966 3922 2279 3550 1908 3523 1930 2092 2399 2036 3011 2192 3036 2335 2647 
VASP - pS239 84 74 129 89 125 166 202 149 44 29 60 50 101 109 176 136 
Wnt3A 5883 12445 6379 14718 13582 35229 7732 20800 11059 10434 2526 4212 18050 21725 4912 6786 
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  48 h TCP GS+   48 h TCP GS- 72 h TCP GS+   72 h TCP GS-   
Analyte 
48h 11 
GS+ 
48h 19 
GS+ 
48h 26 
GS+ 
48h 27 
GS+ 
48h 11 
GS- 
48h 19 
GS- 
48h 26 
GS- 
48h 27 
GS- 
72h 28 
GS+ 
72h 29 
GS+ 
72h 41 
GS+ 
72h 51 
GS+ 
72h 28 
GS- 
72h 29 
GS- 
72h 41 
GS- 
72h 51 
GS- 
ADAM12 55 69 62 77 90 144 72 148 45 47 41 49 143 94 123 120 
AHR (Aryl Hydrocarbon Receptor) 760 1042 1474 1280 1216 1610 868 1579 996 1519 1653 1203 1081 899 1960 2427 
Akt 801 809 711 707 743 675 695 654 521 646 693 842 522 631 644 763 
Akt - pT308 41 86 74 43 152 44 44 255 196 458 435 286 116 40 64 353 
AMPK alpha 136 92 108 86 351 284 330 309 93 132 123 83 283 149 212 152 
AMPK alpha - pT172 1612 1303 1156 1266 4102 3318 3240 3342 977 958 1307 1228 2639 2002 3107 2656 
A-Raf 323 179 343 337 317 250 209 321 303 276 253 231 280 79 289 268 
ASL (argininosuccinate lyase) 3453 3255 1472 1209 11421 13262 5000 3927 1104 3293 1498 3239 3693 12760 5168 13082 
Bax 65 87 75 55 43 37 97 68 36 52 52 86 33 90 65 61 
beta-Actin 55791 72392 50476 77788 76354 86223 64960 91420 50044 63356 49686 68256 83795 78288 83226 82513 
beta-Catenin 3658 4545 5475 5439 5859 5654 9926 8128 4613 3364 4944 3475 6856 5379 7731 5071 
beta-Catenin - p S552 783 1100 1011 1197 1592 1431 1914 2233 1025 921 1416 921 2027 1390 2248 1500 
beta-Catenin - p S675 637 950 962 832 933 1069 1436 1193 734 607 884 694 1105 860 1131 891 
beta-Catenin (non-pS33/37/T41 - active) 72 122 176 144 158 143 325 303 95 62 106 62 194 157 182 107 
C/EBP alpha  - p30 646 828 676 829 991 1098 1172 1305 696 368 632 673 1298 786 1305 1106 
C/EBP alpha - p42 801 988 842 836 1382 1291 1346 1627 744 478 719 683 1275 1130 1442 1413 
C/EBP alpha total 1446 1817 1518 1665 2373 2389 2518 2933 1440 846 1351 1356 2573 1915 2746 2520 
Caseinkinase 1 alpha 143 119 190 235 175 174 264 227 139 102 157 78 139 176 205 75 
Caseinkinase 2 alpha 378 451 511 452 441 401 475 490 382 309 350 409 392 438 380 419 
Catenin gamma     52 26 64 42 65 71 33   46   71 54 70 44 
CDKN2B (p15 INK4B, CDN2B, MTS2) 524 423 303 291 678 682 331 253 294 739 393 750 367 843 429 898 
c-Jun 89 83 78 136 114 153 165 207 86 102 150 137 155 143 114 224 
c-myc 716 941 913 1212 195 165 142 230 1258 917 2087 1324 190 191 177 199 
COX1 1107 990 905 1033 536 774 460 565 721 920 952 1012 468 455 512 727 
CREB 106 57 80 90 149 107 112 134 43 130 110 107 97 95 130 186 
CREB - pS133 163 149 183 176 298 271 385 347 143 171 119 200 349 241 218 361 
Cyclin A         768 745 1189 1249         1068 561 1113 576 
Cyp2B 69072 64213 87816 84103 77795 73393 121628 109187 88943 53534 114592 86193 117988 93518 130169 108642 
Cyp2C (Cyp2C8) 127307 98770 163813 153290 145618 148590 207161 179981 141342 89053 192258 129508 156727 116969 208648 144552 
Cyp2E (Cyp2E1) 95339 76701 128428 124938 4950 4521 5625 5282 86846 50947 117996 69450 5661 5212 6227 5206 
Cyp3A (Cyp3a4 3a1 3a11) 271271 322760 411778 352500 174831 146611 208872 228655 344375 259451 461932 332693 192524 177842 166575 171910 
DKK1   318   332   312 462 562 344   360   473     367 
DPP3 (Dipeptidyl-peptidase 3) 240 197 199 318   37 42 40 335 185 284 174 90 66 61 58 
DUSP4  1051 1065 1136 1772 8025 9503 10123 12907 921 463 1273 750 9072 4170 12374 9565 
E2F4 14129 15794 17060 40032 47863 48902 56912 86776 18678 22903 16303 17820 64357 56503 55499 46455 
E-Cadherin         6897 7532 8405 7055         5926 6761 5856 7128 
E-Cadherin - pS838/S840         14269 12846 16323 13956         11757 9534 11245 14514 
EEF2 1527 1632 1359 1205 1676 1771 2026 1844 1037 1535 1391 1463 1242 1589 1649 1762 
eEF2 pT56 17749 18559 18645 15053 19734 16817 23042 17733 12761 17770 18167 18057 14954 16547 17535 18052 
EGR1 129 115 122 192 53 94 83 148 151 113 253 212 108 71 145 106 
eIF2 alpha 10446 8674 8549 8698 9228 9945 8363 7617 7639 8451 9107 9552 7247 9506 9256 10030 
eIF2 alpha - pS51 553 482 161 138 187 191 83 98 255 344 360 753 89 175 170 314 
eIF4E 1154 1230 1454 1578 1082 1030 1448 1132 1361 1340 1796 1995 1193 1303 1484 1477 
Erk1/2 - ERK1 509 517 469 611 725 645 798 815 347 363 563 389 484 678 572 645 
Erk1/2 - ERK2 957 817 775 831 905 904 1107 942 664 734 925 917 733 996 836 705 
Erk1/2 - pT202/Y204 - ERK1 197 205 391 225 245 251 588 254 239 235 198 320 418 208 169 290 
Erk1/2 - pT202/Y204 - ERK2 465 482 738 246 633 510 1500 481 650 342 413 533 751 341 375 425 
Erk1/2 - pT202/Y204 - total 662 686 1129 472 878 761 2088 736 889 578 611 852 1170 548 544 717 
Erk1/2 - total 1466 1335 1244 1443 1630 1549 1906 1757 1011 1098 1489 1306 1217 1676 1408 1350 
Ets-1 323 334 193 201 247 208 208 208 241 213 297 218 154 240 273 236 
Ezh2 77 96 117 84 91 129 167 174 81 102 124 61 115 126 78 121 
Ezrin / Radixin / Moesin 73 69 80 114 67 68 82 91 95 54 94 52 89 52 131 82 
Ezrin / Radixin / Moesin - pT567/564/558 199 236 923 418 115 138 354 194 457 160 495 160 222 80 236 131 
FAK 104 78 120 80 211 132 160 176 67 67 88 68 150 107 174 108 
FAK - pY397 102     76 112   122 119   69 104   79   117 119 
FDPS - Isoform 1 804 770 747 829 1109 1794 963 1474 986 892 1039 1305 1329 1050 2708 2199 
FDPS - Isoform 2 161 249 147 259 334 373 277 364   209 196 280 273 345 434 576 
FDPS - total 965 1020 894 1089 1443 2166 1242 1838   1101 1234 1585 1603 1395 3142 2774 
FTCD 234 166 105 227 826 833 830 882 184 205 371 240 671 894 1028 802 
Fyn 236 872   503 353 519 753 321 288 267 427 452   641 464 497 
Gab1 397 251 241 371 581 628 421 719 297 195 323 292 701 218 1014 778 
Gadd45 beta 207 253 86 93 72 141 37 56 76 189 103 256 30 136   72 
GAPDH 44 42     89 76   39 39 37 32 61 57 62 71 55 
GAS-2 280 324 205 312 3583 4261 2732 2800 263 240 363 287 2869 3348 3283 3521 
GLS2 (Glutaminase 2)       35 149 173 239 221         128 87 163 129 
GLUT-1 929 504 979 1133 757 877 1404 1419 1114 391 1532 674 1066 496 1676 628 
Glutaminsynthetase 649542 648096 631175 606444 2100 1310 861 1536 470973 494718 554123 628302 906 1024 948 1304 
GSK3 alpha/beta - pS21/9 - alpha 100 120 101 133 148 148 175 128 43 56 76 168 96 185 115 234 
GSK3 alpha/beta - pS21/9 - beta 168 129 138 136 180 154 138 177 84 118 108 161 125 156 126 157 
GSK3 alpha/beta - pS21/9 - total 268 249 239 269 328 302 313 306 126 174 184 329 222 342 241 392 
GSK3 beta 2335 2106 2020 1777 2080 1793 1771 1478 1484 1489 1963 1734 1387 1717 1478 1501 
GSK3 beta - pS9 240 161 176 186 225 199 253 233 123 148 173 286 171 202 159 170 
HAL (histidine ammonia lyase) 109 113 69 69 413 568 280 289 98 97 56 78 291 380 353 519 
Histon Deacetylase 1 (HDAC1) 41 54 69 39   73   60 31 37   32 29 36 29   
Histon Deacetylase 3 (HDAC3) 39 40 34 51 44 37 48 55 34 21     38 49 60 27 
Histon H3 - acetyl K9 5308 3706 5671 3955 5729 7682 6829 6923 2710 3464 4910 4062 5380 5082 5136 6211 
HNF-4 - pS313 122 327 170 250 613 735 965 1021 127 93 161 235 635 436 1066 732 
HNF-4 alpha 176 971 294 419 144 336 460 212 177 151 261 438 138 683 500 480 
HSP70 208 306 223 182 43 62 50 71 285 392 344 270 56 48 70 48 
IDH1 ([NADP] cytoplasmic) 3147 3175 2335 2320 2035 2341 1515 1478 2190 3135 3168 3993 1362 2478 1895 2777 
IDH2 3714 3106 4516 4875 3476 3070 4919 4867 3162 2279 3604 2651 3298 3337 3757 3100 
Ihh (indian Hedgehog) 1564 1274 1951 2398 2345 2422 3657 3784 3117 1559 4134 2630 5062 3196 5439 3797 
IkappaB alpha 63 40 68 37 79 53 89 101   35 30 59 34 60 40   
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  48 h TCP GS+   48 h TCP GS- 72 h TCP GS+   72 h TCP GS-   
ILK1 388 301 403 462 432 426 561 590 337 296 472 367 479 402 587 422 
ILK1 - pS246 49009 54734 62571 71206 148731 162566 212604 224854 43409 35246 50233 47981 172986 121837 211500 164734 
ILK1 - pThr173 31323 34755 37710 43261 107916 119929 140982 153564 26521 20253 29521 28999 116751 80624 140888 108797 
INSL4     967 928 670 368 946 921 409 1663 1186 780 396 714 856 653 
IRAK4 - Isoform 1   349 239 369 305 260 407 606 228   443 262 349 230 446 361 
IRAK4 - p T345/S346 - Isoform 2 107 105 109 110 96 111 95 61 80 111 61 136 65 117 74 118 
JNK/SAPK (p46) 99 243 149 170 192 121 119 130 88 161 147   126 107 126 154 
JNK/SAPK (p54) 188 163 316 200 312 185 247 176 145 163 213 137 153 188 210 268 
JNK/SAPK - total 288 406 465 370 503 307 367 306 233 324 360   279 296 336 422 
KRAS GTPase 101 98 61 122 71 58 107 97 78 71 83 65 89 69 77 70 
KSR1 - pS392 327 329 485 517 568 403 690 955 362 285 416 372 488 493 618 500 
LCK - pY505 1067 1207 849 969 843 929 676 713 590 743 804 1033 530 816 772 981 
MCM2 382 243 423 379 568 365 746 627 253 424 349 417 445 613 341 569 
MEK1/2 - p Ser217/221 79 107 87 33 46 43 42 26 49 65 72 71 32 47 30 29 
N-Cadherin 1692 1487 1675 1275 751 710 790 453 994 1369 931 1243 432 765 472 834 
NF-κB p100/p52 - p100   33   24 106 116 128 67     36   68 73 91 98 
NF-κB p105/p50 - p50 1303 1110 1027 1114 1441 1244 1227 1289 775 819 919 1095 1018 1157 1069 1118 
NF-κB p65 133 90 75 131 123 120 76 126 73 93 111 116 105 60 115 130 
Numb 852 741 888 927 768 1153 714 1017 554 490 783 658 884 528 1262 889 
p38/MAPK 144 141 82 74 149 115 68 56 70 93 89 122 61 116 73 90 
p38/MAPK - pT180/Y182 439 981 1277 310 141 420 665 171 84 128 49 289 323 208 106 234 
p53 89 470 374 235 188 283 875 517 99 141 196 191 227 526 369 333 
p70 S6 kinase 386 371 270 324 269 354 287 234 282 314 320 349 225 201 225 247 
PAK 1/2 - p S144/S141 52 69 50 57 198 302 381 541 26   49 40 306 157 451 188 
PAK 4 140 240 405 575 107 160 171 449 149 342 76 41 241 336 110 250 
PAK 4/5/6 - pS474/602/560 76 76 74 74 53 58 55 85 51 42 80 64 50   93 65 
PARP 977 1135 879 2916 3006 3341 2718 5443 1322 1744 1378 1715 4058 3628 3802 3932 
PDGF Receptor beta 38 64   74 144 163 370 422 55   63 27 263 145 155 92 
PDK1 161 211     113 210 267   143 264 72 66 217 231 248 117 
PGC1 alpha - pS571 397 260 372 367 1310 1470 1434 1113 211 324 204 302 789 1197 1176 1281 
PI3-kinase p85 130 212 121 135 81 94 125 108 141 131 137 147 112 148 104 73 
PI3-kinase p85 alpha   107 105 122   24   27 24   42 43   100   43 
PKA C alpha/beta - pT197 2496 2843 2123 1685 2162 1953 1960 1579 1640 2188 2100 2038 1369 1886 1531 1713 
PKA C alpha/beta/gamma - pT197 204 207 193 139 142 137 143 102 144 190 159 197 101 175 120 170 
PKA Substrate - pSer/Thr - band at 100 kDa 194 203 230 142 255 230 283 216 133 185 186 183 197 204 171 205 
PKA Substrate - pSer/Thr - band at 35 kDa 63 64 93 85   64 78 51 70 76 89 66 51 87 46 38 
PKC (pan) - pS660 223 275 208 266 479 532 475 489 208 176 175 301 510 408 404 412 
PKC alpha/beta II - pT638/641 652 736 650 796 1977 1628 1834 1699 473 421 610 712 1462 1261 1679 1539 
PKG-1 50 113   114 65 109 95 81 29 31 40 34 60 112 60 116 
PP1 alpha 471 488     996 832     446 432       978 306 688 
PP1 alpha - pT320 333 190 257 250 230 304 331 241 172 212 282 198 243 241 203 238 
PP1 gamma 906     830 8129 8835 10460 8328 802   947   9891 6670 13054 9186 
PP2A C - pY307 208 282 1036 439 912 1040 2776 1352 768 624 938 12196 3288 3554 2479 12176 
PPAR gamma 6330 6088 5616 11851 22733 27406 24647 41370 5076 5557 6499 6890 24570 20508 32539 25717 
PPAR gamma - pS112 226 257 227 527 719 900 783 1285 227 270 305 271 788 784 939 898 
PTCH2 (main band) 273 404 733 186         187 178 231 320         
PTEN 792 620 693 509 791 694 764 579 458 529 558 660 516 702 662 684 
PTEN - pS380 386 331 332 276 381 346 354 253 238 208 278 344 205 328 294 313 
PTPN7 (LC-PTP, HEPTP) - 40 kDa Isoform 1 141 189 211 229 755 826 794 854 187 146 177 252 732 482 952 690 
PTPN7 (LC-PTP, HEPTP) - 45 kDa Isoform 2 2644 1469 3198 2899 637 534 755 897 2845 1390 3817 2355 956 772 1075 632 
PTPN7 (LC-PTP, HEPTP) - 52 kDa Isoform 3 1010 1239 1720 2085 831 976 1023 1635 2093 908 3006 1410 1116 761 1449 1300 
RACK1 16135 12320 14513 10746 15054 18161 16562 12681 10511 12784 12085 12718 11403 15681 13085 15407 
RAD23B - Isoform 1 208     289 543 509 495 677 159   213   571 292 677 541 
RAD23B - Isoform 1+2 (or RAD23A/B) 4778     4518 1734 1780 1598 1819 4953   6639   2016 1878 2180 2295 
RAD23B (hHR23b) - Isoform 2 (or RAD23A) 4569 2656 4760 4228 1192 1271 1102 1142 4794 2467 6425 4107 1446 1586 1503 1754 
RBPSUH 202 274 293 265 218 265 335 296 191 178 193 265 252 204 237 284 
RSK 1/2/3 66     53 59 57 96 77 37   69 31 85 89 103 48 
RSK 3 - pT353/356 43 84 48 74 92 129 150 112 49 65 112 112 101 103 106 117 
RXR alpha - 45 kDa (add. band, or RXR beta) 640 624 938 1013 861 958 1207 1302 591 530 617 604 947 830 983 1023 
RXR alpha - 50 kDa (main band) 934 669 1056 1176 1826 2202 3058 2918 1223 617 1303 701 1930 1229 3411 1707 
RXR alpha - 50+45 kDa or RXR alpha/beta 1574 1293 1994 2188 2687 3160 4265 4221 1814 1148 1920 1305 2877 2057 4394 2729 
RPS6 644 601 1002 1015 452 784 1443 907 515 328 645 720 970 853 691 788 
RPS6 - pS240/244 1010 1294 4544 2073 2124 3331 7744 3974 2805 2446 3699 16776 7804 7980 6319 15256 
SDS (serine dehydratase) 517 306 236 151 5292 6393 4302 2914 198 389 279 446 3324 4839 4819 6945 
SerpinE1 / PAI1 740 775 561 523 824 1022 800 1233 666 446 755 734 949 968 1316 1174 
SHP-2 304 223 101 83 249 233 136 181 98 177 125 210 109 157 192 239 
Smad1 160 176 182 249 132 157 191 214 150 101 171 126 161 130 189 106 
Smad3 52 47 65 59 55 50 110 65 42 50 69 57 57 46 63 43 
SPRED2 60 89 67 84 28 36 36 43 71 39 121 104 50 28 57 30 
SPRY2 (Protein sprouty homolog 2) 931 818 595 706 558 641 365 394 637 740 631 790 303 631 376 524 
SPRY3 (Sprouty 3) 40053 35624 41098 50394 48812 57768 77377 66847 33227 24177 36121 31532 59667 41185 58739 50537 
Src 1998 2050 2885 3042 2564 2987 3851 4381 2188 1341 2747 2155 3301 2082 3709 2574 
Src - pY527 2238 2292 1385 1383 2394 2526 1416 1445 881 1778 1225 2148 1029 2132 1267 2221 
Src Family - pY416 108 134 74 92 99 104 85 92 99 77 141 163 109 109 116 189 
STAT 1 1148 2063 984 1518 1115 1580 1473 1150 1122 1502 1579 1510 1334 1967 1582 1605 
STAT 3 1404 1587 1375 1345 1526 1531 1711 1515 946 1018 1341 1222 1199 1514 1728 1199 
STAT 3 - pS727 63 90 91 81 74 86 92 138 47 83 45 82 74 92 96 65 
Strep 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 224904 
Superoxiddismutase (Cu/Zn) 867 685 900 717 617 575 548 457 834 880 1032 987 514 674 519 658 
TBK1/NAK - pS172 53 39 41 72 59 38 49 60 40 35 40 53 54 47 60 60 
TCF4 57 40   35 49 37 60     24   49 25 49 42 44 
Topoisomerase 1 1276 1232 2587 1436 1569 1825 3808 2180 1035 1156 920 1099 1748 1377 1142 1788 
VASP - pS239 31 47 44 70 128 81 85 95 35 31 37 53 64 68 62 92 
Wnt3A 2956 2860 2083 1536 8144 11148 3892 3155 1328 2133 1161 2218 3745 7133 5065 8205 
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12.4 Appendix 4: Data from the Lapatinib resistance 
experiment  
This table contains all DigiWest data from the Lapatinib resistance experiment. All analytes which gave 
analyzable signal at the correct molecular weight are contained. Data are given in [AFI], data are not 
normalized. ‘KB PD’ is short for Kinobead pull-down. 
  H292 Control Lysate H292 Resistant Lysate H292 Control KB PD H292 Resistant KB PD 
  Lysate 1 Lysate 2 Lysate 3 Lysate 1 Lysate 2 Lysate 3 KB PD 1 KB PD 2 KB PD 3 KB PD 1 KB PD 2 KB PD 3 
Analyte [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] [AFI] 
Abl2  504 556 469 468 404 452 2558 3184 2967 1941 2012 2198 
ABL2 (phosphorylated)    257 288 325 161 117 119 3028 3287 3155 1866 2177 2154 
AHR  1271 1191 1171 1256 862 1375             
Akt  70890 72361 73044 75848 81811 75933 214019 218137 185963 205763 188962 180614 
Akt - phospho Ser473 69 75 81 34 33 23 318 254 202 102 106 95 
Akt - phospho Thr308 13 23 29 21 31 17 409 550 512 431 205 235 
AMPK alpha  2457 2422 2181 1731 1833 1625 11069 11860 9692 6871 7669 6614 
AMPK alpha - phospho Thr172 4832 4869 4392 2303 2202 2243 34161 35075 32039 19568 20926 18752 
ASK1  85 94 86 79 53 68 724 759 658 243 222 219 
ASK1 Phospho Thr845 51 46 49 30 16 17 1007 1051 977 316 296 284 
ATF3 3083 3210 3183 2832 2757 2940             
ATM  644 540 816 471 418 505 118 156 154 55 35 40 
Aurora A - phospho Thr288 33 28 26 143 160 151             
Aurora A (AIK)  321 330 334 102 91 79 5899 5808 3900 1315 1137 885 
Aurora A/B/C - phospho Thr288/Thr232/Thr198 59 26 39 29 39 25 166 208 143 79 72 79 
Aurora B (AIM1)  92 111 89 41 29 26 432 404 329 95 119 104 
beta-Actin  271450 271186 254977 294429 277161 259552 5092 4017 2469 5281 3253 3293 
beta-Catenin  46410 44486 37109 72109 68666 68062 2760 2785 1431 2208 2294 2506 
beta-Catenin - phospho Ser675 10613 9696 8113 19291 17706 16892 550 489 259 462 493 538 
beta-Catenin - phospho Thr41/Ser45 65 61 42 103 102 94             
b-Raf  105 125 99 108 123 101 812 802 474 596 656 589 
b-Raf - phospho Ser445 1531 1513 1294 1256 1171 1139 6913 7135 4707 5433 5659 5180 
Caseinkinase 1 epsilon  1368 1655 1345 1298 1313 1135 979 640 589 364 293 220 
Caspase 3  11367 11257 10470 12523 12419 13293 67 48 64 67 85 76 
Caspase 7  5986 5809 5479 12356 11651 12039 95 98 77 193 234 254 
Caspase 8  1998 1963 1725 840 808 871             
Caspase 9  1032 902 816 3172 3210 3027             
Caveolin-1  8381 9549 9836 2352 2494 2588 332 339 265 115 86 94 
cdc2 - phospho Tyr15 961 899 828 619 640 642 1806 1748 1447 1321 1224 1287 
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  H292 Control Lysate H292 Resistant Lysate H292 Control KB PD H292 Resistant KB PD 
cdc2 (CDK1)  8672 9746 7796 3646 3682 4052 1943 1444 1603 275 347 360 
CDK6  95 79 80 375 398 425 23 8 15 69 90 77 
CDK6 (phospho-Tyr13)    3277 2149 1846 3922 2568 2947 456 482 507 731 557 456 
CDK6 (phospho-Tyr24)    468 278 207 404 205 221 764 627 628 346 289 243 
CDKN2B (p15 INK4B, CDN2B, MTS2)  187330 180745 160777 207908 190461 205396             
c-Jun  37 34 25 30 48 34             
c-Jun - phospho Ser63 195 166 183 116 120 124             
c-Jun - phospho Ser73 92 85 74 110 74 94             
c-Kit                          
c-myc  1073 945 950 739 801 754             
c-myc - phospho Thr58/Ser62 2665 2865 2935 2684 2262 2179             
Crk (p38)  1096 1032 926 976 937 910             
Crk (p38) - phospho Tyr221                         
Cyclin A2  125 167 139 143 147 122             
Cyclin B1  801 692 691 182 137 156 3063 3005 2503 182 174 170 
Cyclin B1 - phospho Ser133 196 224 203 167 197 162             
Cyclin D1  420 341 319 288 219 285             
Cytokeratin 7  71440 67790 74837 51024 44915 48292 20219 11158 9315 7943 7052 8601 
Cytokeratin 8  4008 3940 4594 1145 897 1086 795 612 522 213 167 209 
Cytokeratin 8 - phospho Ser23 432 437 543 264 246 262 551 539 293 200 267 256 
DUSP1 - phospho - (MKP-1) Ser296/318 183 99 87 181 125 78             
DUSP1 (MKP1)  4369 3250 2889 5261 3936 3784             
DUSP10 (MKP-5)  302 244 205 158 142 154             
DUSP5 (VH3)  197 196 169 191 186 187             
DUSP6 (MKP3)  541 540 448 32 34 27             
DUSP9 (MKP4, MKP-4)  986 571 533 5262 4857 5002 140 137 136 266 177 126 
E-Cadherin  44784 50096 43821 72565 73979 72414 1778 2183 1247 1415 907 1053 
E-Cadherin - phospho Ser838/Ser840 84059 93627 84345 105570 114051 105951 5336 6576 3718 3028 1963 2044 
EGFR  12169 16160 12012 36640 53335 41327 63777 71488 57802 73 76 71 
EGFR - phospho Tyr1068 2038 2384 2059 467 521 417 2815 2832 2585       
EGFR - phospho Tyr845 472 532 497 182 170 188 677 861 705       
EGFR - phospho Tyr992 1253 1502 1206 1864 2394 1810 4772 5204 4602       
EphA2  2528 2901 2480 835 828 854 53089 55271 53066 16049 17402 15870 
EphA2 Phospho Ser897 158 137 128       2762 2707 2690 170 196 176 
EphA2 Phospho Tyr588 250 331 328 296 377 347 5419 5681 5386 5476 5978 5679 
EphA2 Phospho Tyr594 119 124 123 139 114 101 2583 2693 2447 2454 2878 2519 
EphA2 Phospho Tyr772 2422 2669 2621 2113 2035 1919 43197 45251 43454 27382 28379 27402 
EphA4                31 23 22 113 152 128 
EPHA4 (phospho-Tyr596)                269 293 231 314 281 267 
EphB3                67 74 58 248 310 310 
EphB4                844 874 820 234 235 210 
EphB6                   
EphB6                            
Ephrin B Phospho Tyr324/329 89 90 93 118 113 127 6465 7520 5706 4592 2777 2832 
Erk1/2  37139 35016 28686 36486 36381 34368 334116 327959 293328 349849 382168 378960 
Erk1/2 (MAPK p44/42) - phospho Thr202/Tyr204 1515 1664 1495 569 581 577 15951 14333 12591 6020 5680 6068 
FAK 1  573 620 505 634 543 579 24898 29941 31527 18860 24714 25256 
FAK 1 - phospho Tyr576/Tyr577 154 170 137 221 222 225 2907 3323 3337 3463 3826 3779 
FAK 1 - phospho Tyr861       153 197 158 122 118 108 115 139 150 
Folate Binding Protein (Folate Receptor, FOLR1)                          
Fyn  461 491 434 1182 1112 1164 2964 2933 2534 11651 11869 11705 
Fyn - phospho Tyr530  9169 8114 8526 6882 6531 6593 171340 165707 140987 150366 141554 125728 
GSK3 beta  6833 6786 6779 4802 4738 4562 55376 49899 43613 36331 31169 28604 
GSK3 beta - phospho Ser9 448 478 458 225 205 216 7492 6746 5359 3479 2900 2449 
Her2  3933 4472 3934 9547 9754 9677 211 259 155 173 132 137 
Her2 - phospho Tyr1248 2958 4247 3199 1110 1552 1379 1848 1632 2004       
Her2 - phospho Tyr877                         
HIF1 alpha                          
HIF-1beta (ARNT)  3694 3279 3053 1808 1631 1528             
IKKε  592 482 493 99 91 83 6222 6862 5195 827 837 703 
IKKε Phospho Ser172                         
IRAK4  1614 1438 1534 2949 2041 2180 1023 1093 787 2748 2167 2251 
IRAK4 Phospho Thr345/Ser346 35 40 29 191 207 206 165 169 114 787 783 753 
JNK/SAPK  3253 3325 3114 2475 3348 3163 33010 31671 24305 31852 32565 29554 
JNK/SAPK - phospho Thr183/Tyr185 214 193 170 228 237 231 448 420 368 67 62 56 
LATS2  26 30 32 162 105 127 275 305 310 880 969 926 
LIMK1  2376 2493 2321 1430 1322 1370 6128 6357 4787 2758 2812 2494 
LIMK1 Phospho Thr508 / Thr505 77 71 65 59 48 59 1472 1199 940 1089 1145 940 
LRRK2  79 67 100 77 79 103 290 311 421 97 112 82 
LRRK2 Phospho Ser910             80 93 108 26 46 43 
LRRK2 Phospho Ser935             108 121 131 20 19 27 
MEK1  8026 8740 7873 3914 4076 4046 1139 1064 805 510 458 440 
MEK1 - phospho Thr292 480 423 403 263 204 207 82 79 82 42 39 41 
MEK1/2 - phospho Ser217/221 676 690 669 408 386 362 170 159 151 96 87 81 
MKK3/6 - phospho Ser189/207 83 71 58 70 77 40 218 202 174 605 678 530 
MKK3/MKK6 Phospho S218/T222 S207/T211 808 582 584 768 742 743 1714 1492 1467 3962 3809 3700 
MKK6  1962 2001 1601 4217 4064 4137 19777 17232 15066 57832 55929 55694 
MKK7  805 801 831 1060 1026 979             
MKK7 - phospho Ser271/Thr275 234 254 158 305 172 235             
MLK3 ( MAP3K11)  303 307 316 270 300 300 2879 2963 1933 1576 2215 1818 
MLK3 -phospho ( MAP3K11) Thr277/Ser281                         
Mnk1  773 895 815 1491 1523 1488 206 187 155 218 218 213 
Mnk1 - phospho Thr197/202 1139 1053 1047 831 719 744 600 555 537 228 262 265 
NF-κB p100/p52  2423 3029 2776 1695 1618 1682 116 121 114 55 78 72 
NF-κB p105/p50  21740 23331 21924 20659 21229 20087 1273 1078 758 675 696 635 
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  H292 Control Lysate H292 Resistant Lysate H292 Control KB PD H292 Resistant KB PD 
NF-κB p65  4219 3820 3741 5734 5064 5115 306 348 170 266 232 243 
NF-κB p65 - phospho Ser536 576 606 539 511 591 554             
NIK  62 66 56 87 89 99 517 648 502 280 329 278 
p21/Waf1/Cip1  2723 2746 2406 1107 1064 1204             
p27(Kip1) - phospho - (CDKN1B) Ser10 2865 2735 2445 13684 12913 13358             
p27(Kip1) (CDKN1B)  941 872 762 2947 2670 2772             
p38/MAPK  3051 3511 2950 2717 3035 2629 107223 101467 91429 112247 122314 118966 
p38/MAPK - phospho Thr180/Tyr182 100 85 74 97 45 55 2456 2242 2135 2100 2121 2038 
p53 1801 1870 1755 580 494 539 130       55 73 
p53                          
p53 - phospho Ser20     44                   
p53 - phospho Ser392 244 293 274 146 108 124             
PI3-kinase p110 subunit alpha  205 258 213 207 237 208             
PI3-kinase p85  204 210 215 379 384 348 38 57 48 53 58 46 
PKCθ  126 125 116 29 27 20 1057 1385 806 100 109 107 
PKCθ Phospho Thr538 129 114 114 25 32 26 1172 1472 919 117 109 110 
PP1 alpha  6210 5671 4638 5550 6561 5482             
PP1 alpha - phospho Thr320 3515 3263 2773 3175 3124 2764             
PP2A C  11368 11346 10783 9232 8943 8959             
PP2A C - phospho Tyr307 2227 2490 2213 1942 1884 1829             
PTEN  6263 5907 5369 10726 10010 10279             
PTEN - phospho Ser380 2223 1911 1855 3667 3405 3440             
PTPN7 (LC-PTP, HEPTP)  4992 4135 4144 4252 3246 3401             
PTP-PEST (PTPN12, PTN12)  946 1040 915 814 920 995             
Pyk2 - phospho Tyr402 951 821 776 947 936 911 9897 10676 11167 12980 14934 14857 
Pyk2 / FAK 2  813 1049 968 2474 2512 2744 19880 20336 22105 43334 45116 40518 
RSK 1  3120 3332 3290 7920 8469 8466 25031 29735 20088 79645 74120 72776 
RSK 1 - phospho Thr573             1811 1937 1480 1394 1614 1333 
RSK 1 (p90RSK) - phospho Ser380             702 808 642 248 302 256 
RSK 1/2/3  12221 12097 10718 32732 31238 32964 86063 96201 76349 200290 207071 201109 
RSK 4              291 225 201 338 393 303 
RSK 4 - phospho Ser235 666 795 689 1110 1169 1153 23880 28003 18783 66254 60846 56956 
RXR  1144 1145 1066 1139 1222 1214             
RXR alpha                          
SIK3  241 245 182 258 183 223 811 924 1051 486 426 520 
SIK3 (KIAA0999)    2697 2266 2443 3258 3204 2847 296 327 200 269 223 263 
Smad2 - phospho Ser245/250/255 76 62 92 34 38 31             
Smad2 - phospho Ser465/467                         
Smad2/3  4245 3683 3793 4955 4495 4352 197 190 168 201 110 161 
Smad3 - phospho Ser423/425                         
Src  7739 6908 6829 5484 4897 4704 76401 74750 63646 64814 61679 59917 
Src - phospho Tyr416 3732 4102 3871 1530 1426 1326 30619 31795 27220 16500 14591 13897 
Src - phospho Tyr527 30676 30661 31306 29540 27479 27323 198634 191105 169539 227147 215388 205945 
STEP (PTPN5, PTN5)  48048 47641 54025 96846 85334 102418             
TAK1  4594 4426 3936 5163 4698 4856             
TAK1 - phospho Ser412 1264 1337 1174 1266 1137 1224             
Thrombospondin 2                          
YAP  1507 1342 1216 2652 2743 2535             
YAP - phospho Ser127 1723 1659 1414 4134 4257 4123             
 
 
